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ABSTRACT
Background: No evaluation has been undertaken to assess benefits of the national 
antiretroviral therapy program and the distribution of the benefits to various Thai social 
classes resulting from the roll out the programme in 2001. This study aims to test the 
hypothesis that there was no association between socioeconomic status of the HIV-infected 
patients and their HIV-related mortality. The objectives of this study include identification 
of benefit of the treatment in relation to survival, health-related quality of life, 
immunological improvement and duration on the first-line regimen as well as the 
exploration of factors that might influence those outcomes.
Methods: A survival study was undertaken in May 2007 analysing 501 patients who had 
been treated in the government ART program between May 2001 and May 2006 to identify 
the treatment outcomes. Secondly, a detailed evaluation was undertaken of changes of 
health-related quality of life in 97 participants between 2004 and 2007. The clinical analysis 
was undertaken in three hospitals located in Chiang Mai, Northern Thailand. The variations 
with regard to treatment outcomes among social classes were analysed using Kaplan-Meier 
and log rank test and Cox proportional hazard regression.
Results: About 16% of the patients died, their health-related quality of life tended to be 
stable over the period of three years. Approximately 54% and 24% of the participants could 
have the CD4 cell count achieved level of 200 and 500 cell/uL respectively, and 31% had to 
change the prescribed regimen. Low socioeconomic, not being a member of PLHA self-help 
group and being treated in nurse-led clinic appeared to impose a significant effect on higher 
mortality.
Conclusion: To expand the benefits of the programme, the government must look after 
closely after the underserved people with adjusting the care delivery method
Total word count 66,169 words
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Introduction
1 Introduction
HIV/AIDS is a global health problem which threatens human welfare, economics, 
productivity and the unity of people in society. It is a leading cause of death and is 
considered as a threat to national security in many countries. Fortunately, effective 
antiretroviral therapy (ART) is available to control the progression of disease, although only 
some people gain access and receive benefit from this treatment. Thus, great efforts have 
been made towards expanding the provision of ART to alleviate discrepancies in access 
especially in developing countries where the burden of the disease is highest*. This chapter 
provides an overview of the global situation with regard to HIV/AIDS and its associated 
burden. Moreover, the expanded use of ART in resource-limited settings and disparity of 
access and benefits to the ART are outlined. At the end of this chapter, the research 
hypothesis and objectives are presented.
1.1 HIV/AIDS epidemic and its burden
The HIV/AIDS epidemic is imposing destructive effects in every part of the world; reaching 
into every level of society, impacting on young and old, rich and poor (UNAIDS 2008). The 
disease is dynamic and changing as the virus has developed an ability to mutate into many 
different variants as its environment changes (UNAIDS 2008). The annual number of HIV 
infected people has begun to stabilize since 2000, however, it has been estimated that 33 
million people worldwide were infected with HIV and two million died of AIDS globally in 
2007 (UNAIDS 2008). In relation to HIV prevalence, there has been a trend to decrease in 
Sub-Sahara African countries (See Figure 1-1). However, Sub-Saharan Africa remains home 
to about 67% of PLHA worldwide with the number of people living with HIV/AIDS
* Terms as developed and developing country appeared in this thesis are defined regarding the 
Human Development Index (HDI) which is a comparative measure of life expectancy, literacy, 
education, and standard of living for countries worldwide. It is a standard means of measuring well­
being. especially child welfare. It is used by the United Nation (UN) to determine and indicate 
whether a country is a developed, developing or under developing country. See 
http://hdr.undp.org/hdr2006/statistics/ for lists of the countries and for more detail
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(PLHA) continuing to increase as HIV treatment extends the patients’ lives (UNAIDS 
2008).
Figure 1-1: Number of people living with HIV and HIV prevalence during 1990-2007
N um ber o f people G lo b a l % HIV prevalence,
1990 1991 19921993 1994 1995 19961997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
— Number of people 
living with HIV
N um ber of people  
living with HIV (millions)
S u b -S a h a ra n  A fr ic a  % HIV prevalence, 
adult (15-49)
15%
12%
9.0%
6 .0%
3.0%
0.0%
19901991 19921993 199419951996199719981999 20002001 20022003 20042005 20062007
— % HIV prevalence, 
adult (15-49)
II These bars indicate the range 
around the estimate
Source: UNAIDS report 2008
The focus of the disease has also been shifting; increasingly affecting women and younger 
age groups, with 50% of PLHA worldwide now being women and 45% of newly infected 
people globally being individuals aged 15-24 (UNAIDS 2008). Aside from women and the 
young, analysis undertaken in North America found that the most affected groups were the 
racial and ethnic minorities (UNAIDS 2006). The situation in Western and Central Europe 
is similar with the highest number of new cases and highest incidence being amongst 
immigrants (UNAIDS 2006).
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Wherever the disease is prevalent, it imposes an enormous burden on health, economics and 
society. For instance, in Southern African countries with high prevalence of HIV (exceeds 
20%), the average life expectancy of a person has declined to less than 50 years (UNAIDS 
2008). In Swaziland, Zambia and Zimbabwe, without antiretroviral therapy programmes, 
average life expectancy is expected to drop below 35 (UNAIDS 2004). Aside from the 
shortened life expectancy, the disease also reduces the income and production capacity in 
families with sick members whilst simultaneously increasing household expenses due to the 
cost of medicines and other related costs such as funeral expenses (UNAIDS 2004).
1.2 Antiretroviral therapy in resource-limited setting
The standard of HIV/AIDS care has been developed over time; from single-drug (Fischl, 
Richman et al. 1987); (Volberding and Graham 1994) to combination of multi-drugs 
(Rutherford, Sangani et al.); (Enanoria, Ng et al. 2004). New drug combinations show 
potential to suppress more virus and become a benchmark for HIV treatment. Up till now 
HAART (Highly Active Antiretroviral Therapy) which is defined as drug regimens for 
patients with HIV infections that aggressively suppress HIV replication, is considered as the 
standard care for HIV treatment due to its ability to suppress the viral replication which 
results in lower level of HIV in the plasma, lower mortality and lower morbidity in the HIV - 
infected individuals (Palella, Delaney et al. 1998); (Enanoria, Ng et al. 2004). HAART has 
transformed HIV disease from a fatal disease into a chronic manageable disease bringing 
hope to many people living with HIV/AIDS*.
Introducing HAART into the health system is one of the most complex health care issues 
being addressed in many countries (Silversides 2001). Transferring knowledge based on
* Term as rich-income, middle-income and low-income country which appear in this thesis are 
defined according to the World Bank definition which Economies are divided according to 2005 
Gross National Income (GNI) per capita. The groups are: low income, $875 or less; lower middle 
income, $876 - $3,465; upper middle income, $3,466 - $10,725; and high income, $10,726 or more. 
See http://siteresources.worldbank.org/DATASTATISTICS/Resources/CLASS.XLS for lists of the 
countries and more detailed.
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experiences and success of treatment in developed countries is fraught with difficulties. 
Recently, a meta-analysis of studies analysing ART programmes in resource-limited setting 
has been conducted (Ivers, Kendrick et al. 2005) which demonstrated that ART programmes 
can achieve similar effectiveness to results observed in developed countries. In addition to 
this, some small scale studies using either CD4 counts or viral load to determine the efficacy 
of the treatment programme also obtained similar results to the developed world (Laurent, 
Diakhate et al. 2002); (Djomand, Roels et al. 2003); (Kumarasamy, Solomon et al. 2003). 
These findings emphasised the potential for transferring knowledge and success of 
antiretroviral treatment to settings where resources are more restricted (Moatti, Spire et al. 
2004).
Aside from ARV drugs, inadequacies of health infrastructures, including health personnel 
and excess demands for treatment, are considered to be major obstacles to treatment in 
resource-poor settings (Yazdanpanah 2004); (Kovsted 2005). Resources used for 
implementing ART might also require an upgrading of health infra-structures. Developing 
mechanisms to deliver ART to underserved groups of people, while ensuring high quality of 
care with acceptable costs, is required, while also being sensitive to the cultural context of 
the country being addressed.
In most developed countries, HAART is provided through centres specializing in the care of 
HIV treatment. In contrast, in developing countries, it is unclear whether ART should be 
centralized providing through specialist centres, be integrated with other programmes, such 
as those programmes for tuberculosis, or alternatively be integrated into routine health care 
service (Jaffar, Govender et al. 2005); (Kovsted 2005). Service delivery through hospitals or 
specialist centres which are usually located in cities might lead to limited coverage, 
especially given the difficulty of travelling and associated expenses for patients which 
would be likely to intensify urban-rural inequalities in ART care accessing.
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Expanding the provision of ART in low- and middle- income countries is important and 
requires co-operation of multi-sectors to address the problem (WHO 2002); (UNAIDS 
2004). In 2003, WHO/UNAIDS launched the 3 by 5 initiative which aims to treat three 
million HIV-infected people in low- and middle-income countries by the end of year 2005 
(Ammassari, Antinori et al. 2002); (WHO 2002); (Moatti, Spire et al. 2004). Fortunately, 
this target appears to be achievable (largely due to significant reductions in price and 
enhanced capability to produce cheap local generic antiretroviral drugs. International 
pharmaceutical companies have been pressurized to supply antiretroviral drugs at the lowest 
possible price due to the advocacy groups (Yamey 2000) and politicians such as the United 
Nations Global Fund (Global Fund 2005), the US president’s initiative and the 
Clinton Foundation (Yamey 2000).
Local production of generic antiretroviral drugs has also helped to reduce drug prices. 
Experience from Brazil, India and Thailand emphasized the capacity of developing 
countries to produce drugs to serve local requirements by transferring production to 
developing countries. The domestic production of generic drugs was facilitated by the Doha 
Declaration on the TRIPS (Trade-related aspects of intellectual property rights) 
Agreement and Public Health in 2001 which reiterated the right of Member States to take 
measures to protect public health and to address devastating public health crises such as 
HIV and tuberculosis (Conference 2001). In spite of reduced drug prices in many areas, the 
price of antiretroviral drugs remained relatively high in some countries such as 
Russia, Serbia and other Central and Eastern European countries (WHO and 
UNAIDS).
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Through enhanced accessibility, it has been estimated that as many as 3 million PLHA 
(31%) in middle- and low-income countries will have access to antiretroviral (ARV) drugs 
in 2008, representing a ten fold increase over the period of six years (UNAIDS 2008). By 
improving access to ART, AIDS-related mortality is levelling off. However, the number of 
newly infected patients is also increasing every year leading to a ratio of new patients to 
patients with access to the ARV of 2.5:1 (UNAIDS 2008). Such under-treatment represents 
a threat to the global ART programme unless the overall prevalence is diminished through a 
comprehensive prevention programme. The ART programme should form part of a 
comprehensive HIV/AIDS care, however, it has been reported that only 32% of PLHA with 
tuberculosis received both ART and anti-tuberculosis treatment (UNAIDS 2008).
Figure 1-2: People receiving ARV drug in low-and middle-income countries
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Source: UNAIDS report 2008
1.3 Disparity of access and benefit from HA ART
One of the major concerns in relation to HAART expansion is that enhanced accessibility 
has been slowest in vulnerable and marginalised group of people such as people in low 
socioeconomic class, children, ethnic minority, injecting drug users and sex workers, 
prisoners and refugees even in countries where ARV is free of charge (Andersen, Bozzette
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et al. 2000); (Rapiti, Porta et al. 2000); (Silversides 2001). Aside from inequitable access to 
treatment, variations in the level of benefits experienced from treatment provision amongst 
groups of ART beneficiaries also required detailed analysis. This might be caused by the 
differences of patients characteristics in term of biological background (e.g. women and 
race/ethnicity (Anastos, Gange et al. 2000)) or social status (e.g. low socioeconomic status 
(Wood, Montaner et al. 2002)). Understanding factors that contribute to discrepancies in 
benefit provision will help to ensure equitable benefit when HIV- infected people are 
successful in obtaining access to HAART.
1.4 Aims and objectives o f this research
There is political pressure to provide ART in developing countries in order to expand the 
number of treated individuals in a short period of time. Furthermore, the treatment is life­
long and expensive which makes implementation and expansion of ART in resource-limited 
settings more difficult especially to previously underserved groups. Given the context in 
which ART is provided in Thailand, it was estimated that 61% of HIV/AIDS patients are 
currently receiving through the national government antiretroviral therapy programme 
which provides care free of charge (Kanshana and Simonds 2002); (UNAIDS 2008). 
However, there is growing evidence of both lower levels of access and reduced benefit 
being experienced by vulnerable and marginalised groups of people such as people in low 
socioeconomic class, women and ethnic minorities or in groups of injecting drug users. This 
study aims to explore why ART outcomes appear to be poorer amongst such disadvantaged 
groups and isolate factors that might contribute to those limited outcomes.
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My research question is therefore:-
“What factors affect antiretroviral therapy outcomes following enrolment into the Thai 
national ART programme? ”
As this study focuses on the contribution of the socioeconomic status for the treatment 
outcome, thus, my null hypothesis is:-
“There was no association between socioeconomic status o f the HIV-infected patients and 
their HIV-related mortality following enrolment into the Thai national ART programme ”
And the objectives of this study are:-
1. To explore the characteristics of PLHA who received antiretroviral therapy in 
relation to baseline characteristics and their clinical information and the experiences of care 
provided by different types of ARV clinic (doctor- and nurse-led clinic)
2. To determine the impact of ART on treatment outcomes in relation to survival, 
health-related quality of life, immunologic response (CD4 cell counts) and duration on the 
first line regimen of the ART
3. To explore factors such as age, gender, socioeconomic, education, health insurance, 
being member of PLHA self-help group, native to the ART, baseline CD4 cell count, 
prescribed regimen and type of ARV clinic that may contribute to the treatment outcomes,
For the next chapter, inclusive literatures related to the hypothesis and objectives of the 
present study were reviewed and presented according to the main outcomes of the national 
antiretroviral therapy which were investigated in this study.
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2 Literature Review
The following chapter provides a comprehensive literature review analyzing literature 
relevant to the engaging of HAART in developing countries. The literature review was 
categorized into four main subjects: (i) outcomes of the antiretroviral therapy, (ii) factors 
influenced the treatment outcomes and (iii) delivery of ART in resource limited settings, and 
(iv) the development of national antiretroviral therapy programme in the Thai universal 
health settings. At the end of this chapter, a broad conclusion of the main lessons identified 
in the literature review is presented.
2.1 Methodology
2.1.1 Database searches
Electronic and non-electronic searching was undertaken between September 2005 and Jan 
2007. Re-searching was performed during September-October 2008. The main databases 
searched were Medline (1966-present) and the Cochrane Central Register of Controlled 
Trials (Clinical Trials; CENTRAL). Hand searching was also conducted for the following 
Journals: AIDS (1987-2008); Journal of acquired immune deficiency syndromes (1996- 
2008); AIDS care (1989-2008) and; HIV clinical trials (2000-2008)
2.1.2 Search terms
For Medline and the Cochrane Library searching, keywords were used according to MeSH 
term (Medical Subject Heading) which is the U.S. National Library of Medicine's controlled 
vocabulary used for indexing articles for MEDLINE/PubMed as these terminologies provide 
a consistent way to retrieve information that may use different terminology for the same 
concepts. The MesH terms were used either singly or in various combinations (see Table 2- 
1)
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Table 2-1: Searching results via Medline using MeSH terms
Search using MeSH term via Medline* As major topic; As keywords;
number of article number of article
found found
Survival study regarding ART
Survival; OR 
Mortality; OR 
Survival rate; OR 
Survival analysis;
AND HAART 18 680
AND HAART ; AND Developing countries 
Health-related quality of life
0 16
Quality of life
AND HAART 58 192
AND HAART ; AND Developing countries 
Treatment outcomes of ART
0 1
Treatment outcomes
AND HAART 14 1564
AND HAART; AND Developing countries 
Factors associated with HAART
0 43
Socioeconomic factors; OR 
Health service needs and demand; OR 
Social class; OR 
Population characteristics
AND HAART 288 1608
AND HAART ; AND treatment outcome 0 259
AND HAART ; AND Developing countries 7 79
AND HAART; AND Developing countries; AND 0 10
treatment outcome
ART delivery
National health programs; OR 
Delivery of health care; OR 
Health policy; OR
Delivery of health care, integrated; OR 
Health services accessibility;
AND HAART 576 1418
AND HAART ; AND Developing countries 19 96
* As on September 9, 2008; MeSH=Medical subject heading
2.1.3 Selection process
Titles and abstracts (where available) were scanned; potentially relevant abstracts in English 
were retrieved or downloaded for obtaining full text articles. References or bibliographies of 
retrieved articles were scanned for further relevant articles. References were stored and 
managed using Endnote Programme (version 10; Thomson ResearchSoft)
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2.2 ART treatment outcomes
2.2.1 Survival
As HIV/AIDS is a fatal disease, the successes of the treatment are then usually measured 
through the survival or mortality of the patients. The pattern of mortality has been changed 
since the introduction of HAART in 1996. As described in a French retrospective study 
which showed that the causes of death were no longer AIDS-related (Bonnet, Morlat et al.
2002). This suggests the requirement for changing of clinical monitoring of HIV/AIDS 
patients. The findings agreed with that found in a study from the USA which showed that 
the mortality rate of HIV/AIDS-related death also decreased while the rate of non 
HIV/AIDS-related death was quite stable (Louie, Hsu et al. 2002) or even increased (Lau, 
Gange et al. 2007). A Swiss study also showed the positive impact of HAART. In this 
study, the hospital mortality and length of stay for HIV-related admission of HIV-infected 
patients were declined. The annual number of admission of HIV/AIDS also decreased. 
However, the number of intensive care unit admission of HIV/AIDS patients increased 
(Nuesch, Geigy et al. 2002). Still, the mortality in HIV-infected patients even in those with a 
good initial response to HAART is still higher than in the general population (van Sighem, 
Danner et al. 2005) as HIV infection continues to contribute to the premature deaths among 
adults, mainly because of the late presentation (Kumar, Kilaru et al. 2006).
The positive effect of HAART has also been demonstrated in children. HAART was found 
to be associated with a marked decline in the progression to AIDS, improved survival in 
HIV-1-infected children, reduced incidence of infections and hospitalizations and decreased 
incidence of some organ-specific complications of HIV (Sanchez, Ramos Amador et al.
2003). In developing country such as Puerto Rico, the epidemic of HIV/AIDS mortality has 
also been changed since the implementation of HAART. HIV/AIDS death was significantly 
reduced (Mayor, Gomez et al. 2005). In Brazil which was the first developing country to 
provide fee and universal access to ART, between 1999 and 2004 conditions usually
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considered not to be related to HIV-infection appeared to become more likely causes of 
death over time than reported causes of death among individuals who had HIV/AIDS listed 
on the death certificate than in those who did not (Pacheco, Tuboi et al. 2008). This 
observation has important programmatic implications for developing countries that are 
scaling-up access to antiretroviral therapy
2.2.2 Health- related quality of life
HIV infection is generally associated with low quality of life (Miners, Sabin et al. 2001) and 
has been the subject of evaluation since zidovudine was used in HIV-infected patients (Wu, 
Mathews et al. 1990). Such analyses provide the patients’ perspective such as in the case of 
zidovudine, where single therapy was found to decrease quality of life (Wu, Rubin et al. 
1993); (Lenderking, Gelber et al. 1994). Before the availability of HAART, mortality 
seemed to be the dominant outcome (Mellors, Munoz et al. 1997); (Wu 2000). However, 
now quality of life has become a primary goal of treatment as patients live longer and the 
therapy might cause various adverse effects (Wu 2000); (Henry 2000). The regimen should 
be chosen regarding tolerability of the patients as well as its effectiveness
In health research when we use the term “quality of life”, it usually refers to health-related 
quality of life (HR-QOL) which includes several dimensions such as mental and physical 
perceptions of their health (Wu 2000). Quality of life data have added useful information to 
treatment trials which sometimes supports the findings of the trials (Bozzette, Kanouse et al. 
1995); (Revicki, Moyle et al. 1999); (Nieuwkerk, Gisolf et al. 2000), and sometimes 
contradicts trial outcomes (Saffin, Finkelstein et al. 1996) emphasising the importance of 
obtaining information of adverse effects and tolerability rather than just survival 
(Nieuwkerk, Gisolf et al. 2001) or adherence (Protopopescu, Marcellin et al. 2007)
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Evaluation of HR-QOL through standardized questionnaire is usually less invasive and less 
time consuming compared to laboratory testing. Data collection requires adequate training 
of interviewers or/and investigators to reduce the potential biases that might occur during 
the evaluation. When assessing people with poor literacy and education, data collection 
procedures should be tailored to get adequate and accurate information with missing data 
being reduced as far as possible (Wu 2000). Many standardized questionnaires have been 
proposed to measure HR-QOL, however, no gold standard has yet been established. 
Questionnaires can be divided into two broad categories (i) general measure such as EQ-5D 
(Jelsma, Maclean et al. 2005); (Brown, Thome et al. 2006); (Louwagie, Bachmann et al. 
2007), McGill Quality of life Questionnaire (Cohen, Hassan et al. 1996), Short form (SF) 12 
(Burman, Grund et al. 2008), SF 36 (Carrieri, Spire et al. 2003); (Burgoyne and Renwick
2004); (Preau, Leport et al. 2004); (Liu, Ostrow et al. 2006); (Protopopescu, Marcellin et al. 
2007), World Health Organisation Quality of Life questionnaire (WHOQOL-BREF) (Yen, 
Tsai et al. 2004); (Byme and Honig 2005), NeuroQOL questionnaire (Parsons, Braaten et 
al. 2006) and (ii) disease specific measure such as MOS-HIV (Nieuwkerk, Gisolf et al. 
2001); (Guaraldi, Murri et al. 2008) for HIV-infected patients. Recently, an Italian research 
group has developed the new set of self-administered questionnaire which is called Istituto 
Superiore di Sanita-Quality o f life (ISSQoL) as an instrument to evaluate quality of life 
(Bucciardini, Murri et al. 2006). In children, different questionnaires are used such as Child 
Health Questionnaire parent short form (CHQ-28) (Byme and Honig 2006). Using disease 
specific questionnaires does not guarantee better information as one study comparing the 
qualitative approach against the MOS-HIV found that the questionnaire missed or under­
emphasized certain dimensions of HR-QOL in PLHA (Park-Wyllie, Strike et al. 2007).
A range of studies have shown that improved biological markers such as HIV viral load and 
CD4 cell counts lead to improved health related quality of life (Gill, Griffith et al. 2002); 
(Jia, Uphold et al. 2007), which in turn leads to good adherence to the medication
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(Mannheimer, Matts et al. 2005). Regarding HAART itself, quality of life has been found 
to be poorer in patients who have switched regimen more than once (Protopopescu, 
Marcellin et al. 2007). In relation to patients perception, the baseline support and depressive 
symptoms have been found to be associated with positive and negative changes in physical 
function after 12 months of treatment (Jia, Uphold et al. 2005) and that active social support 
might help patients’ mental health (Miners, Sabin et al. 2001); (Liu, Johnson et al. 2006); 
(Jia, Uphold et al. 2007).
Quality of life tends to be more sensitive to symptom changes rather than immunological or 
virological changes (Burgoyne, Rourke et al. 2004). Some adverse effect such as 
lipodystrophy which can be caused by either Pi-contained or NNRTI-contained HAART 
regimen and can be perceived visually by patients, were found to be strongly associated 
with HR-QOL. Individuals with more severe lipodystrophy has worse quality of life 
(Guaraldi, Murri et al. 2008). In terms of psychomotor, it was found that the success or 
failure of HAART defined using both immunological (CD4 cell counts) and virological 
(HIV viral load) measurement was strongly associated with psychomotor; PLHA with 
slower psychomotor processing were more likely to fail (Parsons, Braaten et al. 2006).
The course of treatment is also significantly related to HR-QOL with quality of life being 
unchanged after the induction phase (Burgoyne and Renwick 2004); (Jelsma, Maclean et al.
2005); (Protopopescu, Marcellin et al. 2007). In one study, HR-QOL was found to be stable 
two years after the initiation of HAART (Burgoyne, Rourke et al. 2004). This can be 
explained by the fact that HAART can restore the patients’ health and most of the changes 
occur during the initiation period. As disease progresses, their health might decline despite 
using HAART. This was confirmed by one small study of 68 participants over ten years 
(1994-2004), where participants’ physical health tended to deteriorate over time while 
mental health was improved by using HAART (Liu, Ostrow et al. 2006).
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Studies regarding quality of life in PLHA being treated with HAART are still limited in 
developing countries. However, some studies from those countries have shown the positive 
effect of HAART on quality of life. A study in South Africa suggested that using HAART 
was associated with higher level of HR-QOL (Louwagie, Bachmann et al. 2007) and similar 
findings arose in Senegal (Poupard, Ngom Gueye et al. 2007) and Uganda (Stangl, Wamai 
et al. 2007). These studies, nevertheless were conducted in the induction phase thus, longer 
follow up is required to assess the effects of HAART on HR-QOL in the long term.
2.2.3 Improvement of CD4 cell count
The CD4 count assesses the level of immune response while HIV is affecting the patients’ 
bodies. It is used to understand how strong the immune system is (Yarchoan, Venzon et al. 
1991); (Butler, Husson et al. 1992); (Allardice, McMenamin et al. 1998); (Chene, Binquet et 
al. 1998). In contrast, the viral load test measures the amount of HIV virus circulating in the 
patient blood. Regular monitoring of the CD4 count and viral load provides a good 
indication of the effects of HIV on patients’ bodies (Hughes, Johnson et al. 1997); (O'Brien, 
Hartigan et al. 1997); (Hill, DeMasi et al. 1998). Test results can be used to interpret in the 
context of the course of HIV disease progression. Results of patients’ CD4 count can help to 
make decisions about time to initiate HIV treatments (Kaplan, Hanson et al. 2003); (Wood, 
Hogg et al. 2004) or therapy to help prevent developing opportunistic infections (Hengel, 
Allende et al. 2002).
In term of the immunological response in relation to CD4 count, after the advent of 
HAART, many studies have demonstrated continuously the benefit of HAART in 
restoration of immune system (DeHovitz, Kovacs et al. 2000) The benefits also included 
preventing of opportunistic infection and HIV/AIDS related carcinoma (Jacobson, Li et al. 
2002). Thus, it is imperative for monitoring of CD4 cell count continuously. Furthermore,
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regarding the 3 by 5 initiative by WHO/UNAIDS, the level of CD4 count is one of the two 
recommended indicators (CD4 count and body weight gain) to monitoring the impact of 
national ART programme in rapid scaling up of the 3 by 5 initiative (WHO 2004); (WHO 
2004) as it is comparatively inexpensive comparing to plasma viral load.
2.2.4 Changing of prescribing regimen
There are two main reasons for the patients to change their prescribed regimens; either 
developing drug resistance or adverse events. In resource-limited setting, clinical and 
immunological assessment (CD4 cell counts) are primarily used for initiation of the 
treatment, therapeutic monitoring and switching of ART regimens as the viral load is not 
always available (UNAIDS 2008). Antiretroviral treatment failure is, however, required to 
be measured by the viral load and genotyping for accurate detection. It is imperative that 
developing countries are equipped with these laboratory tests as drug resistance is 
unavoidable during the course of treatment. In one large survey in the USA three years after 
the widely use of HAART, it was estimated that 76% of patients had developed resistance to 
at least one ARV drug (Richman, Morton et al. 2004). However, as clinical management has 
been improved over time, the occurrence of drug resistance tends to be reduced (Phillips, 
Gazzard et al. 2007). A UK study found that 11% of patients would die in five years 
according to broad failure of three classes of ARV drugs (Phillips, Gazzard et al. 2007). 
Drug resistance might be even more problematic in developed countries and to lower the 
rate of drug resistance, HIV care should enhance adherence as there is an inverse 
relationship between adherence and drug resistance; the higher the rate of drug adherence, 
the lower the level of drug resistance (Moatti, Spire et al. 2004); (Lucas 2005).
Adverse effects are not uncommon for HIV-infected people taking HAART, with about half 
of patients experiencing adverse effects (UNAIDS 2008). ARV drugs have both short term 
and long term side effects. Types of toxicity are varied according to drug class, from
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individual to individual, and could vary in severity from minor skin rashes to pancreatitis 
(Montessori, Press et al. 2004). As the number of drugs increase as the disease progresses, 
the risk of developing adverse drug reaction increases (Sollitto, Mehlman et al. 2001) 
potentially causing patient non-adherence to the medication or to discontinuation of 
treatment altogether. Management of adverse events is an essential part of ARV 
administration, and very challenging as, in developing countries, drug substitution may not 
be as feasible, making management even more complicated (UNAIDS 2008).
2.3 Factors influencing access and treatment outcomes
2.3.1 Gender
The association between gender and the utilization of HAART has gained prominence since 
the invention of HAART even in the developed countries. For instance, in one large 
interview based study the inadequate access to antiretroviral therapy was found among 
African Americans and women after the CD4 cell counts adjustment (Shapiro, Morton et al. 
1999). This was consistent with one study published earlier which demonstrated that women 
were at risk of delay to get the HIV/AIDS care after the HIV diagnosis compared to men 
especially in group of women who learned their HIV status during their pregnancy 
(Ickovics, Forsyth et al. 1996). Similar findings were found in one large cohort of 9,530 
patients, being female and being alcoholic decreased the likelihood to be prescribed with 
HAART (McNaghten, Hanson et al. 2003).
These findings also go in the same direction with results from studies assessing the use of 
HIV/AIDS care at various types of facilities which suggests poorer accessibility to HAART 
of women (Anderson and Mitchell 2000). Moreover, this was that found to be associated 
with perception of the patients which in one Australian study has revealed that men 
expressed more favourable attitudes towards HAART than women (McDonald, Bartos et al. 
2001)
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Gender and the use of HAART in resource-limited settings were recently explored. In 
Malawi, the national antiretroviral therapy programme has initiated in the fourth quarter of 
2004. At the beginning, it was concerned that men rather women would be the majority who 
benefit from the programme (Makombe, Libamba et al. 2006). However, the programme 
has progressed, the disparity between men and women were still low (with the ratio of male 
to female=6:4). However, children were still not the target for the treatment programme, in 
one multi-centre study in 13 countries, the number of women who were prescribed with 
HAART were higher compared to men (Beusterien, Davis et al. 2008). This was later 
confirmed by UNAIDS report in 2008 which shows that the coverage of HAART in women 
is higher or at least equal to men in most of the countries (UNAIDS 2008). This might be 
due to that at the initial stage, women were perceived as risk group for poor access to 
HAART from what have found in previous studies which brought in everyone’ concern 
during the scaling up period. But at the moment after worldwide scale up of ART, the 
evidence came up again that women were better than or equal to men in term of accessing 
HAART.
From the studies above, we found that ethnicity and gender are factors that can determine 
the pattern of HIV/AIDS cares utilization. Aside from the affect of ethnicity/gender on 
access, they also have an effect on treatment outcomes as they are ones of the baseline 
biological determinants of HIV/AIDS. Ethnicity and gender were also found to be related to 
biological difference as shown in one study which suggested that the different in the values 
of HIV-1 RNA and the rate of HIV-1 disease progression might be due to the influence of 
differences in gender and ethnicity (Anastos, Gange et al. 2000).
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2.3.2 Low socioeconomic status
The relationship between socioeconomic status and the outcome of HIV/AIDS care has been 
analysed since it was found to be an independent predictor of HIV disease progression 
before the advent of HAART (Schechter, Hogg et al. 1994); (Chaisson, Keruly et al. 1995). 
Socioeconomic status was found to be a significant predictor of death for low income men 
despite adjustment for age at infection, CD4 count, use of mono or dual therapy, use of PCP 
prophylaxis, and years of infection were also found to be a significant predictor in disease 
progression. However, another study found no association between socioeconomic status 
and progression to AIDS and AIDS-related mortality (Wood, Montaner et al. 2002). Such 
different findings might be due to different care pathways with differences in HIV disease 
progression being due to the poor access or use of HIV/AIDS care among people with low 
socioeconomic status. For instance, it was found that HIV-related mortality was strongly 
associated with socioeconomic status, with persons from low socioeconomic status being 
less likely to be prescribed triple therapy (Wood, Montaner et al. 2002). However, the 
difference in survival by neighbourhood income level disappeared after controlling for 
HAART utilization (McFarland, Chen et al. 2003).
Even in the context of universal health coverage providing HAART at no cost, one Italian 
study showed that differences in survival of persons with AIDS still emerged by 
socioeconomic status. Such results may be explained by poor access to health care and poor 
adherence to treatment (Rapiti, Porta et al. 2000). The findings were similar with that of two 
subsequent studies. A study by Wood found that people from lower socioeconomic status 
were less likely to be prescribed HAART and their mortalities were higher compared with 
patients with high socioeconomic status (Wood, Montaner et al. 2002). A second study 
found that despite adjusting for age and CD4 cell count at start of treatment, less than 70% 
of patients with low socioeconomic status but more than 85% of patients with high 
socioeconomic status survived beyond five years of diagnosis (McFarland, Chen et al.
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2003). These findings suggest that socioeconomic status, by influencing access to HAART, 
significantly affects the outcomes of ART in terms of mortality and disease progression.
2.3.3 Education
High long term adherence is required for the good outcome of the ART, thus, patients' 
education is an important factor to make the patients adhere to the treatment as shown in one 
study that the patients with marginal to low literacy were 3.3 times more likely to be non­
adherence to HAART (Wolf, Davis et al. 2007). Patients' satisfaction with information they 
received about the treatment was also one of the important factor to make patients adhere or 
decline the treatment (Gellaitry, Cooper et al. 2005). Thus, providing information tailored 
to meet the needs of individual patients and address their specific concerns, in order to 
support informed decision making is required in the HIV patients. Moreover, a study from 
the USA has shown that patients with lower educational attainment less likely to gain access 
to HAART (Keruly, Conviser et al. 2002). In General, patients with low education 
attainment were less likely to be benefit from HAART.
2.3.4 Health insurance
It was also found that antiretroviral treatment tended to be prescribed in people with private 
insurance (who are usually richer) rather than other types of payers (Shapiro, Morton et al. 
1999); (Keruly, Conviser et al. 2002); (McKinney and Marconi 2002). A study of nearly one 
thousand HIV-infected patients highlighted type of medical insurance as a factor 
determining receiving ART (Keruly, Conviser et al. 2002). In this study, it also found that 
females, non-white patients, IDUs, patients with lower educational attainment and patients 
with high CD4 cell counts/low viral load were also less likely to gain access to HAART 
(Keruly, Conviser et al. 2002). A study by Bhattacharya demonstrated better performance of 
private insurance over public insurance in protecting against premature death (Bhattacharya, 
Goldman et al. 2003).
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2.3.5 Accessibility
Access to antiretroviral therapy (ART) for patients in low- and middle-income countries has 
become an increasing global public health and political concern. There are three main 
factors that have contributed to the expansion of ART in developing countries (Kovsted 
2005). Firstly, the high and increasing prevalence rate of HIV/AIDS in developing countries 
requiring more resources to contain the problem and greater problems in accessing the 
treatment. Secondly, the concentration by the media on HIV/AIDS which partly results from 
aggressive NGOs driving the confrontation with pharmaceutical companies and negotiating 
on drug prices for poor countries. Thirdly, HAART became perceived as a fundamental 
human right and a high priority within public health.
Equality of access to ART should be a concern of policy makers as there is growing 
evidence that access to treatment is lower in underserved groups of population such as 
people with lower socioeconomic status (Marmot, Smith et al. 1991), ethnic minority 
(Fiscella, Franks et al. 2000) and injecting drug users (Strathdee, Palepu et al. 1998). 
Moreover, treatment outcomes such as HIV-related mortality were found to be poorer in 
these groups (Marmot, Smith et al. 1991); (Hogg, Strathdee et al. 1994); (Strathdee, Palepu 
et al. 1998); (Fiscella, Franks et al. 2000).
2.3.6 Self-help group
The shortage of health manpower in developing countries can severely aggravate the 
problem of poor accessibility to HAART (Muula, Chipeta et al. 2007); (Philips, Zachariah 
et al. 2008). It also poses unfeasible monitoring demands, drain valuable resources from 
more important prevention efforts (Lange and van der Waals 2002) as one study also 
revealed that 85 clinical officers and physicians and 91 nurses had to provide HAART to 
nearly 100,000 PLHA. The requirement was far less use of human resources than would be 
estimated based on the literature from other countries (Muula, Chipeta et al. 2007). The 
group of volunteer health workers might help to alleviate the problem. This role of the group
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requires cooperation with community similar to that described by Farmer in 2001 about a 
community based approach to ART in rural Haiti (Farmer, Leandre et al. 2001). The 
contribution of self help group to the outcome of ART has been demonstrated continuously. 
For instance, it might assist PLHA to adhere to the treatment as well as to support the 
members throughout the course of the treatment as showed in one study (Lyttleton, Beesey 
et al. 2007). However, the study was done qualitatively with no outcome measures. At 
present, the evidences support the benefit of self-help group to the ART still need 
clarification.
2.3.7 Baseline CD4 cell count
Initial CD4 cell count is one of the most important factors that play a role determining the 
point the start to the treatment (Kaplan, Hanson et al. 2003). In developing countries, most 
of the patients start the treatment at a low level of CD4 cell count (usually less than 200 
cell/uL), However, the benefit in term of mortality reduction can still be observed 
(Bogaards, Weverling et al. 2003).
The initial CD4 cell count also implied the physical well being, role function and health 
perception (Gill, Griffith et al. 2002). Moreover, it is also found that the low initial CD4 
cell count was highly associated with the opportunistic infection such as cytomegalovirus 
infection (Salmon-Ceron, Mazeron et al. 2000). It was also considered a prognostic factor 
for the progression of disease, CD4 cell count (less than 200 cell/uL) was a determinant of 
being AIDS (Jacobson, Li et al. 2002); (Hulgan, Raffanti et al. 2005), mortality (Bedell, 
Heath et al. 2003) and a naïve CD4 cell count at baseline influenced the immunological 
recovery in both adults (Michael, Kirk et al. 2002) and in children (Nikolic-Djokic, Essajee 
et al. 2002). From what mentioned earlier, it is challenging to evaluate the effects of the 
CD4 cell count at baseline on the treatment outcomes.
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2.3.8 Disease staging
The staging of HIV/AIDS can be done in a various way; following the definitions of the US 
Centers for Disease Control and Prevention (CDC) or WHO staging (Canestri, Sow et al. 
2007); (Natu and Daga 2007). In 2003, WHO had developed a guideline for antiretroviral 
therapy which was designed to be used in developing countries. From the investigation in 
2006, it has found that the 43 countries with 3 by 5 initiatives had developed their own 
guideline for the ART national programme which mostly derived from the WHO’s 
guideline. According to the guideline , the point for initiation of HAART require not only 
the CD4 cell count but also the clinical staging (Erhabor, Uko et al. 2006); (Canestri, Sow 
et al. 2007). WHO clinical staging has found to be a good predictor of those who needs 
HAART (Lynen, Thai et al. 2006). However, the WHO classification was not sensitive to 
change to see the benefit of the treatment after the initiation of the therapy (Natu and Daga 
2007). In the present study, it might be useful to assess the contribution of the baseline 
WHO staging on the treatment outcomes.
2.3.9 Regimen of ART
The development of ART has been done continuously from single regimen to triple regimen 
which is the current standard treatment for HIV/AIDS. Since the introduction of zidovudine 
in 1987, over 2,000 combinations of ARV regimens have been recorded (Ghani, Donnelly 
et al. 2003) and most of the modification of the treatment in the majority of patients was 
usually due to minor toxicities whose incidence was similar for Pi-based and NNRTI-based 
regimens (Collier, Conway et al. 2009)
In term of effectiveness of different regimens, it found that regimens of ART; NNRTI (Non­
nucleoside Reverse Transcriptase Inhibitor) -based or PI (Protease inhibitors) -based 
regimen were not associated with the immunological benefit of the treatment 2000); 
(Waters, Stebbing et al. 2004). However, a recent study from the USA showed that first-line
25
Literature Review
2NRTIs + NNRTI was cost-effective or cost-saving when compared with Pi-containing 
regimens for all lines of therapy.
One of the concerns for choosing HAART regimen was not only its efficacy but also the 
patients' quality of life. Pi-based therapies often fail due to poor adherence caused by heavy 
pill burden, complex dosing schedules and undesirable side effects. The current trend is to 
switch from Pi-based to Pi-sparing regimens (Zhang, Hamatake et al. 2004). Despite some 
encouraging results from NNRTI-containing therapies, two major concerns in using the 
currently available NNRTIs remain: (i) low genetic barrier to the emergence of drug 
resistance and (ii) cross-resistance due to single mutations that often render the whole class 
of NNRTIs ineffective. In term of adverse event, it was found that Pi-based regimen was a 
significant risk factor for hypercholesterolemia (Tassiopoulos, Williams et al. 2008) while 
stavudine-contained regimens were associated with pancreatitis (Riedel, Gebo et al. 2008) 
and lipodystrophy was the common side effect that can occur from both types of regimen 
(Monnerat, Cerutti Junior et al. 2008). From the review above, it can be seen that different 
regimens yield different outcomes both positive and negative, thus, it is challenging to 
identify the contribution of different types of ART regimens on the treatment outcomes.
2.3.10 Type of ARV clinic: doctor-led versus nurse-led clinic
The Nurse practitioners have been established in North America for several decades
(Brown and Grimes 1995). This was also mainly due to the shortage of doctor workforce. 
Moreover, the increasing roles of nurse practitioners have also been accepted in UK 
(Horrocks, Anderson et al. 2002) and Australia (Offredy and Townsend 2000). In the UK, 
NHS policy regarding NHS walk-in centres, NHS Direct, and nurse led personal medical 
services schemes have been developed and based on nurses rather than physicians acting as 
first point of contact with the health service (Horrocks, Anderson et al. 2002). Factors 
related to this trend of expansion in the role of nurse practitioners are improve accessibility,
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availability and potentially cost saving. One review compared outcomes of care between 
nurse practitioners and physician in primary care in the USA was done in 1995 (Brown and 
Grimes 1995). A review from the USA showed that nurse practitioner had potential to 
deliver cares equivalent to doctor in term of quality of care. This was corresponded with a 
review in the UK assessing of the quality of care in short-term which showed equivalent 
outcome of cares delivered by nurses and doctors.
The shortage of doctors to provide cares in decentralized setting occurs in both developed 
and developing countries, nurses and other trained medical personnel play an important role 
to provide various types of care (Cullum, Spilsbury et al. 2005); (Walsh, Steiner et al. 2005) 
as mentioned earlier which might be able to apply to antiretroviral therapy. However, given 
the complexity drugs themselves, some are specific and some are general, providing cares 
by nurses has both potential advantages and disadvantages
In relation to provider costs, It has been purposed that nurse practitioners have potential to 
save costs of delivery ART due to generally lower salary (labour costs) of nurses compared 
to that of doctors and nurses tend to prescribe drugs strictly to the given protocol or 
guideline. However, two systematic reviews showed no support convincing the possible 
lower costs of care delivery by nurses (Laurant, Reeves et al.); (Bazian 2005). The review 
by Laurant also suggests that the degree of cost saving were depended on magnitude of 
salary differences between doctors and nurses and saving cost might be offset by the lower 
productivity of nurses compared to doctors (Laurant, Reeves et al.). In relation to the user 
costs which related to the expense travel expense to come visiting hospital and opportunity 
costs such as wage lost, this depends on setting of health facilities. In decentralized setting 
where nurses delivered ART cares, patients are more accessible, thus, lower user costs are 
expected.
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Concerning accessibility to the ART, the decentralized settings such as community hospitals 
or health centres play and important role to provide ART. However, due to the usual 
shortage of doctor workforce in those settings, nurses are assigned to respond to works 
previous done by doctors. In this case, trained nurse practitioners delivering ART might be a 
feasible mechanism to scale up the treatment to increase the coverage of the programme. 
Moreover, the reachable decentralised setting would make patients incur less expense to 
come visiting and shorter distance to travel. Regular attendance is, then, anticipated which 
will have an effect on patient compliance to the treatment.
In relation to the services, nurse practitioners usually give services under the supervision or 
collaboration with doctors. Thus, in this case, their tasks are rather specific to the ART 
cares, and they might not be able to deal much with complicated cases. However, they are 
potential to have more time to provide more information regarding ART to patients, longer 
consultation time and shorter waiting time compared to doctors. This corresponds with three 
systematic reviews presented earlier which might result in higher satisfaction and higher 
compliance to the treatment (Laurant, Reeves et ah); (Brown and Grimes 1995); (Horrocks, 
Anderson et al. 2002). In relation to the doctor workloads, the reviews by Laurant made a 
notice that doctor workload, however, might not be reduced by the presence of nurse 
practitioners (Laurant, Reeves et al.). Many potential advantages of the nurse practitioners 
delivering ART have been purposed, however, they are not evident, thus, it is important to 
identify the potential contribution of ART mode of delivery to the treatment outcomes 
which is one of the objective in this study.
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2.3.11 Underserved population for ART
2.3.11.1 Ethnic minority
Ethnicity is considered to be a major factor influencing the disparity in access to HAART. 
In the US, mortality and opportunistic infection were elevated among African American 
patients due to the advanced stage of disease at which treatment is initiated and less frequent 
use of PCP (Pneumocystis carinii pneumonia) prophylaxis (Easterbrook, Keruly et al. 1991). 
In a subsequent study, it was shown that race (African Americans) was the feature most 
strongly negatively associated with being prescribed antiretroviral therapy and PCP 
prophylaxis. No significant differences were identified in respect to age, sex, mode of HIV 
transmission, type of insurance, income, education, or place of residence (Moore, Stanton et 
al. 1994). African Americans have been found to be significantly less likely to be prescribed 
with HAART (Ghani, Donnelly et al. 2003) with race/ethnicity being found to be 
significantly associated with patterns of enrolment and patterns of HAART use for two 
ARV programmes (Medicaid and AIDS Drug Assistance Programme) (Kahn, Zhang et al. 
2002). Such bias results from the eligibility rules, especially financial status which 
emphasizes the role of providers as one of the main barriers to access to HAART (Kahn, 
Zhang et al. 2002) and implies the significant role of State policies in reducing disparities in 
access to HIV drugs (Morin, Sengupta et al. 2002). The relationship between ethnicity and 
HAART was confirmed by one systematic review (see Table 2-2), which emphasized the 
racial/ethnic disparities that existed regarding utilization of HAART and other related 
medication (Palacio, Kahn et al. 2002),
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Table 2-2: Summary of systematic review identifies the association between race/ethnicity and 
HIV- related medication utilization
Objective To identify the association between race/ethnicity and HIV-relation
medication utilization
Systematic review ■ 28 reports including 40 studies were identify
summary ■ 14 studies found to that people whose race/ethnicity other than
white were less likely to be prescribed with HAART 
■ 4 studies found that non white were less likely to be prescribed
with opportunistic infection prophylaxis
Reviewers conclusions The racial/ethnic disparities in term of HAART and related medication 
utilization are existed.
Reference Palacio H, Kahn JG, Richards TA, Morin SF. Effect of race and/or
ethnicity in use of antiretroviral drugs and prophylaxis for opportunistic 
infection: a review of the literature. P u b lic  H ea lth  R ep  
________ 2002;! 17(3):233-51; discussion 31-2.____________________ _________
2.3.11.2 Illicit drug users
Injection drug use is known as a primary risk for getting HIV infection, and the people who 
use these substances (illicit drug user-IDU) are one of the risk groups not to access to 
medical treatment, in relation to HAART, this is no exception. Knowing that patients are 
IDUs can affect the doctor decision to initiate HAART. One review from Ireland has found 
that physicians are generally reluctant to prescribe HAART for these patients due to 
possible poor adherence, and the potential for complex drug interactions to occur (Clarke 
and Mulcahy 2000). This finding was similar to that found from a survey in group of ART 
providers in the USA, it has been shown that there are resistant from the providers to 
prescribe ART to PLHA with history of drug user especially from physicians (Loughlin, 
Metsch et al. 2004). This might be due to the findings of study explored duration of initial 
regimen which showed that duration on first regimen prescribed in group of IDUs was 
significantly shorter comparing to those non-drug users (Chen, Westfall et al. 2003). It 
implied frequent change of drug regimen among this group of patients. This is raising 
another reason for not prescribing HAART to IDUs which is fears that it may result in 
elevated rates of drug resistance, However, there is no current study can demonstrate higher 
rate of drug resistance among IDUs prescribed with HAART (Wood, Hogg et al. 2005); 
(Aceijas, Oppenheimer et al. 2006); (Lert and Kazatchkine 2007). This makes IDUs less
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likely to access to antiretroviral treatment. One USA study has shown that nearly one third 
of IDUs who are eligible for HAART were never been prescribed with HAART 
(Celentano, Galai et al. 2001). And when HAART was prescribed, its findings has shown 
that disease free survival were extended in both drug users and non-drug users, however, 
this benefit were shorter amongst group of IDUs (Poundstone, Chaisson et al. 2001). These 
findings was consistent with the subsequent studies from Norway and multi-centre study in 
Europe which show less explicit of effectiveness of HAART in relation to progression to 
AIDS, life-expectancy and HIV-related mortality in IDUs compared to other group of 
patients (Amundsen and Fekjaer 2003); (Chen, Westfall et al. 2003); (van Asten, Boufassa 
et al. 2003); (Mocroft, Gatell et al. 2004); (Galai, Vlahov et al. 2005); (Lloyd-Smith, 
Brodkin et al. 2006).
The coverage of HAART in IDUs in developing and transitional countries is found more 
problematic, one review has described that among these 50 countries, 34,000 IDUs have 
access to the treatment and approximately 30,000 were in Brazil. The situation is worse in 
South-east Asia where only 1.8% of IDUs can access to the treatment (Aceijas, 
Oppenheimer et al. 2006). However, the poorer effective and prognosis of HAART of IDUs 
in Brazil was not much different found what found in previous studies (Melo, Caiaffa et al. 
2006). The UN AIDS report in 2008 also mentioned that the IDU is a group at risk not to 
accessing HAART (UNAIDS 2008). From the findings above, they suggests the less likely 
for IDUs to get access to the antiretroviral treatment, but when they were prescribed, the 
benefit from the treatment was less clear comparing to other group of patients. This might 
be due to the poor acceptance and poor adherence of the treatment which was the result 
from chaotic lifestyle and complex social background (Zaccarelli, Barracchini et al. 2002); 
(Clarke, Delamere et al. 2003); (Tourret, Tostivint et al. 2007).
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2.3.11.3 Children
In the report by the UNAIDS recently, it has stated poorer access to HIV/AIDS care 
including ART in the group HIV-infected children (UNAIDS 2008) even though there was 
an evidence that the effectiveness of ART in children was similar to that observed in the 
adults (Gortmaker, Hughes et al. 2001). And in spite of the fact that children with 50% of 
children with HIV will died in the first two years without any treatment (Fassinou, Elenga et 
al. 2004) and 89% will died before their third birthday (Taha, Graham et al. 2000), coverage 
of HAART in children tended to be relatively lower compared to adults (UNAIDS 2008). In 
the developed countries like in the USA, the number of children with HIV is now 
diminishing due to one important factor is that they are managed to survive by HAART and 
growing up becoming adults (Harwell and Obaro 2006). By far, the substantial benefit of 
providing antiretroviral treatment in children can be envisaged, and scaling up the ART in 
this population subgroup requires higher attention.
2.3.11.4 Gay men
Gay men are another group at risk of less access to HAART as this might be caused by less 
awareness of HAART in this group. A study in young American gay men (aged 17-22) with 
ethnicity diversity, it has found that they did not aware of HAART after two years since its 
introduction (Koblin, Perdue et al. 2003). In another study which conducted in six thousand 
gay men in five big cities including Paris, London, Melbourne, Sydney and Vancouver, it 
has shown that gay men in these cities were not much optimistic toward HAART despite the 
fact that these cities had provide HAART free of charge for more than four years at the time 
of study conducted (Optimism 2003). In one study, it has shown that nearly 15% of men 
who have sex with men (MSM) were using antiretroviral care less than recommended level 
(poor adherence), and in addition to this, their youth was found to be a barrier to ART (Stall, 
Pollack et al. 2001).
2.3.11.5 Sex workers
Sex workers are another disadvantage group to access to HAART as they are suffered from 
the attitude that they are not worthy of the treatment. They might be also reluctant to seek
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for HIV testing and the initiation of antiretroviral treatment is usually delayed. This can 
cause the treatment less effective and the opportunistic infection may prevent the use of 
ART (Wood, Montaner et al. 2003). People who are in prison also have known to be likely 
to be delay to get HAART (Pontali 2005). Another group is people in place where political 
instability which creates population movement are also considered as vulnerable group of 
ART as continuity of the treatment (adherence) appeared to be difficult (Saracino, El- 
Hamad et al. 2005). Another risk group is people with low education like those mentioned 
in one study from the USA with convenient sample of 204 PLHA, it has shown that around 
one-third of PLHA had limited literacy skill. Moreover, they were tended to have a poorer 
understanding of essential aspects of ART which could cause problem of access and adhere 
to HAART (Wolf, Davis et al. 2005)
2.4 Effects of social inequality on benefit of HAAR T
Most of studies mentioned above aim mainly at studying the access or prognosis of patients 
such as progression of the disease and HIV-related mortality with HIV which were 
influenced by social and biological factors e.g. low socioeconomic, women, ethnicity 
minority and the others. However, in this vulnerable- marginalised people, other differences 
aside from disparity in term of access can also contribute to the differences of outcomes of 
ART which can confound the relationship between those factors and the treatment outcomes
2.4.1 Differences in adherence of the treatment
As HAART has turned the nature of HIV/AIDS to a chronic disease, the clinical goals of the 
treatment are to maximize life expectancy while enhancing quality of life and containing the 
adverse effects. The goals of treatment can be achieved by maintaining suppression of the 
viral load below the level of 50 copies/mL (Pilcher, Miller et al. 1999). At this level, it can 
enhance the immunological restoration as well as prevent the evolution of drug-resistance 
virus (Hermankova, Ray et al. 2001); (Hunt, Deeks et al. 2003). To attain long-term 
suppression of the virus, it requires near perfect adherence to the treatment. For poor
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adherence patient, viral drug resistance can make current treatment ineffective (Hirsch, 
Conway et al. 1998); (Hirsch, Brun-Vezinet et al. 2000); (Hirsch, Brun-Vezinet et al. 2003). 
Moreover, when this drug-resistance strain virus transmits to other people it can limit the 
options for treatment. Concerning relationship between time on treatment and adherence, a 
multi-centre AIDS cohort study has shown that poor adherence tended to develop over time 
of the treatment, and the adherence was associated with patient characteristic and 
medication factor (Kleeberger, Buechner et al. 2004).
Patient-related factors are considered as the most important determinant of good adherence 
(Chesney 2000). This includes patient socioeconomic status, psychosocial status, life style, 
and substance abuse (Bouhnik, Chesney et al. 2002); (Starace, Ammassari et al. 2002); 
(Carrieri, Chesney et al. 2003). For instance, depression which is the one of most common 
mental health problem in HIV-infected patients is considered as a risk that can cause sub- 
optimal adherence (Starace, Ammassari et al. 2002). Low adherence is also found in group 
of patients with substance abuse especially injecting drug users which have been 
demonstrated of failure to adhere to treatment (Bouhnik, Chesney et al. 2002); (Carrieri, 
Chesney et al. 2003). Moreover, interaction such as provider-patient relationship, 
communication, drug information with respect to patient education which advise patient the 
benefit and caution of the treatment are found to influence the adherence as well (Weiss, 
French et al. 2003). It might not be the direct effect of patients’ characteristics over the 
treatment outcomes, but with certain characteristics of the PLHA, it can cause patients 
difficulties to adhere and leads to poor outcomes at the end.
2.4.2 Differences in co-morbidity
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection is an 
important and frequent situation, largely found in injecting drug users (IDUs) (Rockstroh 
and Spengler 2004); (Rockstroh and Vogel 2004); (Mayor, Gomez et al. 2006). In one
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study, the prevalence of HCV was 81% in IDUs, with a predominance of HCV genotype 1. 
Patient with co-infected patients had significantly higher liver damage as a cause of 
mortality when compared with those who were not co-infected (Mayor, Gomez et al. 2006); 
(Nakimuli-Mpungu, Musisi et al. 2006). Another co-morbidity can be found with HIV 
infection are psychiatric disease (Morrison, Petitto et al. 2002); (Himelhoch, Moore et al. 
2004) especially in group of women. In one study, it has found that HIV-seropositive 
women without current substance abuse exhibited a significantly higher rate of major 
depressive disorder and more symptoms of depression and anxiety than did a group of HIV - 
sero-negative women with similar demographic characteristics (Morrison, Petitto et al. 
2002). Some findings has suggested that impairment of the immunological system might be 
the cause of depression (Cruess, Douglas et al. 2005). And, not only depression, mania 
secondary to HIV infection can be observed in people living with HIV/AIDS as well 
(Nakimuli-Mpungu, Musisi et al. 2006). Again, this showed that co-morbidity both physical 
and mental was a hidden factor that influence over the outcome
2.4.3 Differences in living conditions and health behaviour
Living conditions and life style as well as health behaviour have effects that may contribute
to course and disease progression of the HIV infection. Life style factors such as injecting 
drug use, alcohol and substance abuse, unemployment, low socioeconomic status, 
homelessness, incarceration, immigration have influences over their behaviours including 
diet, exercise, smoking, substance abuse (Dray-Spira and Lert 2003). Moreover this could 
aggravate adverse effects of the antiretroviral treatment particularly lipodystrophy 
(Tershakovec, Frank et al. 2004). Moreover, in group of injecting drug users, potential drug 
interactions between methadone, and many of antiretroviral drugs has been anticipated and 
this contribute to non-adherence and poor clinical outcome. Therefore, optimizing ART for 
IDUs is necessarily required (McCance-Katz 2005).
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2.5 Delivery of antiretroviral therapy in resource-limited settings
The treatment of HIV/AIDS has been evolved continuously (Fischl, Richman et al. 1987); 
(Volberding and Graham 1994) till present where combination antiretroviral is recognized 
as a standard of care (Rutherford, Sangani et al.); (Enanoria, Ng et al. 2004) due to its 
ability to suppress the viral replication. According to this, mortality and morbidity in the 
HIV-infected individuals are decreased (Palella, Delaney et al. 1998); (Enanoria, Ng et al. 
2004). The treatment is also accepted as a cost minimizing intervention as the potential to 
lower total health care cost and cost-effective treatment comparing to previous single and 
dual therapies as the benefits from ART were found to be outweigh the high incremental 
cost (Sendi, Craig et al. 1999); (Anis, Guh et al. 2000); (Moore 2000); (Trueman, Youle et 
al. 2000); (Freedberg, Losina et al. 2001); (Schrooten, Dreezen et al. 2002); (Sendi, Gafni et 
al. 2002); (Krentz, Auld et al. 2003) even though the cost study at that time was based on 
the relatively high drug cost that was in existence at the time of the study. This leads to the 
conclusion that cover should be expanded to all individuals who require the treatment. 
Experiences of utilization of ART, however, come mostly from developed countries as 
presented in Table 2-1; it has been shown that relatively less literatures were from 
developing countries. For instance, when combining the search term developing countries 
as MeSH major topic in field of health related quality of life, survival study or treatment 
outcomes of ART, there was no literature found from the Medline search. The applicability 
of knowledge gained in developed countries to developing countries thus is not 
straightforward, irrespective of the quality of the evidence presented. Assessing the extent of 
dissemination or transferability of knowledge is therefore very challenging (Garner, Kale et 
al. 1998); (Murray and Frenk 2001); (Page, Heller et al. 2003); (Gamer, Meremikwu et al. 
2004); (Chinnock, Siegfried et al. 2005); (Moayyeri and Soltani 2005).
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Figure 2-1: Events regarding scaling up of ART in low- and middle-income countries and 
timeline
1996 2000 2 QQi 2002 2003 2005 2006 2QQQ 2010 2 0 1 5
UN General Assembly Special Session Midway to
on HIV/AIDS June 2001/ 189 Member States Millennium Development
signed the Declaration of Commitment Goals
Source: UNAIDS report
In the early stages, the cost of therapy meant that the benefits of HAART were confined to 
those countries in North America and Western Europe who could afford treatment. In this 
manner, the disparity between rich and poor countries regarding ART became increasingly 
noticeable over time. This led the United Nations to initiate the Joint Programme on HIV 
and AIDS (UNAIDS) combined with the World Health Organisation and the World Bank to 
identify methods to increase access to HAART (see Figure 2-1). Medical Access 
Programme was launched by UN AIDS in 1996 which initially benefited countries such as 
Uganda, Ivory Coast, Chile and Vietnam. Later Multi-country AIDS Project (MAP) 
developed by the World Bank allowed countries to use its funds to buy ARV drugs. Later, 
one of the largest efforts of ART expansion was done through the “3x5 initiatives” by 
WHO. Despite of the failure to reach the target of 3 million, the number of beneficiaries 
from HAART in Africa was increased to nearly a million in 2005 (Katabira and Oelrichs 
2007).
The United States’ President’s Emergency Plan for AIDS Relief (PEPFAR) programme 
represented another major initiative to enhance access to treatment. This programme is now 
benefiting 15 countries most affected by the HIV epidemic and which contributes
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approximately 50% of its budget for treatment and the Global Fund for AIDS, TB and 
Malaria. At the same time, the drug industries have lowered the prices of ARV drugs and 
generic versions of these medicines have been introduced (Katabira and Oelrichs 2007). 
However, achieving universal access to HAART in resource-limited setting still has a long 
way to go.
2.5.1 Exemplars of HAART programme in developing countries
Apart from doubts regarding the feasibility of implementing ART in developing countries,
information regarding efficacy of ART in resource-poor settings is still scant, with the vast 
majority of evidence being derived from developed countries where people, resources and 
technologies are vastly different. Box 2-1 shows the differences of health care experiences 
from developed and less developed countries. In relation to HIV/AIDS patients, people from 
less developed world tended to present late; the level of CD4 cell count required to initiate 
the treatment in rich countries is usually higher than that found in developing countries. 
However, one study which explored the provision of HAART to patients in a resource-poor 
setting, found that the therapy could lead to equivalent treatment outcomes to those with 
high CD4 cell counts in those achieved in patients whose CD4 cell count was less than 200 
cell/uL (Bogaards, Weverling et al. 2003).
Box 2-1: Comparison of the Health Care Experiences in the Less Developed and Developed 
Worlds
Features of the typical health care experience of a patient living in the less developed world include
■ late presentation
■ self-medication of “prescription” drugs or traditional treatments
■ poor facilities may delay diagnosis
■ referral (if needed) not easily arranged
■ if a child, may be malnourished
■ if a woman, may be anaemic
■ will experience problems because of shortages of trained staff
■ ... and because of poor infection control
■ .. .and because of a lack of follow-up care
■ patient may be unable (e.g., because of lack of funds) to fully adhere to treatment.
Features of the typical health care experience of a patient in a clinical trial in a developed country 
include
■ none of the above
Source: Chinnock P, Siegfried N, Clarke M. Is evidence-based medicine relevant to the developing 
world? P L o S  M e d 2005;2(5):el07.
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Figure 2-2: Selection process for ARV in Uganda
a Human Immunodeficiency vims 
b Prevention of mother-to-child transmission 
c Acquired Immunodeficiency vims 
d Antiretroviral treatment 
e Highly active antiretroviral therapy
Source: World Health Organisation
Demand for ARV in developing countries usually outstrips supply. To deal with this, 
“targeting priority recipients” have to be identified. The policy makers have to decide who
can access the therapy and who has to wait until the nationwide ART programme is 
available (Bennett and Chanfreau 2005). Eligibility for entering the ART programme in this 
manner can be considered as a form of prioritization. Prioritizing is not new and is common 
in environments where resources are scarce such as Uganda. The ARV programme 
developed from the Joint Clinical Research Centre (initiated in 1992) and Drug Access 
Initiative (1998) (Bennett and Chanfreau 2005). In 2003, the draft policy defines criteria of
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accessing to ART programme was launched. Since then, PLHA will be classified as 
“priority eligibility” which refers to those who can access to the drug immediately and 
“ordinary eligibility” which refer to PLHA who will receive the treatment later. Aside from 
the judgement based on clinical eligibility and likelihood to adhere to the treatment, social 
criteria such as being children and being activists are used for prioritization (Bennett and 
Chanfreau 2005) (see Figure 2-2).
Figure 2-3: Selection process of ISAARV
a Human Immunodeficiency virus 
b Acquired Immunodeficiency virus 
c Highly active antiretroviral therapy
Source: World Health Organisation
In Senegal, the Senegalese initiative for access to antiretroviral drugs (ISAARV) was 
launched in 1998-2001 to treat a total of 339 patients in limited number of hospitals under 
the cost sharing health scheme. It was the pilot project to demonstrate the feasibility and 
efficacy of ART in Africa. HIV-infected patients were included with pre-selection process 
and the infra-structure was set up in a research design. Patients’ residency is the first
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criterion for entering the programme with patients being tested for biomedical data to 
determine the eligibility for ARV drugs and the final stage being an assessment of their 
potential to adhere to ARV and to pay (Bennett and Chanffeau 2005) (see Figure 2-3). The 
programme planned to provide the care to cover 7,000 individuals in 2006 and the 
programme has been free of charge since December 2003 (Desclaux, Ciss et al. 2003).
Figure 2-4: Selection process for ARV in Mexico
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In Mexico, the ART programme was launched in August 2003 with commitment from the 
Mexican President to provide ARV to all patients in need, with the Ministry of Health 
providing the drug free of charge (Bennett and Chanfreau 2005). Aside from clinical 
eligibility, insurance status was another important criterion (see Figure 2-4) with additional 
criteria being applied due to a shortfall of funding leading to interruption of drug supply. To 
enhance funding, the government of each state can contribute extra funding to aid the 
programme; however, this is still not uniform (Bennett and Chanfreau 2005).
In term of efficacy of the programme in the resource-limited settings, some pilot projects 
identified the successful outcomes after implementation of ART. Middle-income countries 
such as Brazil, with advanced ART programmes have shown to improve survival after the 
introduction of ART into the country (Gadelha, Accacio et al. 2002). A significant decrease 
of opportunistic infection incidence among HIV-infected patients after ART was also 
observed (Levi and Vitoria 2002). In relation to benefit in monetary term, it has been 
estimated that $US 1 billion had been saved since the universal access to ARV in 2001 
mostly by reducing hospitalization and other HIV/AIDS care costs (Creese, Floyd et al. 
2002); (Levi and Vitoria 2002); (Nunn, Fonseca et al. 2007). Brazil therefore represents one 
of the most successful examples of large scale ART programmes in middle-income 
countries, countering the belief that prevention represented the only cost-effective method to 
address HIV in resource-poor countries (Creese, Floyd et al. 2002).
In the case of rural Haiti, where resources are even more scarce than Brazil, ART was 
delivered in a small area in the country by integrating the ART programme into the existing 
tuberculosis-control infrastructure using directly observed therapy (DOT-HAART) as a tool 
to improve adherence (Farmer, Leandre et al. 2001). Clinical monitoring was undertaken 
using available basic laboratory facilities. The study was, however, conducted in the well 
controlled environment confined to 60 rural Haitians and DOT-HAART appears to be
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labour intensive for such life-long treatment. However, this study has highlighted the value 
of increasing the cohesion between TB and HIV care as another feasible strategy to deliver 
HAART in resource-limited settings (Abdool-Karim, Abdool-Karim et al. 2004).
In the context of Asian countries, recently a Chinese study was conducted to test the 
feasibility of delivering HAART in rural China in a group of 42 PLHA. This pilot was 
implemented using the existing health infrastructure, only CD4 cell count was available, no 
viral load monitoring and quality of life measured only by the ability of the patients to return 
to work. The study findings have shown that these patients could be effectively supported 
by the programme for a period of one year (Meng, Anderson et al. 2006).
Table 2-3: Summary of meta-analysis of efficacy of antiretroviral therapy programmes in 
resource-poor settings
Objective
Systematic review 
summary
Reviewers conclusions
Reference
To determine the efficacy of ART programmes in the developing world 
and to compare the outcomes with typical outcomes in the developed 
countries
■ Ten studies involving with 2,646 HIV-infected people were 
included
■ Proportion of patients with undetected viral load after 12 months 
of treatment was 0.57 (95% Cl, 0.43-0.72)
■ Provision of free medication was associated with higher of 
probability of and undetectable viral load at 6 and 12 months 
after treatment
Viral suppression in developing countries was similar to that observed in 
developed countries after 12 months of therapy.
Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy 
programs in resource-poor settings: a meta-analysis of the published *3
literature. C lin  In fe c t P i s  2005;41(2):217-24. _______
In assessing the effectiveness of programmes serving low income countries, a recent meta­
analysis of studies related to ART in resource-limited setting has been conducted (Table 2-
3) (Ivers, Kendrick et al. 2005). The review demonstrated that ART was equally effective in 
resource-limited setting as it was in developed countries. A total of ten studies were 
included in this reviews which were all from Africa countries comprised South Africa, Cote
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d’lvore, Senegal, Cameroon, Uganda and Kenya and one multinational*. Moreover, most of 
the included studies were conducted in urban areas. Thus, validity and generalisability of 
success of ART in developing countries are still questioned. Aside from this, some other 
small scale studies in Cote d’lvore, Southern India, China and Senegal using either CD4 
counts or viral load to determine the efficacy of the treatment programme also showed the 
similarity of the results to those developed world (Laurent, Diakhate et al. 2002); (Djomand, 
Roels et al. 2003); (Kumarasamy, Solomon et al. 2003); (Meng, Anderson et al. 2006).
It is important to emphasise, however, that the success of short-term evaluation of ART in 
some developing countries is not a premise for the expansion of HAART to every resource- 
limited country due to the limited ability to generalize and the need for long-term close-up 
monitoring. A study from Lusaka, Zambia exhibited the downside of district-wide 
implementation of HAART. After the ART programme was initiated in the area, a high rate 
of loss to follow-up was noted. For those who were lost to follow-up, only half were 
traceable and half of these traceable patients had died (Krebs, Chi et al. 2008). Findings like 
these are to be expected especially in places where patients are very sick and are provided 
with care under a poor infrastructure. Wide scale expansion of the ART programme, thus, 
needs to be very carefully planned and monitored.
2.5.2 Monetary resources and financing system
The most important objections to the delivery of HAART in resource-poor settings are (i) 
the high drug cost and (ii) poor management of health infrastructures (Farmer, Leandre et al. 
2001). The cost of providing HAART is still one of the biggest obstacles to accessing 
antiretroviral therapy (Steinbrook 2001) despite the significant reduction in drug price. 
Many studies undertaken in developed countries emphasise the potential resource savings 
from HAART. For example, Bozzette analysed three thousand Americans and found that
* Multinational study involved with 743 patients from 7 countries including Malawi, Kenya, South 
Africa, Cameroon, Cambodia, Thailand and Guatemala
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total healthcare cost declined over the study period, with overall costs reduced by 16% and 
hospital costs reduced by 43%, emphasizing the potential for ART to reduce lifetime 
healthcare costs (Bozzette, Joyce et al. 2001). Another study conducted in Medicaid-insured 
patients found that although the cost of drugs increased over the period analysed, the total 
health care cost was stable (Gebo, Chaisson et al. 1999). The same trend was observed in an 
Italian cohort study covering six years, which found that death had declined over the period 
of the study, while costs were relatively stable (Merito, Bonaccorsi et al. 2005).
Concern relating to the cost of HIV/AIDS is still prevalent with Reiser finding that costs 
due to drug resistance might outweigh other aspects of healthcare cost as patients would 
require treatment with more intensive salvage regimens which will lead to significant 
additional cost (Reiser, Nassar et al. 2001). To examine this, in one study, total net costs of 
expanding Medicaid for PLHA to improve access to HAART was modelled using a Markov 
model of HIV disease progression. A total of 38,000 HIV-infected patients were analysed 
over five years and the costs of salvage regimen (multiple-drug ART, 4-6 combination of 
ART regimen) were assessed (Rahn, Haile et al. 2001). Despite the fact that high cost 
regimens were used, the study showed the potential of ART to cut down the total care costs 
but emphasized that the results were sensitive to changes in drug costs and the number of 
patients on salvage regimens.
A recent review analysed the direct costs of providing care for PLHA from nine studies 
from Canada, France, Italy and the USA (Levy, James et al. 2006). Unfortunately, large 
discrepancies were found in the method used, population and components of costs between 
the studies, making direct comparisons between studies and meta-analysis of the findings 
difficult. No conclusion could be drawn based on the existing evidence with regard to costs 
as it depended on the context in which care was provided. However, it emphasizes the 
potential for HAART to lower the health care costs. This potential is enhanced by the fact
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that drug prices have reduced significantly which would affect the findings of all HAART 
analyses undertaken in the past. However, evaluating total healthcare costs also needs to 
take into account other issues including health systems, intellectual property regulations- 
generic drug production, epidemiological profiles, and treatment guidelines in each setting 
(Nunn, Fonseca et al. 2007).
Figure 2-5: Total annual resources available for AIDS 1986-2007
US$ million
10 billion
Notes: [1] 1986-2000 figures are for international funds only 
[2] Domestic funds are included from 2001 onwards
[i] 1996-2005 data: Extracted from 2006 Report on the Global AIDS Epidemic (UNAIDS. 2006)
[ii] 1986-1993 data: Mann.&. Tarantola, 1996
Source: UNAIDS report (UNAIDS and WHO estimation, 2007)
The cost of antiretroviral drugs represents less than 0.1% of the gross domestic product 
(GDP) of high-income countries (Moatti, N'Doye et al. 2003). In contrast, given the 
magnitude of the problem in developing countries, expenditure on ART has the potential to 
consume a major proportion of their health spending and account for a significant share of 
their GDP (Hogg, Weber et al. 1998). Figure 2-5 emphasizes the extensive mobilization of 
resources to resource-limited settings to support ART programme expansion. However, the 
issues of sustainable and self-reliance are still debatable (Steinbrook 2002).
The financial structure of the healthcare system is another important factor underpinning 
access to care. The utilization of healthcare is undoubtedly influenced by health financing
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schemes. For instance, in the United States, HAART was more likely to be used by patients 
who were commercially insured than in other payer groups (Keruly, Conviser et al. 2002). 
To increase access to ART, the government expanded Medicaid eligibility to cover more 
uninsured people, however, the coverage of ART remained limited (Steinbrook 2001), 
(Bailey, Van Brunt et al. 2003); (Bailey, Van Brunt et al. 2004). Moreover, the financing 
system can affect the enrolment process, with patterns of enrolment and patterns of HAART 
use being linked. Such linkage results from the eligibility rules which limits access to 
HAART and represents a major barrier to access to HAART (Kahn, Zhang et al. 2002) but 
which can be used to reduce disparities in the use of HIV drugs (Morin, Sengupta et al. 
2002) through altering structures of medical insurance to enhance access to ART (Keruly, 
Conviser et al. 2002) .With sparse information of effective financing schemes and its 
significant effect on HAART accessibility, countries must choose the detailed service 
specifications to suit their own context
2.5.3 Human resources for HIV/AIDS care
In addition to drug costs, lack of adequate health infrastructure including human resources, 
laboratory testing, monitoring facilities, supplies and distribution management, will also 
constitute a major expense (Yazdanpanah 2004); (Kovsted 2005). Inequality of health 
resource distribution is found in developing countries with most resources being 
concentrated in big cities. This inequality could adversely affect the effectiveness of 
antiretroviral care.
Kober identified a common problem relating to the shortage of medical personnel in 
Malawi, Mozambique, Swaziland, and South Africa (Kober and Van Damme 2004) and 
found that this lack of health personnel represented the biggest obstacle to expanding ART 
in those countries (Kober and Van Damme 2004). Demand for health workers in African 
countries far exceeds their supply. For instance, in Thyolo-a small district in Malawi, only
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40% of health posts in the public sector were filled while the number of patient has 
increased many fold since the launching of 3x5 initiatives with more than 80% of patients 
admitted exhibiting HIV/AIDS associated conditions (Kober and Van Damme 2004). Such 
staff shortages are aggravated by a drain of health personnel due to the movement of health 
personnel from public to private, from rural to urban and from developing countries to 
developed countries which intensifies the scarcity of health manpower. Moreover, the high 
mortality rate of HIV-infection among health personnel also enhances the scarcity of care 
givers (UNAIDS 2001); (USAID 2003).
It was estimated by WHO that 100,000 care trained health personnel were required to 
provide the care to meet the 3 by 5 goal (PEPFAR 2006) requiring enhanced cooperation 
between donors and governments. However, donors projects are usually restricted to the 
provision of resources for capital costs or for foreign exchange requirements (e.g., drug 
supply, training), but not for resource costs such as salary support or enhancement. 
Additionally, the donor projects recruit their own staff which can exacerbate the problem 
(USAID 2003). In a study from Malawi where the number of adults infected with HIV was 
as high as a million cases, it was found that the numbers of physicians and nurse were only 
610 and 4,200 respectively in 2006 (Muula, Chipeta et al. 2007). To deal with this situation, 
the doctor had to see at least 40 patients every day, 30 days a month to reach 1,000 patients 
per doctor (Muula, Chipeta et al. 2007). This situation is not uncommon and can be found in 
many other African countries (see Table 2-4).
Table 2-4: Number of doctors and nurses in selected countries
Country Number of (per 100,000 inhabitants)
Doctor nurse
WHO minimum standard 20 100
Malawi 2 56.4
Lesotho 5 63
Mozambique 2.6 20
South Africa 74.3 393
USA 247 901
UK 222 1170
Source: World Health Organisation (WHO). Working together for health: the World Health Report 
2006. Geneva, Switzerland: WHO, 2006.
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Given the shortage of skilled staff, task shifting for ART delivery becomes essential. Task 
shifting is not a new concept in Africa, specific cadres of non-physician health personnel 
have been initiated to undertake clinical tasks where doctors are inadequate (Philips, 
Zachariah et al. 2008). Task shifting has been opted for in many African countries such as 
Ethiopia, Malawi and Uganda as a model by which to deliver HAART. However, this might 
not be an answer in case of HIV/AIDS care. In the district of Thyolo, Malawi, 450 new 
patients were initiated on ART every day during the early expansion phase of ART which 
was far beyond the capacity of the central hospital. By 2005, new cases had to decentralize 
to health centres, with clinical work being undertaken by medical assistants, nurses and 
other health personnel which required extra clinical staff. In this manner, provision of ART 
required significant additional investments in terms of both finance and human capital 
(Philips, Zachariah et al. 2008).
Aside from quantity (number) of doctors and other health personnel, it has been shown that 
the prognosis of HIV patients is significant related to the experience and knowledge of 
prescribing clinicians (Kitahata, Koepsell et al. 1996); (Stone, Mansourati et al. 2001); 
(Landon, Wilson et al. 2003). The experiences and knowledge of doctors will vary even in 
the developed world as it has been shown that European physicians tended to start ART for 
HIV-infected patients at lower CD4 cell counts than that of American doctors (Valian, 
Moyle et al. 1994). Even in the same country where standard guideline was published, a 
study regarding French physicians has shown that three month after clinical 
recommendations for HAART were made public, disagreement between patterns of ART 
prescription in some complicated cases was identified (Landman, Moatti et al. 2000). In the 
USA, it appears to be that infectious disease doctors are more likely than the general internal 
medicine doctor to prescribe ART (Stone, Mansourati et al. 2001). In a middle-income 
country like Thailand, expanding antiretroviral treatment (ART) for children requires
49
Literature Review
decentralization of the ART programme implying that service provision is managed mainly 
by non-specialist doctors (Ponnet, Frederix et al. 2005). Structures of treatment guidelines 
and types of doctors providing ART will largely depend on the human capital available to 
the country and this will impose a significant impact on the prognosis of the patients.
Treatment for HIV requires knowledge updating to match the changes in field of HAART. 
In developed countries, many non-specialist physicians would seek advice from their 
specialist colleagues (Stone, Mansourati et al. 2001). Thus, regular training is a pre­
requisite as HAART is rapidly changing (Souville, Msellati et al. 2003); (Katabira and 
Oelrichs 2007). Since the introduction of zidovudine in 1987, over 2,000 combinations of 
ARV regimens have been recorded (Ghani, Donnelly et al. 2003).
2.5.4 Underdeveloped health infrastructure
Best practices of ART come almost exclusively from developed countries and are derived 
from cumulative clinical trials and the experience of well-organized treatment centres. In 
most developed countries, antiretroviral therapy is provided through centres specializing in 
the care for people living with HIV/AIDS with highly experienced physicians and staff. The 
care utilized a wide range of ARV drugs and sophisticated laboratory techniques utilised by 
specialists as well as developed surveillance systems for drug resistance (Jaffar, Govender 
et al. 2005).
The standards and techniques utilised in resource-rich countries with access to 
comprehensive therapeutic monitoring are not easily matched in resource-limited countries 
(Gilks 2001); (Loewenson and McCoy 2004); (Jaffar, Govender et al. 2005). Current 
treatment models developed in wealthy countries therefore require simplification and 
decentralization. The challenges of ART delivery in resource-limited countries include 
ensuring uninterrupted drug supplies, laboratory capacity for CD4 monitoring, accessible
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voluntary counselling and testing (VCT), trained healthcare staff and effective monitoring of 
resistance to antiretroviral drugs (Loewenson and McCoy 2004) The optimum point to start 
HAART in developed countries is based on laboratory tests such as CD4 cell count and viral 
load (Aboulker, Babiker et al. 2004). In contrast, in resource-poor settings, CD4 cell count 
is likely to be the only option for initiating and monitoring the progress of HAART 
(Bogaards, Weverling et al. 2003).
Health systems in most developing countries are characterized by limited resources and 
services (Loewenson and McCoy 2004); (Jaffar, Govender et al. 2005); (Katabira and 
Oelrichs 2007). Jaffar suggested three requirements for the introduction of HAART 
programmes in such settings; (i) the possibility for health staff to look after the patients due 
to the shortage of doctors, (ii) possibility to deliver the care through the health peripheral 
health care system and (iii) an effective clinical algorithm to be used for screening, 
diagnosis case management (Jaffar, Govender et al. 2005).To expand the coverage of care 
required to meet the large number of PLHA, peripheral health facilities must take a major 
role in a decentralized structure of services to meet the needs of people in rural areas. The 
distance and cost of transportation to specialist centres located in towns and cities would be 
likely to result in reduced compliance (Jaffar, Govender et al. 2005). Providing care through 
peripheral health facilities such as health centres then would be likely to improve access to 
care. Peripheral health facilities, however, are often poorly equipped and overburdened by 
the demands placed upon them. Standardization of these facilities to deliver HAART is not 
easy and such a model of care is not likely to be feasible for doctor to deliver care due to the 
limited supply of health staff especially doctors or even nurses. Thus there is a role for 
trained health workers to undertake screening, counselling, monitoring and managing of 
adverse events for HAART care. In such circumstances, it is vital that this structure of care 
is evaluated and assessed to identify the clinical and cost-effectiveness of care provision.
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2.5.5 Prevention
Prevention is still required to contain the epidemic of the disease; however, an effective 
HIV/AIDS vaccine is not envisaged in the near future. With comprehensive prevention 
(including twelve prevention interventions and nine care and support activities), it has been 
estimated to potentially save 29 million out of 45 million new cases that were projected to 
occur in this decade (Stover, Walker et al. 2002). Unfortunately, it was estimated that less 
than one in five people globally have access to such preventive services (UNAIDS 2004). 
Ensuring that prevention is comprehensive and interweaves a variety of interventions (e.g. 
voluntary counselling and testing, AIDS education, promote condom use, behaviour change 
programme, community education and prevention of mother-to child transmission) is still 
essential. Lack of prevention measures is highly associated with HIV/AIDS epidemic. For 
instance High risk-behaviours such as injecting drug use, unprotected paid sex and 
unprotected sex between men are found to be an important cause of epidemic in Eastern 
Europe, Asia and Latin America (UNAIDS 2006). Moreover, even where comprehensive 
prevention is encouraged, the prevalence of unprotected sex is showing an upward trend. 
For instance, UNAIDS has reported rates of 10%-20% of unprotected sex amongst groups 
of men who have sex with men (UNAIDS 2006).
Prevention is also considered to be a more cost-effective intervention compared with 
antiretroviral treatment (Creese, Floyd et al. 2002); (Marseille, Hofmann et al. 2002). For 
instance, a systematic review by Creese et al showed that many HIV preventive 
interventions (such as targeted condom distribution with treatment of sexually transmitted 
diseases, single-dose nevirapine and short-course zidovudine for prevention of mother-to- 
child transmission and voluntary counselling and testing (VCT)) together with tuberculosis 
treatment were cost-effective in African countries while HAART, home care programme 
and formula feeding for infants were considered less cost-effective (Creese, Floyd et al. 
2002). It was, thus, suggested that prevention was the most cost-effective option for African
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countries. Such results are largely explained by the fact that (i) primary prevention is easier, 
less costly, and yields more lives saved (ii) studies undertaken in the early HAART era 
utilised costs of antiretroviral (ARV) drugs that were relatively high compared to their 
present lower cost. In addition, there is the ethical dilemma that, irrespective of cost- 
effectiveness, it is difficult for policy makers not to offer known effective intervention such 
as ART to HIV infected people. This demonstrate the disadvantage of ranking programs 
according to the cost-effectiveness ratio which might aggravate disparities in access to 
treatment (Birch and Gafni 1992).
Table 2-5: Summary of meta-analysis of relationship between HAART and sexual health risk
Objective To determine whether being treated with HAART, having an undetectable viral
load, or holding specific beliefs about HAART and viral load are associated 
with increased likelihood of engaging in unprotected sex 
Systematic review ■ 25 English-language studies were identified and examined the association
summary of unprotected sexual intercourse or STIs with receiving HAART (21
findings), having an undetectable viral load (13 findings), or beliefs about 
HAART and viral load (18 findings).
■ The prevalence of unprotected sex was not higher among PLHA receiving 
HAART vs. those not receiving HAART (OR= 0.92; 95% CI= 0.65-1.31) 
or among PLHA with an undetectable viral load vs. those with a detectable 
viral load (OR, 0.99; 95% Cl, 0.82-1.21).
■ The prevalence of unprotected sex was elevated (OR, 1.82; 95% Cl, 1.52- 
2.17) in PLHA, HIV-negative, and unknown serostatus persons who 
believed that receiving HAART or having an undetectable viral load 
protects against transmitting HIV or who had reduced concerns about 
engaging in unsafe sex given the availability of HAART comparing to the 
counter parts
Reviewers conclusions HIV-positive patients receiving HAART did not exhibit increased sexual risk 
behaviour, even when therapy achieved an undetectable viral load. However, 
people’s beliefs about HAART and viral load may promote unprotected sex and 
may be amenable to change through prevention messages 
Reference Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual
risk behaviour: a meta-analytic review. J a m a  2004;292(2):224-36.
Concern has been expressed that the use of HAART may cause higher prevalence of 
unprotected sex and higher incidence of sexually transmitted diseases (STDs) (Huebner, 
Rebchook et al. 2004); (Behjati 2006). In one systematic review regarding sexual behaviour 
after the use of HAART, it has been shown that being prescribed with HAART was not 
associated with engaging in unprotected sex (see Table 2-5). Moreover, it was found that 
there was no association between undetectable viral load and sexual risk behaviour (Crepaz, 
Hart et al. 2004). However, in this study, all identified literature were from westernized
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countries (16 of 25 from the USA), making generalisation of the findings to resource-poor 
settings difficult.
A study from Taiwan published in the same year has suggested that since 1989 in Taiwan, 
the infection rate of HIV decreased by 53%. However, this study was conducted in a 
specific setting where HIV prevalence is very low (0.19%) with extensive screening 
programmes (more than 20 million anti-HIV screenings in 22 million person were 
conducted during 1984-2002) (Fang, Hsu et al. 2004). Despite this success, a continuous 
effort to bring down the transmission rate of HIV is required even through the affect of 
HAART on risk behaviour in the long run seems to be minimal.
2.5.6 Adherence
As the cost of the treatment is relatively high, compliance becomes crucial. However, no 
gold standard for measuring compliance has been derived (Miller and Hays 2000). In 
general, subjective measures are cheap but tend to overestimate compliance while electronic 
measures provide greater information but at higher cost (Miller and Hays 2000).
Non-adherent patients place both themselves and public health at risk; as they are also less 
likely to adhere to drug toxicity screening. As the number of drugs increase due to the 
progression of the disease, there becomes a greater probability of developing adverse drug 
reactions (Sollitto, Mehlman et al. 2001) which may cause patients to abandon the 
treatment. One of the greatest concerns regarding non-adherence is drug resistance to one PI 
or NNRTI in the treatment regimen, causing treatment failures, leading to resistant viruses 
being passed on to sexual partners, people who share needles and others (Sollitto, Mehlman 
et al. 2001). In one review in 2000, it was shown that only an intensive pharmacist-led 
intervention consisting of educational counselling and availability of follow-up telephone 
support with conventional dispensing of HAART can significantly improve adherence and
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subsequently predict undetectable viral load at 24 weeks (Haddad, Inch et al. 2000). Such an 
intervention requires excellent infra-structure and trained personnel which are unlikely to be 
available in resource-poor settings.
Non-adherence is complex behaviour and multi-factorial (Walsh, Home et al. 2001). A 
study HIV patients reported occasional non-adherence with various reasons up to 15 reasons 
in some cases; the higher the number of reasons for missed doses, the lower adherence was 
observed (Walsh, Home et al. 2001). The barriers to adherence were categorized into four 
themes (Alfonso, Bermbach et al. 2006); (Alfonso, Geller et al. 2006)
(i) Medication factors i.e., adverse effects, regimen complexity, dietary 
requirement. This is also the leading cause of non-adherence
(ii) Mood; distressing emotion such as depression, anxiety and anger could 
discourage some participants to adhere to the medication
(iii) Lack of support; the stigmatization of having HIV could cause some 
patients to decline ART
(iv) Outcome expectation as some of the patients did not believe in the efficacy 
of HAART
The threat of social stigma may also prevent PLHA from disclosing their status and thus 
presents a barrier to compliance with HIV treatment (Rintamaki, Davis et al. 2006); (Ware, 
Wyatt et al. 2006); (Rao, Kekwaletswe et al. 2007). However, the positive effect of HAART 
has, to a limited extent, alleviated the problem of stigmatization as HAART was found to be 
associated with less fear of HIV-infected people (Herlitz and Steel 2001). A small Brazilian 
qualitative study has also shown that stigmatization of HIV infection in children could be 
alleviated by universal access to HAART (Abadia-Barrero and Castro 2006). It is important 
to deliver the right message, particularly to the younger population who tend to receive less 
information compared to the older population (Herlitz and Steel 2001).
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Retention rate in the programme is another simple way to measure adherence. Retention 
rates in ART programmes range between 25-44% (d'Arminio Monforte, Lepri et al. 2000); 
(Ahdieh Grant, Silverberg et al. 2001); (Dorrucci, Pezzotti et al. 2001); (Barron, Cole et al. 
2004) with causes of low retention being similar to those of poor adherence. In terms of 
biological factors, a study identified patients with compromised immunologic status (low 
CD4 cell count) were at greater risk of dropping out from treatment (Brown, Thome et al. 
2006); (Protopopescu, Marcellin et al. 2007). Another study suggested that patients who 
stopped the treatment were likely to have lower health-related quality of life (Protopopescu, 
Marcellin et al. 2007). One study identified three reasons for non-adherence; (i) perceived 
necessity for HAART, (ii) concerns about potential adverse effects of taking HAART and 
(iii) satisfaction with perceived personal control over the decision (Cooper, Buick et al. 
2002). This suggests that supporting informed decision-making regarding HAART is 
important from the beginning as it is important that patients feel in control (Cooper, Buick et 
al. 2002). The infrastructure should then ensure that such control continues throughout their 
treatment (Gebrekristos, Mlisana et al. 2005). In fact, HIV infected patients are generally 
actively involved with their providers as partners in decision-making (Marelich, Johnston 
Roberts et al. 2002). The four patterns of PLHA participation with providers about ART 
decision making were; (i) joint decision making between patients and providers, (ii) patients 
taking control of their drug treatment decisions, (iii) initial passivity followed by increased 
involvement, and (iv) patients as knowledge gatherers (revealing where patients get 
treatment information) (Marelich, Johnston Roberts et al. 2002).
2.6 Development of Thai national antiretroviral therapy programme
2.6.1 The epidemic of Thai HIV/AIDS
Thailand is one of middle-income countries in the problem growing region of Southeast 
Asia (UNAIDS 2004). HIV/AIDS has been prevalent in Thailand for more than two 
decades. The Thai responses to the problem have been changed gradually to match
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situations in the country as global knowledge of managing HIV/AIDS problem has been 
growing. The first case of AIDS was diagnosed in Thailand in September 1984 and it was 
declared as the severe communicable disease since then (Thanprasersuk, Lertpiriyasuwat et 
al. 2004); (Ana Revenga, Mead Over et al. 2006). At the early stage, the disease confined 
itself to homosexual (1984-1987) male which later followed by the explosive spread of HIV 
infection among intravenous drug users (IVDUs) in 1987-1988 (Thanprasersuk, 
Lertpiriyasuwat et al. 2004). The disease, then, spread to commercial sex workers and their 
clients. With the heterosexual transmission route, reported of mother-to-child transmission 
started increasing during 1990-1991 (Thanprasersuk, Lertpiriyasuwat et al. 2004). It was 
estimated that by the end of 2008, more than a million of Thais will be infected with HIV 
since the first epidemic in Thailand, half of them already died. This will leave 
approximately 532,522 Thais living with HIV/AIDS in the year 2008. It has also been 
estimated that there would be 12,787 new infected cases which tends to be lower comparing 
to the previous years, and 50,657 new AIDS cases at the end of year 2008 as patients live 
longer from better HIV/AIDS carer (UNGASS 2008) (see Table 2-6).
Table 2-6: Estimated cumulative numbers of HIV/AIDS in 2008
HIV/AIDS Cumulative number
Total HIV infection (adults and children) 1,115,415
Total death (adults and children) 585,830
People living with HIV 532,522
New HIV infection in 2008 12,787
New AIDS cases in 2008 50,657
Number of death from AIDS 26,935
Source: UNGASS country progression report: Thailand, 2008
2.6.2 Government responses to HIV/AIDS
The National Thai AIDS committee was established in 1985. At the beginning, its tasks 
were mainly for public health education, prevention and control and disease surveillance 
among target groups. AIDS prevention policies were described on availability of free 
condom, testing and counselling with confidentiality and anti-discrimination. Non
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Government Organisations (NGOs) were also running their activities for prevention which 
funded by international agencies.
In 1987, the Ministry of Public Health expanded its coordination with NGOs under the 
National Advisory Committee on AIDS. In 1988, WHO initiated technical and financial 
support for the development and implementation of short-term HIV/AIDS plan. This was 
followed by the Thai Cabinet approval of the Plan for the Prevention and Control of AIDS 
(1989-1991). In 1990 the Thai Cabinet announced the official campaign against AIDS by 
making AIDS prevention and controls a national policy.
In 1991, the Prime Minister appointed the National AIDS prevention and Control 
Committee which resulted in multi-sector collaboration establishment. The campaign for 
AIDS prevention and control was launched in that year which involved with two key 
components including reducing the occurrence of male patronage of commercial sex 
workers and improving the safety of the commercial sex trade by means of condom 
utilization, termed the 100% Condom Programme (Buckingham, Meister et al. 2004). The 
mass media and advertisement played an important role in creating awareness for prevention 
of HIV/AIDS.
The government started allocated budget to the Ministry of Public Health (MOPH) to fight 
against AIDS in 1988 with the total money of $US 184,000 and reached $US 7.3 million in 
1991 (Thanprasersuk, Lertpiriyasuwat et al. 2004). However, since 1992, the government 
budgets on HIV/AIDS were distributed through up to 14 Ministries and reached the highest 
in 1996 with the total amount of $US 80 million. In year 2004*, $US 40 million were spent 
for HIV/AIDS activities. Of $US 32 million (80%) were for the Ministry of Public health
* Exchange rate was approximately THB 25/ $US before 1997; and THB 40/$US after that year
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and mainly for antiretroviral therapy. In total, it was estimated that more than $US 1.1 
billion were already allocated from the national budget to fight again HIV/AIDS 
(Thanprasersuk, Lertpiriyasuwat et al. 2004).
2.6.3 Prevention
Without the remarkable success on prevention programme in the past of Thailand, it was 
estimated that Thailand would have to spend $US 18.6 billion in 2012 for treating 
HIV/AIDS patients. For every dollars invested in prevention, it yielded $US 43 can be saved 
for treatment expenditure (Ana Revenga, Mead Over et al. 2006). Thus, possibility of 
scaling up of antiretroviral therapy programme in Thailand is ground on the past successful 
effort on HIV/AIDS prevention (Over, Revenga et al. 2007). Without the multi-measure 
prevention, it was estimated that it would be as many as 7.7 million HIV-infected people 
and up to 850,000 AIDS cases in Thailand (Brown and Peerapatanapokin 2004). Comparing 
to the figure in Table 2-6 presented earlier, it is about 7 times more for HIV-infected cases 
and 14 times higher for AIDS cases. The effort of prevention has started since 1990; 
HIV/AIDS warning messages were publicized through all kinds of media including 
televisions, radio, posters and leaflets. They were aired regularly and repeatedly on 
television as part of the national strategy to minimize transmission of HIV. In 1991, all 
government-sponsored sexually transmitted disease (STD) clinics began to promote condom 
use. The "100% condom program" enlisted the cooperation of sex workers to encourage all 
clients to use condoms when having sex with the supply of 60 million condoms a year by the 
government (Lyttleton 1996); (Phoolcharoen 1998); (Svenkerud and Singhal 1998). The 
changing epidemic of HIV infection in the general population has been exhibited; (i) the 
Royal Thai Army's information on the HIV infection rate among its 60,000 annual military 
conscripts, selected by a draw from 21 -year-old Thai males stated that the rate started to 
incline from 0.5% in 1989 to a peak of 3.7% in 1993 before declining at 1.9% in 1997 
(Institute 1998), (ii) the sero-surveillance tests conducted on samplings of pregnant women 
in all 76 provinces yearly since 1989 also showed that rate of HIV infection was 0.5% in
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1990, then increased to peak at 2.4% in 1995, and declined to 1.7% in 1997 (Health 1998), 
(iii) a cohort of repeat blood donors in the Northern Thailand, incidence rate had decreased 
from 1.7 per 100 person-years in 1989 to 0.5 per 100 person-years in 1994 (Sawanpanyalert, 
Yanai et al. 1996) . However, recent surveillance report form Ministry of Public Health 
Thailand, it found that risk behaviour such as having sex with commercial sex workers, low 
percentage of regular condom use were reports higher among military conscripts and 
married conscripts in 2003 (Health 2006). Comprehensive prevention is, thus, still needed 
in Thai society even though the number of new HIV cases is going down at present.
2.6.4 Multi-sector response to HIV/AIDS
Since the first epidemic of HIV/AIDS in Thailand, A major contributor to the problem has 
been the willingness of the government to alter strategies and policies as knowledge of the 
extent of risk behaviour grew and the social, economic, and cultural roots of the epidemic 
were understood. This willingness helped to identify the role that each sector of Thai society 
to response. Thus, the response of HIV/AIDS has been expanded from the public health 
sector to the social and economic sectors. The strategic alliances have included NGOs, 
private businesses, and community organisations that have worked as partners with the 
government (Phoolcharoen 1998); (Lyttleton, Beesey et al. 2007). The roles of PLHA 
activists have been recognized especially their legal and political advocacy in expanded 
ARV provision in Thailand (Lyttleton, Beesey et al. 2007). Networks of PLHA confront 
new social and political challenges as they also seek to broaden access for marginalised 
groups who remain excluded from these services. Many ethnic minority groups without full 
Thai citizenship have been denied access to subsidised health services including ART. As 
part of a broadening advocacy profile, the PLHA movement is now engaging in a politics of 
difference defined not simply by presence or absence of HIV but also by wider issues of 
national identity and belonging (Lyttleton, Beesey et al. 2007). Among all, the MOPH has 
played the key role in term of main strategic implementer and programme coordinator.
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There has also been an evolution in the cooperation efforts from international agencies to 
government and local funding which is shown in Table 2-7.
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Table 2-7: Roles of international and local organisations
Organisation/Group Cooperation efforts
Department of Disease 
Control, Ministry of Public 
Health
1. Multi- working groups e.g. working group for antiretroviral 
therapy guideline development, working group for 
comprehensive care programme and working group for 
monitoring and evaluation
2. Scaling up and implementation of the government 
antiretroviral therapy programme throughout Thailand
3. Coordinating of antiretroviral programmes existing in 
Thailand
4. Monitor and evaluation of the government antiretroviral 
therapy programme
Office of Disease control in 
12 regions of Thailand, 
Ministry of Public Health
1. Building up the antiretroviral therapy team for providing 
the care in their response areas
2. Monitoring and evaluation of the programme in their 
response areas
Government Pharmaceutical 
organisation (government 
enterprise)
1. Developing new generic antiretroviral drugs especially fix- 
dose combination of triple therapy
2. Manufacturing of antiretroviral drugs
Bumrasnaradura institution, 
Ministry of Public Health
1. Collaborating centre of WHO
2. Clinical management centre of Ministry of Public Health
People living with 
HIV/AIDS (PLHA )
1. Networking among themselves as part of care provider
2. Providing health education among group of PLHA
3. Being part of home visit team
NGO and international 
organisation*
1. Involving in policy making process
2. Negotiating of antiretroviral drug price
3. Developing antiretroviral therapy guideline
4. Setting up campaign for treatment accessibility to needed 
people
5. Networking with people living with HIV/AIDS, NGOs and 
the government
Research institute 1. Conducting research base on the Thai context
2. Support antiretroviral drug free of charge
3. Providing technical support of implementation and expand 
of the antiretroviral therapy programme
4. Developing monitoring and evaluation tool for 
antiretroviral therapy programme
Source: Bureau of AIDS, Tuberculosis and Sexually Transmitted Infection, MOPH, 2004
Another important party in the Thai context of HIV/AIDS care is PLHA self-help groups 
especially in the rural areas. It was estimated that more than 920 groups existed in 2006
* NGOs and international organisation including World Health Organisation/the Joint United Nation 
Programme on HIV/AIDS (WHO/UNAIDS); Thailand MOPH-U.S. CDC Collaboration (TUC), 
Global Fund to fight HIV/AIDS, Tuberculosis and Malaria, Japan International cooperation agency 
(JICA), Oxfam, Medecins Sans Frontieres (MSF), Access Foundation, Thai NGO’s coalition on 
AIDS (TNCA), Thai Network for People Living with HIV/AIDS (TNP+)
62
Literature Review
(Lyttleton, Beesey et al. 2007). In the early stage most of the group were concentrated in 
Northern Thailand as to the response to the epidemic of HIV and mostly were hospital- 
based under the encouragement of hospital staff. At first their activities focused on income 
generation, moral support for public disclosure of HIV status and self-care. They also 
provide voluntary support which closely linked to the provision of ART for PLHA such as 
training courses on various opportunistic infection and comprehensive care to members of 
PLHA groups, the major component of holistic care, promote adherence as who will be lost 
to follow up will be visited by the member of the group. Later the groups have meshed with 
each other and become a network linking at sub-district-, district-, provincial-, regional- and 
national-levels to increase social and politic advocacy which further the access to ARV 
drugs as well as opportunistic infection prophylaxis to the underserved group in Thailand 
(Lyttleton, Beesey et al. 2007).
2.6.5 Evolution of antiretroviral therapy in Thailand
2.6.5.1 Initial stage of antiretroviral therapy
Since the first identified case of HIV/AIDS in Thailand in 1984, the subsequent response 
from all segments of government and Thai society helped to deal with the epidemic of 
HIV/AIDS. In 1991, zidovudine (AZT) was firstly distributed to AIDS cases. The Ministry 
of Public Health had proposed the drug to be included into the National Drug List. Number 
of cases with single therapy with AZT was rising from 15,000 cases in 1994 to 45,000 cases 
in 1995 (Thanprasersuk, Lertpiriyasuwat et al. 2004). Most of the cases were in either 
referral centres or university hospitals. The treatment programme with AZT was later 
evaluated by World Bank, WHO and the Ministry of Public Health (MOPH) in 1995, the 
evaluation showed no evidence of clear survival benefit and high proportion of patients lost 
to follow-up (Prescott N 1996). The government, then, decreased the budget for AZT and 
reallocated the budget for clinical trials network by the Ministry of Public Health instead 
(Phanuphak 2004).
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The evaluation by World Bank and WHO also stated that AZT for preventing mother-to- 
child transmission would be more cost-effective which corresponded with both Thai and 
international studies showing the effectiveness of AZT reducing mother-to-child 
transmission rate (Sperling, Shapiro et al. 1996); (Thaineua, Sirinirund et al. 1998); 
(Shaffer, Chuachoowong et al. 1999); (Lallemant, Jourdain et al. 2000). The Ministry of 
Public Health firstly implemented a short regimen of AZT to all consent HIV-infected 
women to prevent mother-to-child transmission (PMTCT) of the virus through seven public 
hospitals in Phayao province, Northern Thailand (Thaineua, Sirinirund et al. 1998) in 1997. 
At the same time, Glaxo Wellcome reduced 75% of the original price of AZT to $US 100 
per case (Baker 1998). Since year 2001, the programme to prevent mother-to-child 
transmission has been available throughout public hospitals free of charge (Kanshana and 
Simonds 2002); (Phanuphak 2004); (Thanprasersuk, Lertpiriyasuwat et al. 2004).
The Clinical Research Network for antiretroviral therapy was established in 1996 including 
58 referral and university hospitals. In 1998, treatment with two antiretroviral agents (dual 
therapy) was used as the standard treatment. However, only 1,200 patients benefited from 
this research programme (Thanprasersuk, Lertpiriyasuwat et al. 2004). With high demand 
for antiretroviral and high cost of the drugs, co-payment which requested patients to partly 
pay for the expensive drugs such as non-nucleoside reverse transcriptase inhibitors and 
protease inhibitors was initiated in 2000. Still, only few hundred of people participated in 
the scheme (Thanprasersuk, Lertpiriyasuwat et al. 2004).
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Figure 2-6: Access to HIV/AIDS medical care in Thailand
Source: Ministry of Public Health, Thailand
2.6.5.2 National government antiretroviral therapy programme
The development of ART implementation as the national programme under the universal
coverage health scheme has been started since 2001 (Chasombat, Lertpiriyasuwat et al. 
2006). In that year, national antiretroviral therapy programme called “Access to Care” was 
initiated by the Ministry of Public Health. Eight HAART regimens for adult and 12 
regimens for children were prescribed to eligible participants. However, the programme was 
limited in hospitals where a trained staff team for ART were available (Thanprasersuk, 
Lertpiriyasuwat et al. 2004). In 2002, the generic local made GPO-Vir with fix-dose 
regimen was produced by the Government Pharmaceutical Organisation (GPO) at a cost of 
$US 1 per person per day. It was the combination of 3TC (lamivudine) +d4T (stavudine) 
+NVP (navirapine). Since the second year of the national antiretroviral therapy programme 
(Ford, Wilson et al. 2004); (Phanuphak 2004), the programme recommended GPO-Vir as 
the first-line regimen. In 2003, the government by the Ministry of Public Health aimed to 
expand the treatment programme to cover every needed individual. The programme title
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was changed to “National Access to Antiretroviral Programme for People who Living with 
HIV/AIDS” (NAPHA).
The number of patients who benefit from the government ART programme has been 
increase from 3,600 in 2001 to 23,000 in 2002 (Panpanich 2004). The people were entitled 
to the programme under the universal health scheme, the civil servants’ welfare or social 
security scheme. Training for relevant medical personnel including doctors, nurses, 
pharmacists, laboratory technicians, counsellors and social workers was carried out in every 
region of Thailand. Number of hospitals involved in the programme had gradually expanded 
from 112 hospitals in 2001 to 462 hospitals in early 2003 and reached 841 by February 2005 
(Thanprasersuk, Lertpiriyasuwat et al. 2004). Total number of patients recruited into the 
programme reached the total of 13,000. In 2004, the programme was expanded to cover as 
many as 50,000 patients. The budget was four-fold increase compared to that of the year 
2003 (Thanprasersuk, Lertpiriyasuwat et al. 2004). As on May 2006, the World Bank report 
has stated that approximately 77,758 people were receiving through the national ART 
programme, nearly 8,000 were accessed via the Social Security Scheme (SSS) (Ana 
Revenga, Mead Over et al. 2006). In total, it was estimated that 61% of people living with 
AIDS in Thailand are receiving the ART as on 2007 (UNGASS 2008).
The government antiretroviral therapy is mainly delivered through public facilities including 
district, general (provincial), regional and some university hospitals. Generally, the 
antiretroviral (ARV) clinic is ambulatory which serves as a part of out-patient department in 
a hospital. In large hospitals such as general, regional and university hospitals, care is 
usually provided by doctors as the first contact. On the other hand, in district hospitals, ARV 
clinics are either run by doctors or nurses. In case where nurses are the first contact of 
services, complicated cases are handed over to doctors. It was estimated that by the end of 
2004, there were 800 antiretroviral sites to provide care throughout Thailand (Phanuphak
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2004). In Chiang Mai, Northern Thailand, antiretroviral therapy delivery at health centres 
under supervised of district hospital for uncomplicated cases is also being initiated. 
Moreover, to reach the HIV-infected children the national ART programme has tailored the 
guideline and recommendation specific to children and programme for children has been run 
side by side with the adult programme. In recent evaluation, it has found to be the treatment 
is as effective as that found in the adults after 72 weeks of treatment in term of virological 
and immunological response (Puthanakit, Oberdörfer et al. 2005)
2.6.5.3 Production of generic antiretroviral drug
High cost of the antiretroviral drugs was once considered as a major obstacle for 
antiretroviral drug accessibility. Regarding this problem, the Thai government by GPO 
began to conduct researches and developed antiretroviral drugs in 1992. It started first with 
Zidovudine (AZT) and Dideoxypurine nucleoside (ddl). The generic of AZT was later 
produced in 1996; however, generic production of ddl was blocked by the patent hold 
company- Bristol Myers-Squibb (BMS). In November 1999, the GPO submitted a request 
for a compulsory license to override the patent to produce a generic ddl to the Thai 
Department of Intellectual Property. The use of compulsory license was prohibited. In year 
2002, the network of Thai people who living with HIV/AIDS won a lawsuit against BMS 
which claimed that the BMS patent registration for its buffered tablet formulation of the ddl 
(brand name Videx) was illegally amended in an attempt to claim for a wider monopoly 
than the patent description justified (Ahmad 2002); (Kapp 2003). Thus, the Government 
Pharmaceutical Organisation can legally produce alternative form of ddl at the lower cost 
compared to the imported Videx. This was coordinate with World Health Assembly in 2003 
which emphasized on making vital drugs including antiretroviral drug available to the 
people at affordable cost (Kapp 2003). In 2002, the first fix-dose generic antiretroviral drug 
produced in Thailand called “GPO-Vir” was produced. The evidence of its efficacy was 
confirmed by one study which found that GPO-vir was well tolerated and effective in
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increasing CD4 cell counts and suppressing plasma viremia in advanced HIV infection 
during the 48 weeks follow-up period (Getahun, Tansuphasawadikul et al. 2006). The 
present lists of drug price in Thailand are shown in Table 2-8.
Table 2-8: Cost of ARV drugs per patient by regimens in Thailand
Antiretroviral regimen Month cost per 
person (SUS)
Annual cost per 
person (SUS)
First-line regimen (MOPH guideline)
(1) 3TC+d4T+nevirapine 30.0 360.0
(2) d4T+3TC+efavirenz 64.5 773.7
AZT+3TC+efavirenz 95.5 1,145.7
AZT+3TC+nevirapine 60.0 720.0
(3) d4T+3TC+IDV/r 87.5 1,050.0
AZT+3TC+IDV/r 118.5 1,422.0
Second-line regimen
ABC+ddl+LPV/r 570.6 6,846.6
ABC+ddl+SQV/r 552.4 6,628.2
Source: World Bank: The economics of effective AIDS treatment: Evaluating policy option for 
Thailand
2.6.5.4 Financing of AR T
In early stage of antiretroviral drugs in Thailand, people who required for the treatment had 
to pay for the antiretroviral drugs. The high medication costs brought down the accessibility 
to the drugs. Efforts to lower down the drug price were made by the government together 
with NGOs. However, not many people can access to the drugs and free of charge ART 
programme can be benefit limited to some people who can access to the free programme 
providing NGOs or research institutes in some areas of Thailand. The government supported 
ART at the initial stage was also considered as research programme.
In one micro-costing study in Khon Kaen, Thailand during the period of 2001-2002 before 
the nationwide ART scale up, it was found that the average cost per outpatient visit with and 
without antiretroviral drugs was $US294.2 and $US26.1, respectively. The average cost per 
inpatient day with and without ARV drugs was $US368.1 and SUS43.8, respectively. The 
net annual cost of HAART was estimated to be $US5 674 629. This is equivalent to 20.0% 
of the annual budget for the health scheme for adults in Khon Kaen in 2002. The huge 
differences between costs of patients with HAART and without HAART was due to that the
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study was conducted before the invention of generic locally produced ARV in Thailand 
(Kitajima, Kobayashi et al. 2003). Thus, the major of the costs component for those who on 
ART was costs of the brand name drugs which drove the cost in those who one ART ten 
times more expensive than those who were not taking the drugs.
Aside from either full self-pay or free drugs programme, partly pay for the drug or co­
payment was also initiated in 2000. The programme turned the patients from drug receivers 
to co-providers. This project was run by the network of people living with HIV/AIDS 
(PLHA) in Thailand with supports from AIDS Access Foundation and Medecins Sans 
Frontieres (MSF) called the buyer club. The club dealt directly with Government 
Pharmaceutical Organisation to purchase generic antiretroviral drugs as well as the some 
imported drugs such as Efavirenz which hold patent protection in Thailand. Patients were 
prescribed medication by doctors in public hospitals, then, they usually took the prescription 
to the club which dispensed the medicines together with treatment information, counselling 
and assisting in dosage planning as well as the follow-up time schedule. The central stock 
was held in the Thai Networks for people living with HV/AIDS (TNP+) office in Bangkok, 
Thailand. Up till June 2002, there were 21 Buyer’s Club branches and 1,081 people on the 
treatment. However, the number of the patients in this programme had been declining due to 
expansion of the free government programme. New cases would benefit from the free 
government programme and the non-nai've cases also switched to the government 
programme which now accepts previous treated patients (Ana Revenga, Mead Over et al. 
2006).
The government programme which providing antiretroviral care free of charge made an 
attempt to expand to cover every need. By the end of 2007, it was estimated that more than 
61% of PLHA were able to access to the drugs (UNGASS 2008) under three major medical 
insurance schemes in Thailand; the Civil Servant Medical Benefit Scheme (CSMBS), the
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Social Security Scheme (SSS) and the Universal Coverage Scheme (UCS). The first covers 
civil servants, government enterprises’ employees and their family members; the second 
covers employees in formal sectors of private companies and the last covers the rest of 
population. However, self-pay is another option for people who seek for more cares rather 
than what they receive under their schemes and for those who have no insurance 
(Thanprasersuk, Lertpiriyasuwat et al. 2004). The national ART programme is still 
recruiting for more patients. With expansion of the government programme, the NGOs and 
research programme which provide free ART, then, has handover their cases to the 
government programme. Even the nature of free of charge programme, however, the 
government programme was not yet included into the basic service care package in the UCS 
(Thanprasersuk, Lertpiriyasuwat et al. 2004). This was because of the expected long-term 
cost and higher number of patients in the future. High future cost was the result of the fact 
that drug resistant is unavoidable, alternative prescribed regimen is usually more expensive. 
Thus, with limited government subsidy per capita to the care providers for providing cares 
in the UCS, this could cause the financial burden in the long-term. The present overall 
annual cost per person of providing HAART has shown in Table 2-9.
Table 2-9: Annual cost per patient by antiretroviral regimens
Cost component Annual cost per person ($US)
___________________________________________ First-line regimen________ Second-line regimen
(1) ARV drugs 471.2 6,589.2
(2) Laboratory tests 30.3 30.3
(3) OI infection 120.4 120.4
(4) OPD service 69.3 69.3
(5) IPD service 151.0 151.0
(6) ARV+Laboratory test (1)+(2) 501.4 6,619.4
(7) Hospital services (4)+(5) 220.4 220.4
(8) Total ARV cost (3)+(6)+(7) 842.2 6,960.2
Source: Supakankunti et al 2004
A recent report from the World Bank has suggested that the first-line regimen recommended 
by the MOPH (See Table 2-9) was the most cost-effective option for Thailand; at a cost of 
$US 736 per discounted life-year saved compared to $US2,415 per discounted life- year 
saved for that of second-line regimen (Ana Revenga, Mead Over et al. 2006). However, the
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second-line regimen was still affordable and brought in subtle benefits in relation to life year 
saved (Ana Revenga, Mead Over et al. 2006). In the projection by the World Bank, the 
Thailand’s A TPS spending will increase from $US100 million per year to more than 
$US500 million per year by the year 2020 due to the switch to use second-line drug 
regimen. Moreover, in this report, it has been showed that the public financing of ART will 
help ensure equitable access especially when the second-line treatment is of use (Ana 
Revenga, Mead Over et al. 2006). In overall, with the life-prolonging effects by HAART the 
number of ones who need the treatment will increase as well as the more complex and more 
costly treatment in the future, the forthcoming AIDS cares expense could rise substantially 
(Nagelkerke, Jha et al. 2002). In overall, ART is thought of as the cost-effectiveness in 
Thailand. From the projection using epidemiologic/economic model to 2025, the use of 
ART can save the money up to $US 3.2 billion. However, this depends on the use of local 
produced generic ARV (Ana Revenga, Mead Over et al. 2006).
Recently, a study explored the inequality in term of access to HAART in the Thai context 
has been published which showed that people with CSMBS were significantly likely to 
receive ART compared with patients under the UCS (Kitajima, Kobayashi et al. 2005). 
However, the number of study investigating the inequality in relation to benefit from 
HAART among social classes after the roll out of the free-of-charge national programme in 
Thailand is still relatively limited. The country, thus, requires insightful information for 
better equitable distribution regarding benefit of the programme in its own context for its 
own people.
2. 7 Summary
(i) HAART is considered as the standard of care for HIV/AIDS treatment but few 
amounts of people in developing countries can access to the treatment.
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(ii) Scaling up of the treatment has been increasing dramatically over the past few years 
with the great efforts from multi-organisation at both local and international levels, Most 
evidence in relation to treatment outcomes and experiences of ART are from developed 
countries. In contrast, only a little knowledge in this field is from developing countries 
where the majority of PLHA resides. Transferring of knowledge to this part of world 
requires cautious consideration.
(iii) Inequalities among social classes of people in relation to accessibility to the 
treatment and benefits of the treatment still exist in spite of availability of effective 
treatment and falling down on drug prices both in developed and developing countries
(iv) Factors determine success of the ART programme vary according to settings as well 
as its costs which cannot be directly transferred. Countries have to understand their own 
dynamics of ART programmes which are specific to the setting and would benefit people 
both domestically and globally. Given Thailand, which is the middle-income developing 
country, the model that is applicable in this setting might be able to generalise to other 
developing countries whereas model that is inapplicable in Thailand would be difficult to 
induct to other poorer setting.
(v) In Thailand where implementation of a national antiretroviral programme using its 
own produced GPO-Vir was officially initiated since 2003, patterns of HIV/AIDS cares are 
diverse, evidences of benefits of the programme in relation to mortality, disease progression 
and other outcomes are also limited. Moreover, benefit distribution in various social classes 
might vary from group to group. The exploration to have an insightful understanding of the 
programme regarding its characteristics and benefits to a variety of population is needed
For the next chapter, hypothesis and objectives are presented followed by the procedures to 
test the hypothesis and to accomplish the objectives of the present study. Study design, 
study sites, participants, outcomes measures and process of data collection and analysis are 
clearly stated in the next section.
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3 Methods
In Thailand, it was estimated that 61% of PLHA are receiving ART through the national 
government antiretroviral therapy program since the start of the programme in 2001 
(UNAIDS 2008). However, evidences of the impact of ART on survival and other outcomes 
such as health-related quality of life, as well as factors contributing the treatment outcomes 
in Thailand are still scarce.
In this chapter, the hypothesis which the researcher aimed to investigate, objectives of the 
present study, study design, main outcomes measured and the procedure of data collection 
as well as the data analysis are presented according to the objectives which are shown below
3.1 Hypothesis
Null hypothesis: there was no association between socioeconomic status (defining by 
household income) of the HIV-infected patients and their HIV-related mortality following 
enrolment into the Thai national ART programme”
Alternative hypothesis: there was an association between socioeconomic status of the 
participants and their HIV mortality following enrolment into the Thai national ART 
programme since the roll out of the government ART programme; anticipated that 20% of 
patient with household income equal or below the median would die while 10% of the 
patients with household income above the median would die
3.2 Objective
1. To determine the impact of ART on treatment outcomes in relation to:-
i. Survival
ii. Health-related quality of life
iii. Immunologic response (CD4 cell counts)
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iv. Duration of the first-line regimen of the ART
2. To explore factors that may contribute to the treatment outcomes, the factors include
v. Age
vi. Gender
vii. Socioeconomic status
viii. Education
ix. Health insurance
x. Accessibility to the hospital
xi. Being member of PLHA self-help group
xii. Being naive to the ART
xiii. Baseline CD4 cell counts
xiv. Disease staging before starting ART (according to WHO classification)
xv. Initial prescribed regimen
xvi. Type of ARV clinic (nurse-led vs. doctor-led)
3. To explore the characteristics of PLHA who received antiretroviral therapy in relation to 
baseline characteristics and their clinical information and the experiences of care 
provided by different types of ARV clinic (doctor- and nurse-led clinic)
For terminology and definition used in this study, please see Annex-3 for more information.
3.3 Study design
This present study aims to identify the treatment outcome of HAART in those who initiated 
the treatment between March 1, 2001 and April 30, 2004. Thus, all those who started the 
treatment during this period (a total of 501 participants) should be included to avoid the 
selection bias.
During May-July 2004, a survey which was conducted to explore the characteristics of ART 
providers and PLHA who were initiated ART between March 1, 2001 and April 30, 2004
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(Objective 3). To identify the treatment outcome in this group of patients, they were 
followed and assessed for the outcomes as on May 1, 2007. However, due to the sampling at 
that time, only 302 participants were included, thus, another 199 had to be sought. This was 
to identify the effects of ART on the outcomes of overall patients who started the treatment 
during that period as the survival which based on the prospective cohort alone would not be 
able to estimate the accurate survival
This survival study is then a combination of two cohorts (see Figure 3-1, study diagram) 
which are
(i) Prospective cohort; this section was conducted based on the survey in 2004. The 
participants in this group were followed and assessed for the treatment outcome on May 1, 
2007. To identify the outcomes in relation to health-related quality of life, in this cohort, a 
subgroup of 97 participants who were interviewed in the survey were re-interviewed to 
evaluate for the changes of health-related quality of life over the three years period of ART. 
The re-interview was conducted during June-July 2007
(ii) Retrospective cohort; in this part of the study, the treatment outcomes of the patients 
who were not included in the prospective cohort but were initiated the treatment between 
March 1, 2001 and April 30 were sought as on May 1, 2007 (199 participants). And to 
identify factors that might influence the outcomes, baseline characteristics and clinical 
information of the participants in this group were also sought. Again, this cohort did not 
constitute part of the initial sample surveyed; the data on outcomes for this group are likely 
to be less reliable or valid as for the initial sample.
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Figure 3-1 : Study diagram
3.4 Scope of the study
This study aims to focus on identifying the impact of the ART on survival and other 
treatment outcomes including HR-QOL, improvement of the CD4 cell count and duration 
on the first-line regimen. The study also attempts to explore the association between those 
outcomes and patients’ characteristics regarding socioeconomic, gender, accessibility, etc., 
of those who have entered into the national antiretroviral therapy programme in Chiang Mai, 
Northern Thailand in the context of universal health care setting since the rollout of the
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programme in 2001. However, the researcher does not try to identify or assess factors 
determining access to the treatment programme.
3.5 Study sites
The government ART programme has been implemented throughout Thailand since 2003 
under the universal health insurance scheme (Over, Revenga et al. 2007) and services of the 
programme has been delivered through various sizes of health facilities; from small units 
such as district hospital to large units like university hospital. However, the services have 
been provided mainly through hospitals under the Ministry of Public Health (MOPH) 
(Thanprasersuk, Lertpiriyasuwat et al. 2004); (Chasombat, Lertpiriyasuwat et al. 2006); 
(Thanprasertsuk, Lertpiriyasuwat et al. 2006). The services are also available in some 
private health facilities with partial support from the MOPH, but this is still uncommon 
(Thanprasersuk, Lertpiriyasuwat et al. 2004).
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Figure 3-2: Map of Chiang Mai and Thailand
Source: http://www.bmair.nl/Informatie/Thaiiand/Kaarten/Kaart-Thailand-Chiang-Mai.gif 
(Accessed April 2008)
This study began firstly in 2004 in the area of Chiang Mai. It is the third biggest province in 
Thailand regarding its population (Thailand 2005). It is located in upper Northern Thailand 
which is about 750 kilometres away from Bangkok. Its population was 1.6 million in 2003 
with slightly more of women to men. In relation to HIV/AIDS, Chiang Mai is only the 
second most affected area of HIV/AIDS to Bangkok since the beginning of the HIV/AIDS 
era. Up till March, 2008, there are about 21,915 cases reported form Chiang Mai which 
account for 6.6% of total AIDS cases in Thailand (21,915 out of 328,864 cases) and 21% of 
cases in Northern region (MOPH 2005). The incidence rate of AIDS cases has been
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declining, however it is still relative high compared to nationwide incident rate; in 2004, the 
incidence rates of AIDS in Chiang Mai and Thailand were 38.8 and 32.0 per 100,000 
population respectively and were 27.6 and 14.9 per 100,000 population in 2007 (MOPH 
2005). According to what mentioned above, Chiang Mai was chosen by the Ministry of 
Public Health to pilot the national antiretroviral treatment programme 2 years prior to the 
rest of the country, thus, it has more experiences of ART and patients with longer follow up 
duration comparing to other places in Thailand (Thanprasersuk, Lertpiriyasuwat et al. 2004).
Table 3-1: Registered health facilities in Chiang Mai
Health facility Number
Ministry of Public Health
General hospital 1
District hospital
■ 120-bed 1
■ 90-bed 2
■ 60-bed 1
■ 30-bed 14
■ 10-bed 2
Health centre 255
Other Ministries
Hospital 5
Private
Hospital 13
Clinic 276
Dental clinic 64
Mid wife clinic 24
Drug stores 298
Source: Annual report of registered health facility in Chiang Mai year 2004 by Chiang Mai Provincial 
Health Office.
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Table 3-2: Information about three selected ARV clinics in fiscal year 2003 (Oct 2002-Sep 2003)
Information ARV clinic 1 ARV clinic 2 ARV clinic 3
Type of practitioner in ARV clinic Doctor-led clinic Large nurse-led Small nurse-led
Number of responded doctors 1 2 1
Number of responded nurses 3 6-7 2
Number of patients in the 163 218 94
government ART programme*
Hospital type General District District
Number of bed 531 120 30
Distance from Chiang Mai city 10 25 20
centre (Km)
Year founded 1992 1982 1982
Number of hospital staff
Doctors 66 12 6
Dentists 7 5 3
Pharmacists 23 8 5
Nurses 405 94 43
Other medical staff 558 31 66
OPD
Number of patients 135,997 38,340 28,857
Number of visits 325,801 173,494 121,324
IPD
Number of beds 531 120 30 (53)
Number of admissions 28,671 8,141 3,509
Number of in patient days 182,503 52,772 16,711
Number of deaths 1,125 93 19
Number of referrals 149 2,515 419
OR and LR
Operations 13,878 987 40
Deliveries 1,804 332 189
Source: annual report of year 2003 of the three hospitals
3.6 Selected facilities
In Chiang Mai, general (provincial) and district hospitals have played an important role of 
the services delivery to promote the programme coverage especially to the outreach areas 
(see Table 3-1). The programme is usually delivered strictly through hospitals, however, the 
programme services for uncomplicated cases have been initiated in some well-organized 
sub-district health centres to reduce burden of workloads in the hospitals as well as to 
decrease waiting times and expenses of the patients as the health centres are usually located 
in the community and easier for patients to get services.
To demonstrate the delivery of ART in various types of health facilities in Chiang Mai, 
three ARV clinics from three hospitals were selected as the study units from the list of
* Information on July 31, 2004
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hospitals operated under the Ministry of Public Health in Chiang Mai as public hospitals are 
the major provider of the government ART programme. One doctor-led ARV clinic in 
general hospital and two nurse-led ARV clinics (large and small clinics) from two district 
hospitals was included (see Table 3-2). Two different sizes of nurse-led clinics, which 
determined by number of patients registered to the clinics, were selected because different 
capacity of facilities would instigate differences of characteristics of the patients as well as 
effectiveness of the programme.
3.7 Participants
The participants were both men and women patients aged 18 or older who were treated with 
HAART in the government ART programme from the selected facilities. This study 
included all who initiated the treatment during March 1, 2001 till April 30, 2004. The 
calculation of the sample size was performed to test the study hypothesis; the computation 
was based on the association between socioeconomic status and mortality rate
Null hypothesis', there was no association between socioeconomic status (defining by 
household income of the participants) and their HIV-related mortality following enrolment 
into the Thai national ART programme since the roll out of the government ART 
programme.
Alternative hypothesis: there was an association between socioeconomic status of the 
participants and their HIV mortality following enrolment into the Thai national ART 
programme since the roll out of the government ART programme; anticipated that 20% of 
patient with household income equal or below the median would die while 10% of the 
patients with household income above the median would die
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Calculation: using the EPI Info TM 2002, at the statistic significant level = 0.05; power =
0.8; ratio 1:1, with two sides test, total required sample size was approximate to 219 in each 
group (total required =438). However, this study would include participants up to 500 to 
allow the drop out.
[Alternative method use to calculate the sample size was shown in Annex 5]
Regarding the sample size, two methods to calculate the sample size were used to ensure 
that the required number of participants was adequate. However, the number was based on 
the projection of the mortality rates between two groups of household income in which no 
known data regarding this projection was available. Moreover, the participants were also 
recruited more than what calculated by two methods to increase the power of the study and 
allow for drop out of the participants from the study.
3.8 Data procedure
In the present study, the outcomes of the ART were assessed on May 1, 2007 based on the 
501 participants from the two cohorts (prospective and retrospective; see section 3.3) who 
initiate the treatment during March 1, 2001-April 30, 2004. The data of the factors that 
might influence the outcomes were also collected based on the baseline characteristics of the 
participants.
(i) In the prospective cohort of 302 participants, it was based on a survey which was 
undertaken during May-July 2004, clinical information as well as baseline 
characteristics of patients were gathered. In relation to health-related quality of life, 
a subgroup of 97 patients of the prospective cohort was randomly drawn from the 
list of those who still survived and were interviewed for their HR-QOL in the 
survey in 2004. They were re-interviewed using the Modified McGill Questionnaire
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and EQ-5D during June-July 2007 to evaluate the changes in their HR-QOL after 
the period of three years on HAART
(ii) For retrospective cohort, the treatment outcomes of 199 were followed up and were 
determined at the same time as the prospective cohort on May 1, 2007. Baseline 
characteristics and clinical information were also sought to identify their association 
with the treatment outcomes. Still, this cohort did not constitute part of the initial 
sample surveyed; the data on outcomes for this group are likely to be less reliable or 
valid as for the initial sample
The data procedures in the present study were separated regarding to these two cohorts.
3.8.1 Prospective cohort
3.8.1.1 Baseline data from the survey in 302 participants
This was the first part of the study which aims to understand the situation of national
antiretroviral therapy programme after the roll out in Chiang Mai since 2001, and to retrieve 
the baseline characteristics, clinical information and their health-related quality of life of the 
participants. During the survey, clinical information of the participants was extracted while 
patients’ characteristics were gathered using patient interviews
3.8.1.1.1 M edical record review
Medical record and the visit forms of each participant were reviewed and extracted. The 
retrieved clinical information included
(i) Age
(ii) Gender
(iii) Health insurance
(iv) Status before start the antiretroviral treatment (naive or experienced)
(v) WHO HIV/AIDS staging before initiation of ART
(vi) Date start the treatment
(vii) Duration of follow up at the clinic
(viii) Regimen of ARV used
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(ix) Baseline CD4 cell counts, CD4 cell counts at 6- and 12-month after initiation of 
ART
(x) Baseline body weight, body weight at 6- and 12-month after initiation of ART
(xi) Initial prescribed regimen
Both extreme values and missing values were verified and sought before recording onto the 
excel spread sheet.
3.8.1.1.2 Questionnaire and patient interview
Information regarding patient characteristics, socioeconomic status, access to the hospital, 
and other related issue were identified by doing patient interviews. The interviews using 
structured questionnaire by trained interviewers in Thai language were performed. Please 
see Annex-4 for full questionnaire. The interviews were conducted during May-July 2004. 
Two to three volunteers PLHA in each hospital were trained to be the interviewers by the 
researcher. The interviews could be arranged to do in other places at other times at their 
convenience under the agreement and permission of the participants; the interviews could be 
carried out at patients’ house and patients’ working places. The given information from each 
participant was gathered and analyzed by the researcher
The interview took on average half an hour for each patient. The patients were informed of 
the rational, objectives, risks of the study, confidentiality as well as their right to participate 
and quit from the study before proceeding with the interviews. Possible risks from the 
interviews were minimized as much as possible. Clarifications were verbally provided by 
the interviewers when required.
The questionnaire was newly built. This structured questionnaire contained of both multiple- 
choice questions and some open-ended questions which covered the following nine main 
areas (see Table 3-3)
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Table 3-3: Data from the interview of 302 participants during May-July 2004
Information_______
Patient characteristic
Socioeconomic status
Accessibility
Adherence
Social issue and
stigmatization
Sexuality
Services at the ARV 
clinic
Adverse event 
HR-QOL*
_______________________________ Description_______________________________
Age, gender, religion, highest education level, type of health insurance, marital 
status, number of people in the household, number adult with HIV infection, number 
of children with HIV infected, number of treated with ARV
occupation, main wage earner, income, household income, type of accommodation 
distance, travelling time, method used to come to the hospital 
number of doses not taken within a week and number of doses not taken within a 
month, number of doses taken late then usual time more than 30 minutes within a 
week, number of doses taken late then usual time more than 30 within a month, last 
dose of drug not taken, reason not to take, any intention not to take the medicine, 
method use to remind taking medication, number of missed appointment within 3 
months
support from the PLHA self-help group, HIV status know by his/her couple, family, 
community, experience of people turn away,
Sexual activity within 3 months, number of people having sex within 3 months, 
usage of condom
Time spent at the ARV clinic, feeling about time at the clinic, see doctor for the last 
visit, time spent with doctor, feeling about time spent with doctor, received 
information regarding ARV, feeling about information given, feel private enough in 
the room, conceived of dislike from hospital staff, hospital action when missed 
appointment
Experience of adverse effect; stopping the medication after experience the side effect, 
who is the first consultant
Health related quality was measured by using modified McGill and EQ-5D
* HR-QOL were re-evaluated during June-July 2008
3.8.1.1.3 Adaptation and translation of questionnaire
The questionnaires used to measure HR-QOL were derived from two widely used 
questionnaires which are McGill quality of life questionnaire and EQ-5D (VAS). The EQ- 
5D (VAS) was used in the original Thai version without any changes. However, McGill 
quality of life questionnaire was translated and modified to match the context of the patients 
in the study site (Box Annex-1).
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Box 3-1: Method of translation and modification of the McGill quality of life questionnaire 
Method of translation of McGill Questionnaire
Two Thai medical doctors including the researcher independently translated the original McGill 
questionnaire from English to Thai in a way that the patients could easily understand and answer. 
Three medical and one public health officers reviewed the translations. Then, the questionnaire was 
back-translated form Thai to English again. The original and back-translated questionnaire were 
compared and revised by the medical and public health officers together with the researcher as well 
as the PLHA.
Modification of the McGill Questionnaire
Like the original McGill questionnaire, participants were asked to report their quality of life within 
the last 2 days. However, there were some modifications which were the result from piloting the 
questionnaire (see section below). The modification were
1. One question was added which asked the participants to compare overall quality of life in the 
past 2 day to just before entering the government ART programme.
2. Scale was reduced from 11 scales (0-10) to 5 scales (0-4) which is more convenient and more 
understandable for Thai context
3. There was short description for every scale in each question e.g. “Level I” (1) means “Very 
bad” and “Level V” (5) means “Excellent”
4. The questionnaire was magnified at 2 questions per page including the 0-4 scales; this was 
used during the interviews. It allowed respondents to read ,visualize and point out the scale 
which suit their health status for more accurate answer
3.8.1.1.4 Improving reliability and validity of the questionnaire
For a survey, construction of the questionnaire is one of the important issues. To develop a 
tool to measure the five areas of interest, related literatures search was performed. The 
contents of the questionnaire were constructed by the researcher together with people who 
living with HIV/AIDS to improve the validity of the questionnaire. Multiple-item scales 
were applied in the questionnaire wherever possible to enhance reliability of the 
participants’ given results. Criterion validity of the study has been improved by using mfti- 
measures to reveal the effectiveness of the programme. Then, the first draft was produced
Ambiguous questions were avoided, as were statements that included more than one issue. 
Statements were kept short and language simple. Participants would be asked to respond to 
individual statements and allow the interviewers to circle the chosen choices. The second 
draft of the questionnaire was reviewed for face validity with five patients of various ages 
from 3 hospitals. Difficult questions were reworded and ambiguous questions excluded. 
Some relevant questions were also added. The third draft was reorder. Non-randomized, 
convenience sample of 30 patients were requested to complete the questionnaire on the
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purpose of pilot study wording and coding in the questionnaire was carefully checked again. 
However, the results were only tested for internal consistency which involved testing for 
homogeneity of the results (inner-item correlations and Cronbach’s alpha) due to the single 
administration of the questionnaire.
3.8.1.1.5 Pilot study of the questionnaire used for the survey
The pilot study was conducted in Mae-On district which is 25 kilometre away from Chiang 
Mai province to check for the completeness of the questionnaire. The questionnaire was 
piloted with 30 PLHA who were currently being treated with antiretroviral drug under the 
programme at one district hospital. Two leaders of PLHA from hospital in that district were 
trained, using the steps of training mentioned above, to use the questionnaire. The piloting 
took 2 weeks to complete the interviews. Problems related to word in questions, frame of 
reference, description in the questionnaire occurred during the pilot study were recorded 
discussed between the trained interviewers and the researchers. Information from 30 
respondents was tested for validity (face, content, construct) and reliability (internal 
consistency using Cronbach’s alpha). The questionnaires were, then, revised and modified. 
Some questions were omitted and added. Order of questions was re-arranged. Words were 
clarified and simplified to use among PLHA. After piloting, the final version of 
questionnaire was produced and was used to determine effectiveness.
3.8.1.2 Treatment outcome
The treatment outcomes of the present study of the both prospective and retrospective 
cohorts consists four main measures including survival of the participants, health-related 
quality of life, immunological improvement of the CD4 cell count and duration on the first- 
line regimen. Their definitions as well as sources of information were shown in Table 3-4.
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Table 3-4: Treatment outcomes of 302 participants
Treatment outcome Definition Source of information*
Survival All-cause mortality occurring during the follow- ■ Patient medical record
up period were executed on a continuous basis ■ Contact related facilities where
from physician reports and through record patients referred to
linkages carried out with ICD 10 (international 
classification of the disease version 10) death 
classification
■ Contact with patient family
Health-related quality Changes in health-related quality of life Interviewed using the questionnaires
of life measured using modified McGill questionnaire 
and EQ-5D
Immunological CD4 cell counts approached the level of 200 ■ Patient medical record
response and 500 cell/uL ■ Contact related facilities where 
patients referred to
■ Contact with patient family
Duration on 1st line Duration on 1st line regimen before changing ■ Patient medical record
regimen regimen and reason for changes ■ Contact related facilities where 
patients referred to
■ Contact with patient family
* For those who might die or be referred to other hospitals as well as patients who terminates due to 
other causes, their outcome were sought through medical record, contact to related facilities (if they 
were referred out) and contact (both directly and indirectly) with their families.
The survival is the key outcome measure for success of the treatment as the HIV/AIDS is 
considered as a fatal disease. It was also measured as the researcher aimed to compare the 
success rates of the treatment in developed and developing countries. In the present study, 
all-cause mortality of the participants was used as an outcome measure.
As the treatment has turned the disease into a chronic manageable disease, quality of life 
data have added useful information to treatment trials which sometimes supports the 
findings of the trials (Bozzette, Kanouse et al. 1995); (Revicki, Moyle et al. 1999); 
(Nieuwkerk, Gisolf et al. 2000), and sometimes contradicts trial outcomes (Saffin, 
Finkelstein et al. 1996) emphasising the importance of obtaining information of adverse 
effects and tolerability rather than just survival. Moreover, studies regarding quality of life 
in PLHA being treated with HAART are still limited in developing countries.
Health-related quality of life (HR-QOL); The widely used measurement of HR-QOL for 
HIV-infected individuals can be classified into 2 groups; generic measures , such as SF-36
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(Arpinelli, Visona et al. 2000); (Garcia Ordonez, Mansilla Francisco et al. 2001); (Wu, 
Jacobson et al. 2002) and Euroqol (EQ-5D) (Wu, Jacobson et al. 2002); (Ichikawa and 
Natpratan 2004), and HIV specific measures, such as MOS-HI (Ichikawa and Natpratan 
2004). However, there is no consensus regarding the best measurement approach.
In the present study, two approaches were used to measure HR-QOL, which are (i) EQ-5D 
Thai version and (ii) Modified McGill Quality of Life Questionnaire. The former 
questionnaire was used as it is simple, easy to use and available in Thai version. However, 
in each domain of the EQ-5D, only three possible choices can be answered. To add more 
information regarding quality of life, another measure was used. At the beginning, the 
researcher aimed to use the specific measure like MOS-HIV. However, at it was still 
underdevelopment at the time the study conducted in 2004. Thus, the researcher had to 
search for another general quality of life measure which adds more information rather than 
five domains in the EQ-5D. At that time, McGill Questionnaire was chosen as some 
domains such as existential feeling and support are interesting and might allow us to have an 
insight about quality of life of HIV/AIDS patients
This subgroup of the prospective cohort was randomly drawn from the list of those who 
managed to survive and who was interviewed during the survey (May-July 2004). This 
follow up study of 97 participants was conducted during June-July 2007 to identify the 
changes of HR-QOL after the period of three years on ART. However, in this subgroup, the 
sample size was not calculated as the research aimed only to have some information 
regarding quality of life of the patients
For immunological improvement, CD4 cell count, which is the surrogate marker for 
initiating and monitoring the treatment was also measured. As we know that at patient with 
CD4 cell count lower than 200 cell/uL of CD4 cell count is at risk of developing 
opportunistic infection and at the level of 500 cell/uL was associated with AIDS free
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duration (Kawado, Hashimoto et al. 2006). Thus, the two cut points were used as the 
outcomes measures in this present study. For the duration on the first-line regimen, this aims 
to identify the ability of the care provider in term of adverse effect and choice of regimen 
used as well as the chance to develop drug resistance of the patients.
3.8.2 Retrospective cohort
On May 1, 2007, similar treatment outcomes as those used in prospective cohort of 199 
participants were assessed (see section 3.8.1.2). However, their baselines which also 
gathered in the prospective cohort had to be sought regarding
i. Age
ii. Gender
iii. Socioeconomic status
iv. Education
v. Health insurance
vi. Accessibility to the hospital
vii. Being member of PLHA self-help group
viii. Being naive to the ART
ix. Baseline CD4 cell counts
x. Disease staging before starting ART (according to WHO classification)
xi. Initial prescribed regimen
At the time of initiation of the treatment were attempted to identify through medical record, 
contact to related facilities (in case they were referred out) and contact (both directly and 
indirectly) with their families by the researcher and trained interviewers. However, as this 
part was done retrospectively, the chance of missing data was also higher. However, the 
information at the baseline and outcome were sought and verified for accuracy as much as 
possible with the constraints imposed by the retrospective cohort nature.
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3.8.3 Quality assurance for the interview
As the interviews were one of the important methods in the present study to retrieve 
information during the survey, evaluation of HR-QOL and identification of baseline 
characteristics of the patients in retrospective cohort, to avoid bias of the interviewers being 
overly optimistic about the programme, the following processes were conducted.
1. All interviewers were trained carefully to ensure the validity of information. The 
purposes and objectives of the study were informed. Possible bias was documented 
and interviewers were asked to avoid these.
2. Every interviewer was required to read every single question and choice in the 
questionnaire. Testing for their understanding was performed, at the end of each 
question, the meaning of the question and choice was informed after discussion.
3. The researcher was at the interview room together with the interviewer team. Any 
inquiries would be solved by the team together. In case where the researcher was 
not available, other interviewers can consult via the mobile phone at all time
4. During the interview, the interviewers read every single question for the patients. 
Answers were record directly onto questionnaire. The questions and their scales 
were magnified and were given to the patients. The patients were informed about 
the scale instructions. Then, they were asked to choose the scale that suited their 
health status the most. This allowed the patient getting along with the questions
5. At the end of each day after finishing all of the interviews sessions, the interviewers 
discussed and validated the given information. If there were any enquiries, the 
interviewer team, then, would arrange to talk with the respondent again to rectify 
any possible mistakes
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3.8.4 Data testing and cleaning
Before proceeding with the analysis, all data both from the medical record and from the 
patient interview were entered using double entry verification and were tested for logical 
consistency set up in the coding specification and were checked for wide codes by 
generating a frequency distribution for each variable by the researcher. Any missing data 
was where possible validated with the staff at the hospital by comparing to the original copy 
of patient visit form and the patient’s OPD card.
3.8.5 Data Analysis
Data were analysed using SPSS for Windows, version 14.0 (SPSS Inc., Chicago, IL, USA). 
For the treatment outcomes like survival, the immunological improvement and duration on 
the first-line regimen, the survival and time to event analysis were used. For the survival 
analysis, all patients were taken into account. Cumulative incidences of the outcomes were 
estimated using Kaplan-Meier methods.
To compare the contribution of the investigated variables to the outcomes, survival and time 
to event function were compared between groups using the log-rank test. Cox proportional 
hazards regression was used to compute single variable and adjusted relative hazards and 
95% confidence interval (Cl). The time since the initiation was measured in weeks. The 
assumption of proportional hazards was validated by the inspection of log (-log (survival 
function)) estimates against log time plots. Participants who were still alive at the end of the 
study period were considered as right censored as of May 1, 2007. The proportional hazard 
models were adjusted for all variables that were significant in single variable Cox model. 
Variables considered to have influence on survival are show in the Table 3-5. Repeated 
analyses for other treatment outcomes (see 3.7.1.2 for treatment outcomes) were done 
similarly with the survival.
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Variables from the participants characteristic and effectiveness were analysed using 
methods of descriptive to summarize and describe the variables, and inferential statistics to 
describe to infer and predict outcomes of the study. The Chi-square statistic (X2) was used 
to test for associations between categorical variables (Fisher's exact test was used if 
appropriate). The ANOVA test was also used to test for differences among continuous 
variables. All tests were two-tailed, with a statistical significance level of P < 0-05.
Table 3-5: Baseline characteristics of the participants that might affect the outcomes
Potential confounder Measure
Gender Initial interview and medical record
Age Initial interview and medical record
Socio-economics
Main occupation Structured set of questions in interview to assess
Being main wage earner household income (questions 5 to 7 in the interview
Monthly income schedule given in Annex 4 6.4.5)
Monthly household income
Education Initial interview
Health scheme Initial interview and medical record
Distance between the hospitals and their houses Initial interview
Being member of PLHA self-help group Initial interview
Being naive to the ART Initial interview and medical record
Baseline CD4 cell counts Medical record
Baseline WHO stage IV Medical record
Initially prescribed with Pi-based regimen Medical record
Type of ARV clinic Staff interview
*see Chapter 2 for literatures regarding factors that might influence the treatment outcome
This chapter has summarised the methodology employed to evaluate the null hypothesis that 
socioeconomic status was irrelevant in determining outcome of patients enrolled into the 
National ART programme in Thailand. Chapter 4 progresses to analyse the results obtained 
using this methodology to ascertain factors that were identified as being significant in 
determining outcomes generated by the programme.
94
T
ab
le
 3
-6
: 
Pl
an
 o
f d
at
a 
an
al
ys
is
Results
CHAPTER 4 
RESULTS
96
Results
4 Results
In this chapter, the results of the present study are shown regarding the main objectives and 
outcomes of ART (see section 3.2). These sections were:-
1. Outcomes of the ART in relation to survival of 501 cases, health-related quality of 
life in the subgroup of 97 participants during the period of 3 years (between 2004 
and 2007), improvement of the CD4 cell count and duration on the first-line 
regimen.
2. Investigation of the factors that might influence the ART outcomes
3. Survey of ART programme in Chiang Mai, Northern Thailand to identify the patient 
and health care provider characteristics;
4.1 Outcomes of the antiretroviral therapy
A total of 501 cases were initiated on ART between March 1 2001 and April 30 2004. This 
also included 73 cases who started the treatment slightly earlier than that date. The 
outcomes on treatment were assessed on May 1 2007; 139 from doctor-led ARV clinic, 251 
from large nurse-led clinic and 111 from small nurse-led clinic. Of these participants, 28 
were lost to follow up. At the baseline, 56% were women (see Table 4-1), the average age 
was 36, most were general labourers (61.0%), and 57% were the main wage earner in their 
families.
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Table 4-1: Baseline characteristics of 501 participants
Characteristics N=501
Mean age: Year (SD) 36.0(18.3-60.5)
Gender
Male 217 (43.4)
Female 283 (56.6)
Main Occupation: N (%)
Unemployed 70(15.2)
Farmer or gardener 26 (5.6)
Self employed 57(12.3)
General Labourer 282 (61.0)
Housewife 25 (5.4)
Other 2 (0.4)
Being main wage earner: N (%) 277 (57.9)
Median monthly income: 1,000 THB (IQR) 3.0 (2.0-4.5)
Median monthly household income: 1,000 THB (IQR) 4.5 (3.0-7.0)
Education: N (%)
No formal educational 126 (26.6)
Primary school 214(45.1)
Secondary school 105 (22.1)
Higher than secondary school 29 (6.2)
Health insurance: N (%)
Civil servant medical benefit scheme 20 (4.1)
Fee for service 15 (3.0)
Social security scheme 43 (8.8)
Universal coverage 409 (84.0)
Being member of people who living with HIV/AIDS self-help group: N (%) 252 (53.8)
SD= standard deviation; IQR=inter-quartile range
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Table 4-2: Clinical information of 501 participants
Clinical information N=501
Previously treated with antiretroviral therapy: N (%) 123 (26.5)
Median time between HIV diagnosis and initiation of the treatment: Year (IQR) 5.0 (2.0-8.0)
Years on antiretroviral treatment: N (%)
2.0-4.0 years 276 (61.9)
4.1-6.0 years 142 (28.9)
6.1 or more 73 (14.9)
Median (IQR) 3.7 (3.5-4.9)
WHO staging before treated: N (%)
Stage II 50(10.6)
Stage III 98 (20.8)
Stage IV 324 (68.6)
Present WHO staging: N (%)
Stage II 45(11.4)
Stage III 81 (20.5)
Stage IV 269 (68.1)
Median baseline CD4 cell counts: cell/pL (IQR) 61 (18-173)
Initial regimen: N (%)
GPO-VIR (3TC+d4T+NVP) 355 (81.8)
AZT+3TC +SQV+RTV 23 (5.3)
D4T+3TC+EFV 20 (4.6)
AZT+DDI+NVP 19 (4.4)
AZT+3TC+EFV 17(3.9)
Latest regimen: N (%)
GPO-VIR (3TC+d4T+NVP) 229 (66.0)
GPOZ (AZT+d4T+NVP) 72 (20.7)
AZT+3TC+EFV 17 (4.9)
EFV+IDV+RTV 16 (4.6)
AZT+3TC +SQV+RTV 13 (3.7)
SD=standard deviation; IQR=inter-quartile range; NA=not applicable; GPO=Govemment 
Pharmaceutical Organisation; AZT=Zidovudine; d4T=Stavudine; 3TC=Lamivudine; 
NVP=Nevirapine; EFV=Efavirenz; IDV=Indinavir; RTV=Ritonavir; SQV=Saquinavir
In relation to clinical information, three quarters of them were naïve to ART, with the
median time since initiation of ART in the national programme being 3.7 years (see Table 4-
2). At initiation, nearly 90% of the patients were in an advanced stage (either in WHO Stage 
III or IV) with initial CD4 cell counts being low (median= 61 cell/uL). Most patients (70%) 
were started with the first-line regimen recommended by the national ART programme 
(GPO-Vir). More than half remained on this regimen by May 2007. Despite the fact that 
GPO-Vir was the recommended first-line regimen in the programme, not all patients 
received this regimen due to (i) the drug becoming recommended in 2003, but participants 
had been treated since 2001 and (ii) before prescribing this regimen, participants were tested 
for tolerability and side effects.
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In this study, the effects of ART on survival was analysed in detail using information 
regarding all participants who started treatment between May 2001 and May 2004. The 
treatment outcomes of this study were analysed as at May 2007. With a median follow up 
period of 3.7 (IQR=3.6-4.9) years, 76 patients died, 13 cases had disease progression 
leading to a change in the WHO staging (see Table 4-3) and 31% had to change prescribed 
ART regimens from their initial therapy. Five cases had decided to terminate the treatment 
themselves, eight cases were lost to follow up and seventy-five cases were transferred to 
nearby health facilities (information regarding treatment outcomes of those who transferred 
to other hospitals was obtained from their new health facilities). More than half CD4 cell 
counts approached 200 cell/uL and a quarter of them approached 500 cell/uL. 
Approximately 20% of patients experienced adverse reaction from using ART with 20 of 
them being resistant to the prescribed treatment. Table 4-4 provides details of four 
treatment outcomes including mortality, CD4 cell counts of 200 and 500 cell/uL and 
changing of prescribed regimen and were analysed through a hazard function and either 
survival or time to event density function.
Table 4-3: Treatment outcomes
Treatment outcomes N (%)
Death 76(16.0)
CD4 cell counts
More than 200 cell/pL 271 (54.2)
More than 500 cell/pL 121 (24.2)
Changing of treatment regimens 157(31.3)
Adverse event 93 (18.6)
Drug resistance 24 (4.8)
Advance staging 13(2.6)
Self-decided to termination of antiretroviral therapy 5(1.0)
Lost to follow up 28 (5.6)
Referring out to other hospitals 75 (15.0)
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Results
4.1.1 Mortality
In relation to all-cause mortality, 76 patients died during the period of analysis. These 
included two cases that committed suicide (hanging and poison drinking) and one case from 
a motorcycle accident. In these 76 cases, their average age was 36 years old and 60% of 
them were male. 56% of deaths occurred in the large nurse-led clinic; 32% in the small- 
nurse-led clinics and 12% in the doctor-led clinic. Nearly all patients who died were in the 
universal health scheme but only half of them were members of the PLHA self-help group. 
From a clinical perspective, generally they were in WHO stage IV with very low baseline 
CD4 with a median of 18 cell/uL. In relation to ART, GPO-Vir (d4T+3TC+NVP) was the 
regimen initially prescribed to 70% of patients who subsequently died. The mean survival 
time was 93.1 months (SD=1.8), however, as less than 50% of the participants died during 
the period of analysis, thus, no median survival time could be determined (see Table 4-4)
4.1.2 Health-related quality of life
4.1.2.1 Health related quality of life in 302 participants in 2004
In this study, two sets of questionnaire were used to determine patient’s aspect of health-
related quality of life; modified McGill’s questionnaire and EQ-5D (Thai version). They 
were used to measure the impact of the government ART programme on the patient’s 
emotional, social and physical wellbeing. Questions related adverse effects of the ART, 
stigma, sexual behaviour and questions which asked the participants to directly compare 
health status before and after ART were presented in section 4.3.7 - section 4.3.9.
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Table 4-5: HR-QOL using Modified McGill questionnaire-single question
Modified McGill Questionnaire, Single 
question
Doctor-led 
clinic: N (%)
Large nurse- 
led clinic: N 
(%)
Small nurse- 
led clinic: N
_____ (%)_____
Total: N (%)
Quality of life in the past 2 days
Level I (Very bad) 5 (5.0) 2(1.6) 2 (2.5) 9 (3.0)
Level II 16(16.0) 11 (9.0) 11 (13.8) 38(12.6)
Level III 51 (51.0) 71 (58.2) 39 (48.8) 161 (53.3)
Level IV 23 (23.0) 33 (27.0) 21 (26.3) 77 (25.5)
Level V (Excellent) 5 (5.0) 5 (4.1) 7 (8.8) 17 (5.6)
Quality of life in the past 2 days comparing to before entering the governmental antiretroviral treatment
programme
Level I (Extremely worse) 0 0 0 0
Level II 0 2(1.6) 3 (3.8) 5 (5.7)
Level III 23 (23.0) 13 (10.7) 10(12.5) 46(15.2)
Level IV 61 (61.0) 89 (73.0) 47 (58.8) 197 (65.2)
Level V (Extremely better) 16(16.0) 18(14.8) 20 (25.0) 54(17.9)
For the modified McGill’s questionnaire, the participants were asked to answer each
question with the range of Level I to Level V. They were given the meaning of the 2
extremes (Level I and Level V). For instance, Level I means extremely bad while Level V 
means extremely good. Then, the participants were asked to choose either Level I, II, III, IV
or V that match them the most for each questions. The questions consist of two single-item
scale (SIS) questions and 16 sub-measure questions. The first two SIS questions were used
to ask the participant for overall quality of life in the past 2 days and in the past 2 days 
comparing to just before starting the ART. The other 16 questions were used to measure
HR-QOL in sub-dimensions.
From the first SIS question which asked participants to document their health status in the 
previous 2 days, about half of the 302 participants documented their health in the past at 
level of 2 (fair health status) (see Table 4-5). For the second SIS question which asked 
participants to compare their quality of life in the past 2 days and the just before entering the 
programme, about 80% reported of better health after taking the ART. However, there were 
5 cases (1.7%) reported of worse health status comparing to before taking the ART. In these 
5 participants, 2 of them used to experience minor adverse effects from the ART and 1 of 
them had severe side effects and stopped taking the medicine. Four of them also showed 
good compliance to the medicine.
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In relation to the sub-measures including the evaluation of physical well being, 
psychological status, existential feeling and supports given, the findings were shown in 
Table 4-6 till Table 4-9. The level of HR-QOL of the participant were similar across the 3 
clinics
Table 4-6: Physical well being using modified McGill questionnaire
Physical well being in the past 2 days... Doctor-led 
clinic: N (%)
Large nurse- 
led clinic: N 
(%)
Small nurse- 
led clinic: N 
(%)
Total: N (%)
I have felt that my physical is 
Level I (extremely weak) 2 (2.0) 0 0 2
Level II 9(9.1) 3 (2.5) 3 (3.8) 15(5.0)
Level III 28 (28.3) 38(31.1) 28 (35.0) 94 (31.2)
Level IV 55 (55.6) 71 (58.2) 46 (57.5) 172 (57.1)
Level V (very well) 5(5.1) 10(8.2) 3 (3.8) 18(6.0)
Table 4-7: Psychological status using modified McGill questionnaire
Psychological status in the past 2 days Doctor-led 
clinic: N (%)
Large nurse- 
led clinic: N 
(%)
Small nurse- 
led clinic: N 
(%)
Total: N (%)
I have been depressed
Level I (not at all) 61 (61.6) 97 (79.5) 62 (77.5) 220 (73.1)
Level II 30 (30.3) 17(13.9) 14(17.5) 61 (20.3)
Level III 5(5.1) 5(4.1) 3 (3.8) 13 (4.3)
Level IV 3 (3.0) 3 (2.5) 1 (1.3) 7 (2.3)
Level V (extremely) 61 (61.6) 97 (79.5) 62 (77.5) 220 (73.1)
I have been nervous or worried
Level I (not at all) 58 (58.6) 88 (72.1) 52 (65.0) 198 (65.8)
Level II 21 (21.2) 20(16.4) 18(22.5) 59(19.6)
Level III 13(13.1) 5(4.1) 2 (2.5) 20(18.0)
Level IV 5(5.1) 7 (5.7) 6 (7.5) 18 (6.0)
Level V (extremely) 2 (2.0) 2(1.6) 2 (2.5) 6 (2.0)
How much of the time did you feel sad
Level I (never) 54 (54.5) 67 (54.9) 49 (61.3) 170 (56.5)
Level II 35 (35.4) 47 (38.5) 25 (31.3) 107 (35.5)
Level III 3 (3.0) 4 (3.3) 4 (5.0) 11(3.7)
Level IV 6(6.1) 4 (3.3) 1(1.3) 11(3.7)
Level V (always) 1 (1.0) 0 (0.0) 1 (1.3) 2 (0.7)
When I thought of the future, I was
Level I (not afraid) 39 (39.4) 63 (51.6) 33 (41.3) 135 (44.9)
Level II 30 (30.3) 30 (24.6) 29 (36.3) 89 (29.6)
Level III 20 (20.2) 16(13.1) 13 (16.3) 49(16.3)
Level IV 7(7.1) 6 (4.9) 2 (2.5) 15 (5.0)
Level V (terrified) 3 (3.0) 7 (5.7) 3 (3.8) 13 (4.3)
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Table 4-8: Existential feeling using modified McGill questionnaire
Existential feeling in the past 2 days Doctor-led 
clinic: N (%)
Large nurse- 
led clinic: N 
_____ (%)_____
Small nurse- 
led clinic: N 
(%)
Total: N (%)
My life has been
Level I (utterly meaningless and 2 (2.0) 3 (2.5) 2 (2.5) 7 (2.3)
without purpose)
Level II 14(14.1) 16(13.1) 12(15.0) 42 (14.0)
Level III 39 (39.4) 54 (44.3) 29 (36.3) 122 (40.5)
Level IV 29 (29.3) 33 (27.0) 26 (32.5) 88 (29.2)
Level V (purposeful and 15(15.2) 16(13.1) 11 (13.8) 42 (14.0)
meaningful)
When I thought about my whole life, I 
felt that in achieving life goals I have
Level I (made no progress 15 (15.2) 20 (16.4) 8 (10.0) 43 (14.3)
whatsoever)
Level II 32 (32.3) 42 (34.4) 26 (32.5) 100 (33.2)
Level III 33 (33.3) 40 (32.8) 36 (45.0) 109 (36.2)
Level IV 12(21.1) 13 (10.7) 8(10.0) 33 (11.0)
Level V (progressed to complete 7(7.1) 7 (5.7) 2 (2.5) 16(5.3)
fulfilment)
When I thought about my life, I felt that 
my life to this point has been
Level I (completely worthless) 6(6.1) 1 (0.8) 1(1.3) 8 (2.7)
Level II 16(16.2) 12(9.8) 6 (7.5) 34(11.3)
Level III 53 (53.5) 83 (68.0) 45 (56.3) 181 (60.1)
Level IV 18(18.2) 16(13.1) 22 (27.5) 56(18.6)
Level V (very worthwhile) 6(6.1) 10(8.2) 6 (7.5) 22(7.3)
I have felt that I have
Level I (no control over my life) 0 1 (0.8) 0 (0.0) 1 (0.3)
Level II 15 (15.2) 5 (4.1) 11 (13.8) 31 (10.3)
Level III 52 (52.5) 72 (59.0) 36 (45.0) 160 (53.2)
Level IV 28 (28.3) 31 (25.4) 29 (36.3) 88 (29.2)
Level V (completely control over 4 (4.0) 13 (10.7) 4 (5.0) 21 (7.0)
my life)
I felt good about myself as a person
Level I (completely disagree) 5(5.1) 5(4.1) 1(1.3) 11(3.7)
Level II 60 (60.6) 73 (59.8) 46 (57.5) 179 (59.5)
Level III 27 (27.3) 33 (27.0) 23 (28.8) 83 (27.6)
Level IV 7(7.1) 11 (9.0) 10(12.5) 28 (9.3)
Level V (complete agree) 
The past 2 days were
Level I (burden) 1(1.0) 0 2 (2.5) 3(1.0)
Level II 14(14.1) 12 (9.8) 6 (7.5) 32(10.6)
Level III 64 (64.6) 82 (67.2) 60 (75.0) 206 (68.4)
Level IV 16(16.2) 23 (18.9) 10(12.5) 49(16.3)
Level V (a gift) 4 (4.0) 5 (4.1) 2 (2.5) 11(3.7)
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Table 4-9: Evaluation of support using modified McGill questionnaire
Support in the past 2 days Doctor-led 
clinic: N (%)
Large nurse- 
led clinic: N
_____ (%)_____
Small nurse- 
led clinic: N 
(%)
Total: N (%)
The world has been
Level I (an impersonal unfeeling 0 0 1 (1.3) 1 (0.3)
place)
Level II 0 3 (2.5) 2 (2.5) 5 (1.7)
Level III 73 (73.7) 76 (62.3) 58 (72.5) 207 (68.8)
Level IV 18(18.2) 32 (26.2) 14(17.5) 64 (21.3)
Level V (caring and responsive to 8(8.1) 11 (9.0) 5 (6.3) 24 (8.0)
my needs)
I have felt supported
Level I (not at all) 40 (40.4) 15 (12.3) 21 (26.3) 76 (25.2)
Level II 18(18.2) 30 (24.6) 20 (25.0) 68 (22.6)
Level III 24 (24.2) 61 (50.0) 27 (33.8) 112(37.2)
Level IV 11(11.1) 13 (10.7) 9(11.9) 33 (11.0)
Level V (completely) 6(6.1) __ i m __ 3 (3.8) 12 (4.0)
In relation to EQ-5D, nearly all participants stated their health status as no problem or with 
minor problem in 5 dimensions of EQ-5D (see Table 4-10). For the EQ-5D (VAS) 
participants were requested to mark their health status on the date of the interviews directly
onto the provided scale. Additionally, with the scale 0-100 of the EQ-5D visual analogue
scale (VAS), the mean score was 79 with only 1 case marked the score at 0. The rest of the
participants marked the score at 30 or above (see Table 4-10). This showed the overstated of 
health status when using EQ-5D (VAS), thus, using this tool to measure health-related 
quality of life warrants careful interpretation in Thai culture.
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Table 4-10: HR-QOL using EQ-5D
EQ-5D Doctor-led 
clinic: N (%)
Large nurse- 
led clinic: N 
(%)
Small nurse- 
led clinic: N 
(%)
Total
Mobility
I have no problems in walking about 89 (89.0) 115(94.3) 57(71.3) 261 (86.4)
I have some problems in walking 10(10.0) 7 (5.7) 23 (28.8) 40(13.2)
about
I am confined to bed 1(1.0) 0 0 1(1)
Self-Care
I have no problems with self-care 98 (98.0) 121 (99.2) 78 (97.5) 297 (98.3)
I have some problems washing or 1(1.0) 1 (0.8) 2 (2.5) 4(1.3)
dressing myself
I am unable to wash or dress myself 1(1.0) 0 0 1 (0.3)
Usual activities
I have no problems with performing 92 (92) 118(96.7) 72 (90.0) 282
my usual activities
I have some problems with performing 6 (6.0) 4 (3.3) 7 (8.8) 17 (5.6)
my usual activities
I am unable to perform my usual 2 (2.0) 0 1(1.3) 3(1.0)
activities
Pain/Discomfort
I have no pain or discomfort 64 (64.0) 94 (77.0) 52 (65.0) 210(69.5)
I have moderate pain or discomfort 36 (36.0) 28 (23.0) 28 (35.0) 92 (30.5)
I have extreme pain or discomfort 0 0 0 0
Anxiety/Depression
I am not anxious or depressed 56 (56.0) 99 (81.1) 59 (73.8) 214(70.9)
I am moderately anxious or depressed 43 (43.0) 23 (18.9) 19(23.8) 85 (28.1)
I am extremely anxious or depressed 1(1) 0 2 (2.6) 3(1.0)
Visual Analogue Scale (VAS)
Mean (standard deviation) 76.9(17.6) 80.9(12.1) 78.5 (18.0) 79.0(15.8)
Range 40.0-100.0 40.0-100.0 0.0-100.0 0.0-100.0
With multi-question used to document HR-QOL, their correspondences were tested. It was 
found that there were a strong correlation regarding modified McGill questionnaire (2 SIS 
questions and 5 sub-measures) and the EQ-5D (VAS) with Pearson correlation, p< 0.01. 
(Table 4-11).
Table 4-11: Correlation between health-related quality of life measures
Correlation Physical
symptom
Physical
well-being
Psychological Existential Support SIS-1 SIS-2 EQ-5D
(VAS)
Total 0.53** 0.70** 0.63** 0.67** 0.60** 0.52** 0.29** 0.48**
Physical symptom - 0.42** 0.27** 0.11 0.01 0.13* 0.07 0.25**
Physical well-being - - 0.27** 0.31** 0.15** 0.37** 0.25** 0.38**
Psychological - - - 0.21** 0.18** 0.37** 0.11 0.33**
Existential - - - - 0.49** 0.46** 0.32** 0.26**
Support - - - - - 0.28** 0.14* 0.27**
SIS-1 - - - - - - 0.26** 0.30**
SIS-2 - - - - - - - 0.19**
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
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4.1.2.2 Health-related quality of life of a subgroup of 97 participants in 
2004 and 2007
In this study, a group of 97 participants who were alive in 2007 and had been interviewed in 
2004 were randomly selected to assess the impact of their treatment on their health-related 
quality of life. A simple randomization technique was used, allocating identification 
numbers randomly to participants. They were later interviewed to identify the impact of 
ART on HR-QOL during the three years of their treatment (2004-2007) together with 
characteristics which may explain any changes in the 97 participants. HR-QOL results in 
2004 were not a true baseline (before initiation of HAART), but consisted of patients who 
had already experienced a variable amount of treatment time on ART. As such, the length of 
time individuals had been on ART in 2004 was a major factor influencing treatment 
outcomes in relation to HR-QOL. During initiation of ART in the early stage, HR-QOL will 
improve significantly prior to reaching a plateau and stabilizing. In 2004, the median 
interval time between initiation of ART and interview was 7.7 months (IQR=5.8-14.7), thus, 
some participants may already have improved HR-QOL and might express no change in 
HR-QOL at the reassessment three years later.
Of the 97 participants, 28 came from the doctor-led ARV clinic in provincial hospital, 38 
from the large nurse-led clinics and 31 from the small nurse-led clinic from the two district 
hospitals, with 32% of participants being men, and 68% women (see Table 4-12). The 
average age was 38 years for both men and women at the time of interview in 2004 with the 
majority of participants (70%) having either no formal education or simply having 
completed primary education. The mean length of time since they became aware of their 
HIV status was about ten years and nearly 90% of them were prescribed with first line 
regimen (GPO-Vir; locally-produced cocktail regimen of 3TC+d4T+NVP). In all 
characteristics, this sub-group were not significantly different from the group of 302 
participants from which they were drawn in relation to age, gender, education, health 
insurance and prescribed medication. Comparing with the subgroup of 97 participants and a
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total Of 302 who were interviewed in 2004, it found that their characteristics were quite 
similar, the only difference was that the number of participants
Table 4-12: Baseline characteristics of the subgroup of 97 participants comparing that of 302 
participants from the survey in 2004
Baseline characteristics N=97 N=302
Mean age: Years (SD) 37.9 (6.7) 37.1 (7.1)
Gender: N (%)
Male 31 (32) 119(39.4)
Female 66 (68) 183 (60.6)
Education: N (%)
No formal educational 28 (28.9) 82 (27.2)
Primary school 53 (54.6) 164 (54.3)
Secondary school 13(13.4) 36(11.9)
Higher than secondary school 3(3.1) 20 (6.6)
Marital status: N (%)
Single 12(12.4) 43 (14.3)
Married or living with partner 38 (39.2) 119(39.7)
Separated/Divorcc 8 (8.3) 30(10.0)
Widow/ widower 39 (40.2) 108 (36.0)
Type of health insurance: N (%)
Universal coverage 89 (91.8) 243 (80.7)
Civil Servant Medical Benefit 5 (5.2) 44(14.6)
and Social security scheme
Others 2(2.1) 14(4.7)
Being member of the PLHA self-help group: N (%) 56 (57.7) 182 (60.3)
History of previous treated with ART; N (%) 20 (20.6) 73 (24.3)
Mean time between HIV diagnosis and initiation of 10.7 (8.7) 5.2 (3.7)
treatment: Years (SD)
Median duration of ART : Months (IQR) 7.4 (5.8-13.4) 7.7 (5.75-14.65)
Median baseline CD4 cell counts: cell/uL (IGR) 70(22-153) 78.5 (26.5-171)
SD=standard deviation; IQR=inter-quartile range
1 1 0
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Table 4-13: Changes of 97 participants’ economic characteristics and other characteristics
Characteristics Interview in 2004 Interview in 2007
Occupation; N (%)
General labourer 60 (61.9) 55 (56.7)
Self employed 10(10.3) 12(12.4)
Farmer or gardener 9 (9.3) 8 (8.2)
Housewife 9 (9.3) 2(2.1)
Others 9 (9.3) 17 (17.7)
Main wage earner; N (%) 59 (60.8) 53 (54.6)
Median monthly income: 1,000 THB (IQR) 3.0 (3.0-6.0) 3.0 (1.5-4.5)
Median monthly household income: 1,000 THB (IQR) 4.4 (2.5-6.9) 5.0 (3.5-8.0)
Median monthly household expenditure: 1,000 THB (IQR) NA 4.5 (3.0-6.0)
Adherence more than 95%*
In the past five days; N (%) 91 (93.8) 93 (95.9)
In the previous month; N (%) 95 (97.9) 96 (98.9)
ART regimen used: N (%)
First line regimen ;GPO-Vir (d4T+3TC+NVP) 84 (86.6) 50 (51.5)
Alternate first line regimen; (d4T+3TC+EFV) 2(2.1) 4(4.1)
GPOz (AZT+3TC+NVP) 0 27 (27.8)
Others regimen 11 (11.3) 16(16.6)
SD=standard deviation; IQR=inter-quartile range; NA=not applicable; GPO=Government 
Pharmaceutical Organisation; d4T=Stavudine; 3TC=Lamivudine; NVP=Nevirapine; EFV=Efavirenz; 
* Accounted for missed dose only
In relation to socioeconomics, nearly all participants had remained in the same job between 
2004 and 2007 and more than half of them were the main wage earner in the families. 
However, over the period of three years their monthly incomes are quite stable. In contrast, 
their average household income had risen (from 5,700 in 2004 to 6,500 in 2007). This 
appeared to indicate that other household members had become more economically active to 
compensate for their reduced earning capability. When asked about their expenditures, it 
appeared that their expenditures were in excess of their monthly income, leaving little
money left each month.
Their adherence was also assessed in terms of self-reported adherence, with more than 90% 
of respondents reporting having taken more than 95% of doses of ART both in the past five 
days and in the previous month. This indicates that adherence in 2007 had increased 
compared to 2004 (see Table 4-13). The regimens of prescribed ART had also been 
adjusted; in 2004, GPO-Vir was the dominant treatment, however, in 2007, only half of 
them were still on this regimen. Another half the participants were prescribed with 
alternative regimens to GPO-Vir as they either experienced side effects or had required
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transfer to second line therapy (see Table 4-13). For further details of changes in prescribed 
regimens, please refer to section 4.1.5
4.1.2.3 Modified McGill Questionnaire
Two questionnaires were used to determine patient’s health-related quality of life; modified 
McGill’s questionnaire and EQ-5D (Thai version) in order to measure the impact of the 
government ART programme on the patient’s emotional, social and physical wellbeing. For 
the modified McGill’s questionnaire, participants answered each question with the range of 
Level I to Level V with Level I (floor score) indicating extremely bad, and Level V (ceiling 
score) indicating extremely good. The questions consisted of two single-item scale (SIS) 
questions and 16 sub-measure questions. The two summary SIS questions were used to ask 
the participant to assess their overall quality of life in the past two days and their 
comparative quality of life in the past two days compared to just before starting ART. The 
other 16 questions were used to address individual aspects of HR-QOL in sub-dimensions.
Table 4-14: HR-QOL using Modified McGill questionnaire-single question
Modified McGill Questionnaire, Single question Interview in 
2004: N (%)
Interview in 
2007: N (%)
P value
Overall quality of life in the past two days 0.24
Level I (Very bad) 3(3.1) 4(4.1)
Level II 13 (13.4) 8 (9.3)
Level III 51 (52.6) 50(51.5)
Level IV 22 (22.7) 32 (33.0)
Level V (Excellent) 8 (8.2) 3(3.1)
Overall quality of life in the past two days comparing to before 0.76
entering the governmental antiretroviral treatment programme
Level I (Extremely worse) 0 0
Level II 2(2.1) 2(2.1)
Level III 17(17.5) 12(12.4)
Level IV 59 (60.8) 62 (63.9)
Level V (Extremely better) 19(19.6) 20 (20.6)
Approximately 80% of the respondents, when asked to rate their HR-QOL over the period 
of 3 years on ART, stated that their health status was Level III, IV or V (Level V 
=excellent). When they were asked to compare their current health status with that 
experienced before initiation of ART, more than 80% reported feeling Level IV or V (Level
1 1 2
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V=extremely better). This pattern was observed in both surveys (see Table 4-14) with no
statistical differences between the two interviews.
Table 4-15: Physical well being using modified McGill questionnaire
Physical well being in the past 2 days... Interview in 
2004: N (%)
Interview in 
2007: N (%)
P value
Level of trouble some physical symptom 1 (if any) 
Level I (No problem) 65 (67.0) 61 (62.9)
0.26
Level II 18 (18.6) 21 (21.6)
Level III 11 (11.3) 15 (15.5)
Level IV 3(3.1) 0
Level V (Tremendous) 0 0
Level of trouble some physical symptom 2 (if any) 
Level I (No problem) 87 (89.7) 78 (80.4)
0.18
Level II 3(3.1) 10(10.3)
Level III 5 (5.2) 5 (5.2)
Level IV 2(2.1) 4(4.1)
Level V (Tremendous) 0 0
Level of trouble some physical symptom 3 (if any) 
Level I (No problem) 93 (95.9) 92 (94.8)
0.95
Level II 2(2.1) 2(2.1)
Level III 1 (1.0) 2(2.1)
Level IV 1 (1.0) 1 (1.0)
Level V (Tremendous) 0 0
I have felt that my physical is 
Level I (extremely weak) 0 2(2.1)
0.39
Level II 4(4.1) 8 (8.2)
Level III 33 (34.0) 34 (35.1)
Level IV 55 (56.7) 50 (51.5)
Level V (very well) _____! £ 2 ) _____ 3(3.1)
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Table 4-16: Psychological status using modified McGill questionnaire
Psychological status in the past 2 days... Interview in 2004: 
N (%)
Interview in 2007 : 
N (% )
P value
I have been depressed 0.17
Level I (not at all) 74 (76.3) 65  (67.0)
Level II 17(17.5) 28 (28.9)
Level III 4(4.1) 3(3.1)
Level IV 2(2.1) 0
Level V (extremely) 0 1 ( i . o )
I have been nervous or worried 0.14
Level I (not at all) 61 (62.9) 45 (46.4)
Level II 21 (21.6) 27 (27.8)
Level III 7 (7.2) 15 (15.5)
Level IV 5 (5.2) 8 (8.2)
Level V (extremely) 3(3.1) 2(2.1)
How much of the time did you feel sad 0.22
Level I (never) 56 (57.7) 64 (66.0)
Level II 35 (36.1) 26 (26.8)
Level III 1(1.0) 4(4.1)
Level IV 4(4.1 1 ( i . o )
Level V (always) 1(1.0) 2(2.1)
When I thought of the future, I was 0.90
Level I (not afraid) 44 (45.4) 44 (45.4)
Level II 29 (29.9) 29 (29.9)
Level III 14(14.4) 12(12.4)
Level IV 4(4.1) 7 (7.2)
Level V (terrified) 6 (6.2) 5 (5.2)
Tables 4-15 to Table 4-18 provide details of the sub-measures of the Modified McGill
Questionnaire used to evaluate the physical well being, psychological status, existential
feeling and support received by participants respectively. All of these were unchanged
between the two interviews, except certain questions related to emotional well being which
showed that fewer participants reported negative feeling in 2007 (see Table 4-17). In both
interviews, more than 80% of respondents reported their physical well being as level III, IV
or V (Table 4-15). The questionnaire requested the patients to provide three physical
symptoms they had experienced during the past two days. The frequently noted symptoms 
were feeling weary, numbness, hearing difficulty, rash, tremor and body pain, however, 
these caused only limited problems for them. Regarding their psychological status (Table 4- 
15), there were also no significant differences between the two interviews in relation to level 
of depression, nervousness or worry, time of feeling sad and their fear with regard to the
future.
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Table 4-17: Existential feeling using modified McGill questionnaire
Existential feeling in the past 2 days Interview in Interview in P value
2004: N (%) 2007: N (%)
My life has been 0.006
Level I (utterly meaningless and without purpose) 2(2.1) 0
Level II 19(19.6) 8 (8.2)
Level III 38 (39.2) 28 (28.9)
Level IV 30 (30.9) 42 (43.3)
Level V (purposeful and meaningful) 8 (8.2) 19(19.6)
When I thought about my whole life, I felt that in 
achieving life goals I have
0.001
Level I (made no progress whatsoever) 12 (12.4) 7 (7.2)
Level II 37 (38.1) 9 (9.3)
Level III 38 (39.2) 53 (54.6)
Level IV 7 (7.2) 26 (26.8)
Level V (progressed to complete fulfilment) 3(3.1) 2(2.1)
When I thought about my life, I felt that my life to this 
point has been
0.51
Level I (completely worthless) 5 (5.2) 4(4.1)
Level II 8 (8.2) 10(10.3)
Level III 62 (63.9) 51 (52.6)
Level IV 17 (17.5) 24 (24.7)
Level V (very worthwhile) 5 (5.2) 8 (8.2)
I have felt that I have 0.50
Level I (no control over my life) 0 1 (1.0)
Level II 12(12.4) 6 (6.2)
Level III 48 (49.5) 53 (54.6)
Level IV 33 (34.0) 32 (33.0)
Level V (completely control over my life) 4(4.1) 5 (5.2)
I felt good about myself as a person 0.49
Level I (completely disagree) 4(4.1) 1 (i.o)
Level II 65 (67.0) 1(1.0)
Level III 21 (21.6) 65 (67.0)
Level IV 7 (7.2) 19(19.6)
Level V (complete agree) 
The past 2 days were
0 10(10.3)
0.08
Level I (burden) 2(2.1) 1 (1.0)
Level II 12(12.4) 3(3.1)
Level III 69 (71.1) 70 (72.2)
Level IV 13 (13.4) 20 (20.6)
Level V (a gift) 1 (1.0) 3(3.1)
Six questions addressed their existential feeling (see Table 4-17). The responses identified 
that patients tended to have improved relation to their feelings about their life and the 
achieving of goals in their lives (statistical significant; p=0.006 and 0.001 respectively)
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between 2004 and 2007. However, their answers were similar between the two interviews 
regarding other questions in this sub-measure. In terms of their perceived support structures, 
they felt less supported in 2007 however; this did not achieve statistical significance (see 
Table 4-18)
Table 4-18: Evaluation of support using modified McGill questionnaire
Support in the past 2 days Interview in 
2004: N (%)
Interview in 
2007: N (%)
P value
The world has been
Level I (an impersonal unfeeling place) 1 (1.0) 1(1.0)
0.09
Level II 79 (81.4) 6 (6.2)
Level III 12(12.4) 64 (66.0)
Level IV 5 (5.2) 19(19.6)
Level V (caring and responsive to my needs) 0 7 (7.2)
I have felt supported 
Level I (not at all) 0 29 (29.9)
0.09
Level II 27 (27.8) 19(19.6)
Level III 19(19.6) 27 (27.8)
Level IV 39 (40.2) 17(17.5)
Level V (completely) 12(12.4) 5 (5.2)
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4.1.2.4 EQ-5D
Table 4-19: HR-QOL using EQ-5D
EQ-5D Interview in Interview in P value
2004: N (%) 2007: N (%)
Mobility 0.09
I have no problems in walking about 82 (84.5) 89 (91.8)
I have some problems in walking about 15(15.5) 8 (8.2)
I am confined to bed 0 0
Self-Care 0.00
I have no problems with self-care 95 (97.9) 66 (68.0)
I have some problems washing or dressing 
myself
2(2.1) 31 (32.0)
I am unable to wash or dress myself 0 0
Usual activities (e.g. Work, study, housework 
family or leisure activities)
0.11
I have no problems with performing my 
usual activities
90 (92.8) 83 (85.6)
I have some problems with performing my 
usual activities
6 (6.2) 14(14.4)
I am unable to perform my usual activities 1 (1.0) 0
Pain/Discomfort 0.07
I have no pain or discomfort 65 (67.0) 51 (52.6)
I have moderate pain or discomfort 31 (32.0) 45 (46.4)
I have extreme pain or discomfort 1 (1.0) 1(1.0)
Anxiety/Depression 0.80
I am not anxious or depressed 65 (67.0) 79 (81.4)
I am moderately anxious or depressed 31 (32.0) 18(18.6)
I am extremely anxious or depressed 1 (1.0) 0
Median of visual analogue scale: IQR 80 (70-90) 80 (70-90) 0.74
IQR=Inter-quartile range
In relation to EQ-5D, the five dimensions were found to be unchanged between the two 
interviews in term of mobility, usual activities, pain/discomfort and anxiety/depression. 
However, in the area of self care, more participants reported having experienced additional 
problems washing or dressing themselves in 2007 (see Table 4-19). The overall evaluation 
of HR-QOL assessed in the visual analogue scale did not experience any significant change 
(see Table 4-20). However, using the index score, it was found that the median of the score
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in 2007 was like to be lower than that identified in 2004 (statistically significant, Wilcoxon
Signed Ranks test, p=0.001).
Table 4-20: Descriptive statistics of EQ-5D index scores using Japan* preference weights
EQ-5D Mean SD Median Q25 075
EQ-5D index score
In 2004 0.90 0.12 0.85 0.81 1.00
In 2007 0.85 0.12 0.83 0.78 0.83
VAS
In 2004 78.64 16.07 80.00 70.00 90.00
In 2007 77.99 17.79 80.00 70.00 90.00
*Japanese weight was used as (i) Thai weight was not available and (ii) it has been shown by one 
study that the Japanese weight is more preferable psychometric property than that of the US, and the 
UK model (Sakthong 2008)
When we compared the HR-QOL reported by each individual to identify who were better 
off or worse off from the ART programme, it has found that majority of the people reported 
an unchanged quality of life in nearly all dimensions of HR-QOL (see Table 4-21). 
However, the number of people who reported improvements as a consequence of ART was 
fewer than respondents who reported feeling worse off in nearly all dimensions of the 
questionnaires except for the VAS and index score of the EQ-5D where more than 40% of 
the participants reported of better off as time elapsed
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Table 4-21: Intra-person comparison of HR-QOL from two interviews (2004 and 2007) using
the Modified McGill Questionnaire
Health-related quality of life questionnaire Number of people reported 
Worse off No changes
as*: N (%) 
Better off
Single question
■ Overall quality of life in the past two days 26 (26.8) 44 (44.4) 27 (27.5)
■ Overall quality of life in the past two days 28 (28.7) 47 (48.5) 22 (22.8)
comparing to before entering the programme 
Sub dimension
Physical well being
■ Level of physical symptom 1 (if any) 24 (24.7) 52 (53.6) 21 (21.7)
■ Level of physical symptom 2 (if any) 15 (15.4) 73 (75.3) 9 (9.3)
■ Level of physical symptom 3 (if any) 4(4.1) 90 (92.8) 3(3.1)
■ I have felt that my physical is 16(16.5) 54 (55.7) 27 (28.7)
Psychological status
■ I have been depressed 21 (21.6) 62 (63.9) 14(14.5)
■ I have been nervous or worried 34 (35.0) 51 (52.6) 12(12.4)
■ How much of the time did you feel sad 15 (15.4) 62 (63.9) 20 (20.6)
■ When I thought of the future, I was 28 (28.9) 41 (42.2) 28 (28.9)
Existential feeling
■ My life has been 48 (29.5) 26 (26.8) 23 (23.7)
■ When I thought about my whole life, I felt that in 53 (54.6) 26 (26.8) 18(18.6)
achieving life goals I have
■ When I thought about my life, I felt that my life 31 (31.8) 45 (46.4) 21 (21.7)
to this point has been
■ I have felt that I have 30 (30.9) 42 (43.3) 25 (25.8)
■ I felt good about myself as a person 21 (21.6) 60(61.9) 16(16.5)
■ The past 2 days were 24 (24.8) 65 (67.0) 8 (8.2)
Support
■ The world has been 20 (20.6) 59(60.8) 18 (18.6)
■ I have felt supported 38 (39.1) 27 (27.8) 32 (33.0)
* Compared with the participants reported in the interview in 2004;
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Table 4-22: Intra-person comparison of HR-QOL from two interviews (2004 and 2007) using 
EQ-5D
Health-related quality of life questionnaire Number of people reported as*: N (%)
Worse off No changes Better off
E Q - 5 D
•  Mobility 5(5.1) 80 (82.5) 12(12.4)
■ Self-Care 36(37.1) 60 (61.9) 1 (1.0)
■ Usual activities 12(12.4) 80 (82.5) 5(5.1)
■ Pain/Discomfort 27 (27.8) 59 (60.8) 11 (11.3)
■ Anxiety/Depression 12 (12.4) 59 (60.8) 26 (26.8)
■ VAS 35 (36.1) 2(21.6) 41 (42.3)
■ Index score 25 (25.8) 22 (22.7) 40(51.5)
4.1.3 Improvement of the CD4 cell count
As many as 271 participants with a baseline CD4 cell count of less than 200 cell/uL were 
found to also have CD4 cell counts above 200 cell/uL during the follow up period. Of these 
271, their mean age was 36.2 years old (SD=7.0), and about 42% of them were male. For 
their health insurance status, roughly 90% were in the universal health scheme and about 
63% of them were the members of PLHA self-help groups. In relation to their clinical 
information, 30% of them were in WHO stage I, II or III. Their median baseline CD4 cell 
count was 92 cell/uL and nearly all were prescribed initially with NNRTI-based regimen. 
Moreover, only 70% of patients were naive to treatment. Time to event analysis revealed 
that their median time from the initiation of ART to exhibiting a CD4 cell count of below 
200 cell/uL was 33.6 months (SD=3.6) while the mean time was 44.4 months (SD=1.7). The 
hazard function in Table 4-4 suggests a constancy of risk during the follow up period.
4.1.4 CD4 approached the level of 500 cell/ pL
Achieving a CD4 cell count of 500 cell/uL was used to assess the effect of ART on immune 
recovery as this level of CD4 cell count can effectively protect the patients from possible 
opportunistic infections. During this follow up period, 121 participants with baseline CD4 
cell counts below 500 cell/uL developed CD4 cell counts above 500 cell/uL. Their 
characteristics were similar to those identified in the patients who developed CD4 counts of 
200 cell/uL or more. Their mean age was 36 years (SD=7.0) and most were female (69%).
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About 63% were members of PLHA self-help groups, and most of them were in UCS. In 
relation to clinical information, nearly 60% were naive to treatment, and half were in Stage 
IV at baseline. The median of their baseline CD4 cell counts were 154 cell/uL (IQR=47- 
335) which was relatively high compared to the rest of the participants, and most of them 
(85%) were prescribed initially with NNRTI-based regimen. From the time to event 
analysis, the mean time of CD4 cell counts from the initiation of ART to reach the level of 
500 cell/uL was 75.7 months (SE=1.9) with a constant risk of the increase of CD4 cell 
counts over the follow up period (see Table 4-4).
4.1.5 Duration on the first-line regimen
During this three year period of analysis, prescribed regimens were changed in 157 
participants. The two main reasons for changing treatment regimen were that the patients 
either developed drug resistance or experienced adverse events. Of these 157, their average 
age was 36 years old (SD=7.1) and most were female (62.4%). More than 80% of them 
were in the universal health scheme and only half of them were members of PLHA self-help 
groups. In relation to clinical information, nearly 60% of them were naive to ART and about 
55% of them were in stage IV of WHO classification. Their baseline CD4 cell counts were 
116 cell/uL and 90% were initially prescribed with NNRTI-based regimen. About half of 
them were from the large nurse-led clinic, 30% from doctor-led clinic and 20% were from 
the small nurse-led clinic. In relation to time since initiation of treatment to alteration of 
regimen (time to event analysis), the median time on the first regimen was 73.9 months 
(SD=8.3) while the mean time was 64.3 months (SD=1.9) (see Table 4-4).
4.1.5.1 Development o f  adverse reaction
The two main reasons for changing the prescribed regimen were (i) occurrence of an 
adverse reaction from ART and (ii) development of drug resistance. For the former 
category, it was found that 93 cases experienced adverse reaction. Nearly 50% were 
lipodystrophy which usually caused by the stavudine in the GPO-Vir (3TC+d4T+NVP) and 
had to substitute with zidovudine (see Table 4-23). Another common side effect was severe
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rash which is common caused by nevirapine and had to change to the alternative first-line 
regimens including AZT+d4T+NVP, AZT+3TC+EFV, EFV+IDV+RTV or AZT+3TC 
+SQV+RTV. When we analyzed the quality of life comparing those who reported 
experiencing side effects and those who did not, it was found that the quality of life 
measured by Modified McGill and EQ-5D questionnaire were similar between the groups 
(Chi square test > 0.05). But, again this was based solely on the 97 participants who were 
interviewed for their HR-QOL.
Table 4-23: Adverse reactions
Adverse reaction N (%)
Lipodystrophy 44 (8.8)
Severe rash 26 (5.2)
Hepatitis 10(2.0)
Others 13 (2.6)
Total 93 (18.6)
4.1.5.2 Drug resistance
In the national ART programme, those who have been treated with ART for over a year and
(i) develop new opportunistic infections, (ii) no rise or falling of CD4 cell counts and (iii) 
viral load more than 1,000 copy/ml are suspected of developing drug resistance and will be 
sent for a test of HIV drug resistance. Two types of test are used: Ultrasense Cobas 
Amplicor HIV-1 and TRUEGENE HIV-1 Genotyping in case of viral load higher than 
2,000 copy/ml (Srasuebkul, Ungsedhapand et al. 2007).
Twenty-four participants developed drug resistance which was initially indicated by a 
worsened clinical presentation (e.g. high viral load despite treatment, advance staging, 
developing new opportunistic infection) and ultimately confirmed by the test for drug 
resistance during the period of the study. Their average age 33 years (SD=8.0) and fourteen 
of them were male. For their clinical information, seven cases were naive to treatment and 
their baseline CD4 cell counts were 180 cell/uL. Almost all (21 cases) were in stage IV and 
the majority were prescribed NNRTI-based regimen.
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4.1.5.3 Other causes o f  changing drug regimen
A range of other reasons were identified for altering drug regimen. These included; (i) 
patients with allergies to some drugs such as nevirapine, (ii) patients developed tuberculosis 
during treatment, the regimens then were adjusted to avoid toxicity, (iii) after finishing 
treating tuberculosis, the patients were switched back to their previous regimens and (iv) the 
first phase of ART programme (2001-2002) was ended, during the phrase, the patients were 
prescribed with one of eight regimens which was reduced to 3 recommended regimens as 
the programme expanded.
4.1.6 Other treatment outcomes
Changing of WHO staging; for this treatment outcome, only 13 cases were found to have 
disease progression defined by an advance in WHO staging (see Table 4-24). This low event 
rate is largely due to the fact that more than 90% of the participants were already in stage IV 
and therefore the survival analysis was not appropriate to apply for this outcome. Of these 
13, their average age was 35 years (SD=6.7) and nine of them were male. In relation to 
clinical information, eight of them had previous experience of ART. Their mean baseline 
CD4 cell counts were relatively high (259 cell/uL) as they were in either Stage II or III 
before the disease progressed. Twelve of them were initially prescribed with NNRTI-base 
regimen. Ten patients whose disease progressed were treated in the doctor-led clinical. No 
patients treated in the small nurse-led clinics were identified as suffering deterioration in 
terms of WHO staging.
Table 4-24: Disease progression determined by changing of WHO classification
WHO staging N
From stage II to stage III 3
From stage II to stage IV 2
From stage III to stage IV 8
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4.2 Factors affecting the treatm ent outcomes
4.2.1 Factors affecting mortality (survival)
Out of 15 potential variables that would affect the patients’ survival, using the log rank test 
which is a nonparametric test to compare the survival distributions of groups; it was found 
that participants tended to die faster if they were male, unemployed, not a main wage earner, 
no income, treated under universal health scheme (USC), naive to ART, having a baseline 
CD4 cell count less than 50 cell/uL, in Stage IV at baseline, and initially treated with PI- 
based regimen and being treated in nurse-led clinics.
Table 4-25: Log rank test for factors affecting mortality
Predictor
Gender
Main occupation
Survival function
Survival Functions
Gender (1= Male, 2= 
Female)
-f- 1-censored 
-f- 2-censored
Survival Functions
Main occupation 
(1=Unemployed, 
2=General labour, 3= 
Others)
+  1-censored 
+  2-censored 
3-censored
Time (month)
P-value
0.001*
0.000*
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Being Main wage earner 0.000*
Survival Functions
Monthly income: THB
Survival Functions
Being main wage 
earner (1= No, 2=Yes)
-f- 1-censored 
+  2-censored
0.000*
Health insurance scheme
Monthly income: THB 
(1=No income, 2=1- 
3000, 3=3001 or more)
3
-f- 1-censored 
+  2-censored 
3-censored
Time (month)
0 .01*
Survival Functions
Health insurance 
scheme (1= Universal 
health scheme, 2= 
Non-universal health 
scheme)
—i—' 2
■+■ 1-censored 
+  2-censored
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Being naïve to ART
Survival Functions
Being naive to ART 
(1=No, 2=Yes)
+ 1- censored
2- censored
Baseline CD4: cell/|aL
Survival Functions
Baseline CD4 cell 
count: cell/uL (1=50 or 
fewer, 2=51-200, 
3=201 or more)
—r-1 2
3
-f- 1-censored 
- f 2-censored 
3-censored
Baseline WHO staging
Survival Functions
0 .000*
0 .000*
0.000*
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Initial prescribed regimen 0 .000*
Survival Functions
Type of ARV clinic
Initial prescribed ART 
regimen (1=NNRTI- 
based regimen, 2=PI- 
based regimen)
+  1-censored 
4- 2-censored
0.009*
Type of ARV clinic 
(1=Doctor-led, 2= 
Large nurse-led, 3= 
Small nurse-led)
3
-f- 1-censored 
- 2-censored 
3-censored
*=Significant at p value<0.05
** Full details of Log Rank test for this outcome are provided in Annex 2
The Cox proportional hazard regression is based on a modelling approach to the analysis of 
survival data. The purpose of the model is to simultaneously explore the effects of several 
variables on survival. It allows us to isolate the effects of interesting factors from the effects 
of other variables. From the Cox model of survival of 501 participants, it identified being 
male, unemployed, being a general labourer and low household income as leading to lower 
survival and with being a member of PLHA self-help group were associated with higher 
mortality while being treated in a doctor-led or large nurse-led clinic leading to greater 
survival. Full details of the Log Rank test and Cox proportional hazard regression for CD4 
cell counts are provided in Annex 2
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Table 4-26: Cox proportional hazard regression for mortality*
Variable Regression
coefficient
Hazard ratio P value
Male 0.64 1.90 0.04*
Main occupation
Unemployed 2.61 13.65 0.000*
General labourer 1.52 4.56 0.015*
Monthly income 0.001 0.99 0.000*
Being member of PLHA self-help group 0.84 2.31 0.005*
Type of ARV clinic
Doctor-led -2.35 0.10 0.002*
Large nurse-led -1.28 0.27 0.002*
*=Significant at p value<0.05
**Full details of Cox model for this outcome are provided in Annex 2
4.2.2 Factors determining changes in quality of life
A bi-variate analysis was undertaken to identify factors that might influence changes in HR- 
QOL (worse off, no changes, better off). No variable appeared to be associated with the 
change in quality of life using the first question of Modified McGill questionnaire which 
asked the participants to rate the overall quality of life in the past two days at the time of 
interview. However, when using EQ-5D visual analogue scale, it was found that being a 
member of PLHA self help group was strongly associated with improvements in self- 
reported quality of life (Chi square test, p=0.027) (see Table 4-27).
Table 4-27: P-values of factors determining changes HR-QOL from bi-variate analysis
Variable Overall health in the past 2 day 
(Modified McGill 
Questionnaire); P-value
EQ-5D visual analogue scale 
(VAS); P-value
Gender 0.71 0.76
Age 0.86 0.93
Main occupation 0.47 0.82
Being main wage earner 0.41 0.45
Monthly income 0.49 0.20
Monthly household income 0.15 0.27
Education 0.32 0.51
Health insurance scheme 0.77 0.79
Distance from the hospitals to their houses 0.16 0.97
Being PLHA self-help group member 0.78 0.027*
Being naive to the ART 0.12 0.57
Baseline CD4 cell counts 0.15 0.96
Baseline WHO staging 0.14 0.23
Initial prescribed ART 0.29 0.73
Type of ARV clinic 0.11 0.26
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4.2.3 Factors affecting improvement of the CD4 cell count
4.2.3.1 CD4 cell count approached the level o f 200 cell/uL
To identify the effect of the interesting variables on this outcome using the log rank test, it
was found that participants who were employed, with high income, being under the USC, 
lived near the hospitals, being member of PLHA, with high baseline CD4 cell count and 
being treated in the nurse-led clinics would develop CD4 cell counts of 200 cell/uL faster 
significantly.
Table 4-28: Log rank test for factors affecting improvement of the CD4 count approached the 
level of 200 cell/uL
Predictor__________________________  Time to event (l-survival)function
Main occupation
One Minus Survival Functions
Main occupation 
(1=Unemployed, 
2=General labour, 3= 
Others)
3
+  1-censored
2- censored
3- censored
Monthly income: THB
P-value
0 .001* "
0.005*
One Minus Survival Functions
Monthly income: THB 
(1=No income, 2=1- 
3000, 3=3001 or more)
+  1-censored 
+  2-censored 
3-censored
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Health insurance
S c h e m e  One Minus Survival Functions
Health insurance 
scheme (1= Universal 
health scheme, 2= 
Non-universal health 
scheme)
1-censored 
■+■ 2-censored
Distance between 
hospitals and their 
houses: Kilometre
Being member of 
people who living with 
HIV/AIDS (PLHA) 
self-help group
One Minus Survival Functions
Distance from the 
hospitals to their 
houses: Kimometre 
(1 =9 or shorter, 2=10 
or more)
+  1-censored 
+  2-censored
One Minus Survival Functions
Being member of 
PLHA self help group 
(1=No, 2=Yes)
+  1-censored 
2-censored
0.009*
0.001*
0.000*
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Baseline CD4: cell/pL
One Minus Survival Functions
0.000*
Time (month)
Baseline CD4 cell 
count: cell/uL (1=50 or 
fewer, 2=51-200, 
3=201 or more)
3
■+• 1-censored 
-f- 2-censored 
3-censored
Type of ARV clinic 0.000*
One Minus Survival Functions
Time (month)
Type of ARV clinic 
(1=Doctor-led, 2= 
Large nurse-led, 3= 
Small nurse-led)
3
■+■ 1-censored 
-J- 2-censored 
3-censored
*=Significant at p value<0.05
** Full details of Log Rank test for this outcome are provided in Annex 2
To eliminate the confounding influence from the other factors using the Cox proportional 
hazard regression, being employed, being a general labourer, being a member of PLHA self 
help group, having higher monthly income or household income, being naive to treatment 
and being treated in nurse-led clinic were found to be associated with better response of 
CD4 cell count (faster to reach the level of 200 cell/uL). Full details of the Log Rank test 
and Cox proportional hazard regression for CD4 cell counts are provided in Annex 2.
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Table 4-29: Cox proportional hazard regression for having CD4 approached the level of 
200cell/uL
Variable Regression
coefficient
Hazard ratio P value
Main occupation 
Unemployed -0.71 0.49 0.011*
General labourer -0.38 0.68 0.018*
Monthly income 0.001 0.99 0.008*
Monthly household income 0.001 0.99 0.033*
Being member of PLHA self-help group 0.35 1.42 0.018*
Being naive to the ART 0.37 1.45 0.034*
Baseline CD4 cell counts 0.44 1.56 0.000*
Type of ARV clinic 
Doctor-led -2.68 0.07 0.000*
Large nurse-led -0.10 0.90 0.57
*=Significant at p value<0.05
** Full details of Cox model for this outcome are provided in Annex 2
4.2.3.2 CD4 cell count approached the level o f 500 cell/uL
From the log rank test, it was found that being women, high income, previous treatment
with ART, high CD4 cell counts at baseline, being in the WHO stage I, II or III at baseline 
and being treated by the nurse-led clinics tended to approach the level of 500 ccll/uL faster.
Table 4-30: Log rank test for factors affecting improvement of the CD4 count approached the 
level of 500 cell/uL
Predictor________________________________ Time to event (l-survival)function
Gender
One Minus Survival Functions
P-value
0.001*
Gender (1= Male, 2= 
Female)
+  1-censored 
-F  2-censored
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Monthly income: THB
One Minus Survival Functions
Monthly income: THB 
(1=No income, 2=1- 
3000, 3=3001 or more)
3
■+■ 1-censored 
- f  2-censored 
3-censored
Being naïve to ART
One Minus Survival Functions
Being naive to ART 
(1=No, 2=Yes)
2
1- censored
2- censored
Baseline CD4: cell/fo.L
One Minus Survival Functions
Baseline CD4 cell 
count: cell/uL (1 =50 or 
fewer, 2=51-200, 
3=201 or more)
—r~> 2 
3
+  1-censored 
■+- 2-censored 
3-censored
0.048*
0.000*
0.000*
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Baseline WHO staging
Type of ARV clinic
U.UUi*
One Minus Survival Functions
Baseline WHO Staging 
(1=Stage l-lll, 2= Stage 
IV)
+ 21- censored
2- censored
0.000*
One Minus Survival Functions
Type of ARV clinic 
(1=Doctor-led, 2= 
Large nurse-led, 3= 
Small nurse-led)
3
■+■ 1-censored
2- censored
3- censored
*=Significant at p value<0.05
* * Full details of Log Rank test for this outcome are provided in Annex 2
To eliminate the confounding influence from the other factors using the Cox proportional 
hazard regression, being female, with high baseline CD4 cell count and being treated in 
small nurse-led clinic were associated with faster response of CD4 cell counts to achieve the 
level of 500 cell/uL. Full details of the Log Rank test and Cox proportional hazard 
regression for CD4 cell counts approaching the level of 500 cell/uL are provided in Annex
2 .
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Table 4-31: Cox proportional hazard regression for having CD 4 count approached the level of 
500 cell/uL
Variable Regression
coefficient
Hazard ratio P value
Male -0.63 0.53 0.004*
Baseline CD4 cell counts 0.60 1.82 0.000*
Type of ARV clinic 
Doctor-led -2.66 0.07 0.000*
Large nurse-led -0.29 0.75 0.33
*=Significant at p value<0.05
* * Full details of Cox model for this outcome are provided in Annex 2
4.2.4 Factors affecting duration on the first-line regimen
From the Log rank test, it was found that participants who used to be treated with other
ARV drugs, Stage IV WHO classification at baseline, being prescribed with NNRTI-based 
regimen and being treated in the doctor-led clinic made it more probable that their regimen 
would be changed
Table 4-32: Log rank test for factors affecting duration on the first-line regimen
Predictor Time to event (l-survival)function P-value
Being naive to ART 0 . 0 0 1 *
One Minus Survival Functions
1.0-
r
Being naive to ART 
(1=No, 2=Yes)
0.8-
m>E
J —' 2+ 1-censored -f- 2-censored
(O 0.6-
E3Ü
M
C 0.4-
i
»c
O
0.2-
0 .0-
i i i i i
0 20 40 60 80
Time (month)
100
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Baseline WHO staging 0.001*
One Minus Survival Functions
Initial prescribed regimen
Baseline WHO Staging 
(1=Stage l-lll, 2= Stage 
IV)
_ n i
—I—12
-f 1-censored 
4 2-censored
0.028*
One Minus Survival Functions
Initial prescribed ART 
regimen (1=NNRTI- 
based regimen, 2=PI- 
based regimen)
—J—124* 1-censored 
f 2-censored
Type of ARV clinic 0.014*
One Minus Survival Functions
Type of ARV clinic 
(1=Doctor-led, 2= 
Large nurse-led, 3= 
Small nurse-led)
_r~> 3
4" 1-censored 
4“ 2-censored 
3-censored
*=Significant at p value<0.05
** Full details of Log Rank test for this outcome are provided in Annex 2
To eliminate the confounding influence from the other factors using the Cox proportional 
hazard regression, it was found that only being treated in a doctor-led clinic was associated 
with an increased probability of changing of treatment regimen (see Table 4-33).
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Table 4-33: Cox proportional hazard regression for factor affecting duration on the first-line 
regimen*
Variable Regression
coefficient
Hazard ratio P value
Type of ARV clinic 
Doctor-led 0.82 2.28 0.006*
Large nurse-led 0.46 1.58 0.11
*=Significant at p value<0.05
** Full details of Cox model test for this outcome are provided in Annex 2
4.3 Sum m ary o f  the m ain fa c to r  affecting the outcomes
Table 4-34 gives the summarisation of the p-values from the analysis of the 15 potential 
baseline characteristic that might associate with the four treatment outcomes using Cox 
proportional hazard regression.
Table 4-34: P-values from Cox proportional hazard regression of patients’ baseline 
characteristics predicting four outcomes
Variable Mortality CD4
approached 
200 cell/uL
CD4
approached 
500 cell/uL
ART
regimen
changed**
Male 0.04* 0.26 0.004* 0.97
Age
Main occupation
0.52 0.58 0.90 0.05
Unemployed 0.000* 0.011* 0.58 0.26
General labourer 0.015* 0.018* 0.04 0.23
Being main wage earner 0.96 0.80 0.47 0.80
Monthly income 0.000* 0.008* 0.08 0.45
Monthly household income 
Education
0.72 0.033* 0.39 0.41
No formal education 0.36 0.59 0.58 0.99
Primary education 0.31 0.94 0.63 0.27
Universal heath scheme 0.67 0.26 0.05 0.75
Distance between the hospitals and 
their houses 0.45 0.34 0.30 0.29
Being member of PLHA self-help 
group 0.005* 0.018* 0.69 0.43
Being naive to the ART 0.41 0.034* 0.55 0.25
Baseline CD4 cell counts 0.15 0.000* 0.000* 0.90
Baseline WHO stage IV 0.45 0.88 0.44 0.19
Initially prescribed with Pi-based 
regimen
Type of ARV clinic
0.14 0.89 0.61 0.17
0.021*
Doctor-led 0.002* 0.000* 0.000* 0.006*
Large nurse-led 0.002* 0.57 0.33 0.11
*=Significant at p value<0.05
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4.4  Survey o f  A R  T program m e in Chiang M ai
4.4.1 Participants characteristics
There were 302 participants recruited in the survey part of this study; 100 from the doctor- 
led ARV clinic in the provincial hospital, 122 from the large nurse-led clinic and 80 from 
the small nurse-led clinic from the two district hospitals. Of the 302 participants, 40% were 
men, and 60% were women, and this pattern was consistent across all three clinics (see 
Table 4-35). The average age was 37 for both men and women and almost all of the 
participants were Buddhist. The majority of the participants had completed primary or 
secondary education and 40% were either married or lived with partners and nearly 36% 
were widow-widowers.
The majority (80.7%) of the participants received services under the universal coverage 
health scheme (see Table 4-35) and 60% were members of ‘people who living with 
HIV/AIDS (PLHA)’ self-help groups in their hospitals. Amongst these 302 participants, 53 
were from the households with two PLHA including the participants themselves. In relation 
to number of children, there was about one child per household. Only six participants had 
HIV-infected children in their houses with five of these children being on ART.
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Table 4-35: Demographic characteristics of the 302 participants
Demographic characteristics Doctor-led
clinic
Large nurse- 
led clinic
Small nurse- 
led clinic
Total
N 100 122 80 302
Gender: N (%)
Male 35 (35.0) 53 (43.4) 31 (38.8) 119(39.4)
Female 65 (65.0) 69 (56.6) 49 (61.3) 183 (60.6)
Mean age: Years (SD) 36.1 (6.6) 38.1 (7.1) 36.9 (7.6) 37.1 (7.1)
Education: N (%)
No formal educational 17 (17%) 40 (32.8) 25 (31.3) 82 (27.2)
Primary school 53 (53.0) 69 (56.6) 42 (52.5) 164 (54.3)
Secondary school 17(17.0) 9 (7.4) 10(12.5) 36(11.9)
Higher than secondary school 13 (13.0) 4(3.3) 3 (3.8) 20 (6.6)
Marital status: N (%)
Single 16(16.0) 16(13.1) 11 (14.1) 43 (14.3)
Married or living with partner 40 (40.0) 45 (36.9) 34 (43.6) 119(39.7)
Separated/Divorce 9 (9.0) 15 (12.3) 6 (7.7) 30(10.0)
Widow/ widower 35 (35.0) 46 (37.7) 27 (34.6) 108 (36.0)
Type of health insurance: N (%)
Self-pay 7(7.1) 0 2 (2.5) 9 (3.0)
Universal coverage 66 (66.7) 110(90.2) 67 (83.8) 243 (80.7)
Civil Servant Medical Benefit 24 (24.2) 10(8.2) 10(12.5) 44 (14.6)
and Social security scheme
Others 2 (2.0) 2(1.6) 1(1.3) 5(1.7)
Status as member of the PLHA self- 29 (29.0) 103 (84.4) 50 (62.5) 182 (60.3)
help group: N (%)
SD= Standard deviation; PLHA=People who living with HIV/AIDS
In relation to education, participants receiving service from the doctor-led clinic were better
educated (Table 4-35); being less likely to have no formal education, and more likely to
have participants with education beyond secondary school in comparison to nurse-led
clinics (statistically significant, Chi-square test with p< 0.01).
In relation to the health insurance scheme, the doctor-led clinic received patients from either 
the Civil Servant Medical Benefit Scheme (CSMBS) or Social Security Scheme (SSS) 
(statistically significant, Chi-square test with p< 0.01). However, only 29% of participants 
from that clinic were members of PLHA self-help group compared to 84% and 62% of 
participants from the large and small nurse-led clinics respectively (statistically significant, 
3x2 Chi-square test with p< 0.01). Despite the universal health access to ART provided by 
the government, nine participants (3%, n=301) had to pay for the treatment as they had 
initiated treatment before the nationwide expansion of the service.
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4.4.2 Socioeconomic status
More than half of the participants (58.5%) were the main wage earner for their families, 
although 34% of these main wage earners had no formal education with 62% of them 
working as general labourers. These characteristics were consistent across the three clinics. 
About half (55.0%) of the participants lived in other people’s houses, including their 
parents’ houses while 40% of them owned houses. Only one participant reported no 
permanent residence.
The average monthly income and monthly household income of the participants were THB 
4,417 and THB 5,972 respectively (see Table 4-36), however, five participants (1.6%) 
earned less than THB 830 per month which was Thailand’s official poverty line for the 
Northern region of Thailand in 2004 (NESDB 2004). 28 participants reported themselves as 
being unemployed; most of whom were male (57%), had primary education (67%) and were 
under the universal coverage health scheme (85%). In terms of both monthly income and 
monthly household income, participants from the doctor-led clinic were richer compared to 
those from the two nurse-led clinics (statistically significant ANOVA test with p< 0.01).
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Table 4-36: Socio-economic characteristics of the participants
Socio-economic characteristics Doctor-led
clinic
Large nurse- 
led clinic
Small nurse- 
led clinic
Total
N 100 122 80 302
Main occupation: N (%)
Unemployed 12(12.0) 10 (8.2) 6 (7.5) 28 (9.3)
Farmer or gardener 6 (6.0) 8 (6.6) 8 (10.0) 22 (7.3)
Self-employed 14(14.0) 14(11.5) 11 (13.8) 39(12.9)
General labourer 60 (60.0) 84 (68.9) 44 (55.0) 188 (62.3)
Housewife 8 (8.0) 6 (4.9) 11 (13.8) 25 (8.3)
Main wage earner: N (%)
Yes 61 (61.6) 77 (63.1) 39 (48.8) 177 (58.8)
Mean income per month: THB 6.0 (5.9) 3.4 (2.6) 4.1 (2.0) 4.4 (4.0)
1,000 (SD)
Mean of household income per 7.8 (6.6) 4.5 (3.9) 6.0 (3.6) 6.0 (5.1)
month : THB 1,000 (SD) 
Present accommodation: N (%)
Own occupied 40 (40.0) 51 (41.8) 28 (35.0) 119(39.4)
Rented house/room 8 (8.0) 4 (3.3) 4 (5.0) 16(5.3)
Live with others 52 (52.0) 66 (54.1) 48 (60.0) 166 (55.0)
Vagabond 0 1 (0-8) 0 1 (0-3)
SD=Standard deviation
4.4.3 Service utilization
4.4.3.1 Access to the clinics
Regarding mode of transport, motorcycles were the main options for 70% of participants 
(see Table 4-37). The average distance from home to clinic was 15 kilometres with an 
average travelling time of 39 minutes. However, one patient lived in another province about 
450 kilometres away from the clinic, having refused to receive treatment from an ARV
clinic closer to home.
Table 4-37: Participants’ behaviour for ARV clinic visiting
ARV clinic visiting Doctor-led
clinic
Large nurse- 
led clinic
Small nurse- 
led clinic
Total
N 100 122 80 302
Usual method used to come to the 
hospitals: N (%)
By bicycle 4 (4.0) 7 (5.7) 1(1.3) 12 (4.0)
By motorcycle 50 (50.0) 96 (78.7) 67 (83.8) 213 (70.5)
By private car 18(18.0) 10 (8.2) 7 (8.8) 35 (11.6)
By bus/coach 28 (28.0) 7 (5.7) 4 (5.0) 39(12.9)
Others 0 2(1.6) 1(1.3) 3(1.0)
Mean of distance to the hospital: 25.5 (50.8) 8.8 (7.0) 11.4(16.5) 15.0 (31.6)
kilometres (SD)
Mean of time spent to come to 35.7 (39.5) 21.9(12.2) 24.0 (26.9) 27.0 (28.3)
hospital: Minutes (SD)
SD=Standard deviation
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Both distances and travelling times to the doctor-led clinic were significantly further and 
longer compared to the other two clinics (statistically significant, ANOVA test p=0.001). 
This led to differences between participants’ means of travelling to the clinics with 
participants from doctor-led clinics being more likely to travel by bus/coach and less likely 
to travel by motorcycle (statistically significant, Chi-square test p=0.001).
4.4.3.2 Time spent at the AR V clinic
The mean time spent at the ARV clinic was 2.5 hours (see Table 4-38), with a time with the 
doctor of 7.6 minutes and only one half of patients seeing doctors on their last visit.
Table 4-38: Time spent at the ARV clinic of the participants
Time spent at the ARV clinic Doctor-led
clinic
Large nurse- 
led clinic
Small nurse- 
led clinic
Total
N 100 122 80 302
Mean of time spent at the ARV 3.6 (0.9) 2.5 (1.1) 1.1 (0.5) 2.5 (1.3)
clinic: Hours (SD)
Mean of time spent at with doctors at 7.4 (4.5) 8.6 (3.9) 6.1 (4.2) 7.6 (4.3)
the clinic: Minutes (SD)
Saw doctor at the last visit: N (%) 84 (84.0) 44(36.1) 25 (31.6) 153 (50.8)
Attitude toward time spent at the 
ARV clinic; N (%)
Too short 0 1 (0.8) 1(1.3) 2 (0.7)
Appropriate 51 (51.0) 74 (60.7) 72 (90.0) 197 (65.2)
Too long 49 (49.0) 47 (38.5) 7 (8.8) 103 (34.1)
Attitude toward time spent with 
doctor; N (%)
Too short 8 (8.2) 15 (12.3) 11 (14.5) 34(11.5)
Appropriate 90 (91.8) 106 (86.9) 65 (85.5) 261 (88.2)
Too long 0 1 (0.8) 0 1 (0.3)
SD=Standard deviation; ARV=antiretroviral
For the nurse-led clinics, HIV-infected cases were looked after primarily by nurses with 
only the complicated cases being handed over to doctors. Only one third of participants 
from nurse-led clinics saw doctors for the last visit compared to 84% from doctor-led clinics 
(statistically significant, Chi-square test p=0.001). There was no significant difference in 
consultation time with doctors in both types of clinic.
The average time spent at the ARV clinic (statistically significant, ANOVA test p=0.001) 
was shorter in the small nurse-led clinic than either the large nurse-led or the doctor-led
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clinic. Half of the participants from the doctor-led clinic reported that they had experienced
too long waiting times.
4.4.3.3 Hospital appointment and H IV education
In relation to the hospital appointments, the mean interval between follow-up* was 1.2 
months. Twelve participants (4.0%) reported that they had missed at least one appointment 
in the past three months (Table 4-39) of which six immediately visited the hospital when 
they realised their missed appointment.
Table 4-39: Hospital appointment and ART education
Behaviour of service utilization Doctor-led
clinic
Large nurse- 
led clinic
Small nurse- 
led clinic
Total
N 100 122 80 302
Mean of follow-up duration: Months (SD) 1.8 (0.7) 1.0 (0.2) 1.0 (0.2) 1.2 (0.6)
Miss hospital appointment in the 6(6.1) 2(1.6) 4(5.0) 12 (4.0)
past 3 months; N (%)
Inform benefit and harm of ART ; N (%) 89 (89.0) 120 (98.4) 78 (97.5) 287 (95.0)
Level of understanding in case 
benefit and harm were informed; N
(%)
Not at all 0 0 0 0
Partly understood 28(31.5) 31 (25.8) 20 (26.0) 79 (27.6)
Fully understood 61 (68.5) 89 (74.2) 57 (74.0) 207 (72.4)
First consultant if had problem; N (%)
Hospital staff 27 (61.4) 50(51.5) 30(61.2) 107 (56.3)
Family member 8(18.2) 12(12.4) 12(24.5) 32 (16.8)
Other PLHA 2(4.5) 13 (13.4) 6(12.2) 21 (11.1)
NGO 1 (2.3) 0 0 1 (0.5)
Others 6(13.6) 22 (22.7) 1 (2.0) 29(15.3)
SD=Standard deviation; PLHA=People who living with HIV/AIDS; NGO=Non-govemment 
organisation
The follow-up duration based on the last hospital visit were also significantly different 
between the three clinics (statistically significant, ANOVA test p=0.001); being 1.8-months 
in the doctor-led clinic and approximately one-month for the nurse-led clinics, in 
comparison to the national ART programme guideline of one month follow-up. The longer 
duration of follow-up in the doctor-led clinic might be due to the greater number of patients 
being treated by a limited number of doctors.
* Information regarding hospital follow-up duration was from hospital records
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Regarding health education about ART, 15 participants (5.0%) reported never having been 
informed about the benefit and risks of antiretroviral therapy. In case where information was 
provided, 72% of participants reported fully understanding the information provided. When 
the participants had any questions regarding ART, only 56% consulted hospital staff with 
the remainder preferring to consult with family members or other PLHA.
The participants from the doctor-led clinic were less likely to be informed about the benefits 
and risks of ART (statistically significant, Chi-square test p=0.003) with no significant 
difference in level of understanding among the participants from the three hospitals (see 
Table 4-39). Participants from nurse-led clinics were less likely to consult hospital staff for 
problems related to ART (statistically significant, Chi-square test p=0.018).
4.4.4 HIV clinical information
Three quarter of the participants discovered their HIV status through their own or their 
spouses/sex partners being requested to test for HIV while receiving medical treatment and 
being suspected of HIV infection (Table 4-40). The mean time since HIV diagnosis was 
approximately 5.2 years and the average duration of treatment was 11.8 months.
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Table 4-40: HIV clinical information of the participants in the three clinics
HIV clinical information Doctor-led Large nurse- Small nurse- Total
clinic led clinic led clinic
N
Reason for HIV testing; N (%)
100 122 80 302
During you/spouse having 
medical treatment
70 (70.0) 89 (73.0) 69 (86.3) 228 (75.5)
Premarital testing 4 (4.0) 4 (3.3) 0 8 (2.6)
ANC testing 13 (13.0) 10 (8.2) 8(10.0) 31 (10.3)
Voluntary testing 5 (5.0) 5(4.1) 1(1.3) 11(3.6)
For job application 5 (5.0) 0 0 5(1.7)
For blood donation 2 (2.0) 4 (3.3) 1(1.3) 7 (2.3)
Others 1 (i.o) 10(8.2) 1(1.3) 12 (4.0)
History of previous ART; N (%) 23 (23.0) 40 (32.8) 10(12.7) 73 (24.3)
Mean time since HIV diagnosis: 5.1 (3.9) 5.7 (3.8) 4.8 (3.4) 5.2 (3.7)
Years (SD)
Mean of duration of ART: Months 
(SD)
ART regimen used: N (%)
12.9(11.8) 10.9 (9.8) 11.8(9.9) 11.8(10.5)
First line regimen ;GPO-Vir 
(d4T+3TC+NVP)
89 (89.0) 97 (79.5) 72 (90.0) 257 (85.4)
Second line regimen; 
(d4T+3TC+EFV)
3 (3.0) 10(8.2) 0 13 (4.3)
Third line regimen; 2 (2.0) 1 (0.8) 0 3(1.0)
(d4T+3TC+IDV+RT V) 
Others regimen 6 (6.0) 14(11.5) 8 (10.0) 28 (9.3)
Median of baseline CD4 cell counts: 
cell/pL (IQR)
98 (23-220) 94 (32-186) 55 (29-141) 98 (23-220)
Mean of baseline body weight: 52.5 (9.8) 52.0 (9.4) 51.0(9.8) 51.8(9.6)
Kilograms (SD)
SD=Standard deviation; GPO=Govemment Pharmaceutical Organisation; d4T=Stavudine; 
3TC=Lamivudine; NVP=Nevirapine; EFV=Efavirenz; IDV=Indinavir; RTV=Ritonavir
Regarding history of previous treatment, only 24% of participants reported having previous 
ART (Table 4-40). This emphasized the programme flexibility as the government ART 
guidelines stated that only naïve individuals should be eligible for the programme.
It was found that the large nurse-led clinic had more participants with a history of previous 
ART before entering into the government ART programme (statistically significant, Chi- 
square test p< 0.01) (Table 4-40). Participants with a history of previous treatment were 
generally female (64.4%) with an average age of 38 years. Their average duration on ART 
was 8.3 months which is shorter than those who are treatment naive*. About 60% of them
* Time was counted since entering the government ART programme, duration on previous treatment 
was not taken into account
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were members of the PLHA self-help group and nearly half of them (49%) had initial CD4 
cell counts higher than 200/pL.
No difference in socioeconomic status was detected between those naive to treatment and 
those previously treated; gender, age, education, monthly income and status as a member of 
PLHA self-help group were also similar between the two groups. However, participants 
with history of previous treated with ART tended to have higher of initial CD4 cell counts 
(mean =227 /p.L) compared to participants new to the treatment (mean =96 /pL) 
(statistically significant, t-test p< 0.01).
4.4.4.1 ART regimen
According to government ART programme guidelines, three antiretroviral regimens are 
available to prescribe; GPO-Vir as the first line and the other two as alternative first-line 
therapies (see Table 4-40). Nearly all of the patients thus received medication in accordance 
with the guideline and, as such, a similar regimen was used in all three hospitals. However, 
28 patients were treated using regimens not recommended in the guideline, with 3 of these 
patients having previously received ART. In all cases, regimens were prescribed according 
to the physician experiences and tailored to the needs of individual patients concerning 
effectiveness, adverse effects and toxicity or the regimen.
4.4.4.2 CD4 cell counts
The average initial CD4 cell counts of participants were 128 /pL (see Table 4-41). The 
majority of participants (79.6%) had initial CD4 cell counts less than 200 /pL and this was 
similar across the three clinics. Amongst these, six participants had 0 /pL CD4 cell counts 
just before starting ART, while nine participants had CD4 cell counts greater than 500 /pL 
upon entering the programme. The participants from small nurse-led clinic had the lowest 
initial CD4 cell counts; however, this difference was not statistically significant.
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Table 4-41 : CD4 cell counts and body weight of the participants
Variable Doctor-led
clinic
Large nurse-led 
clinic
Small nurse-led 
clinic
Total
CD4 cell counts: /pL 
Median at baseline (IQR) 
Median at 6-month (IQR) 
Median at 12-month (IQR)
98 (23-220) 
169(124-296) 
175 (151-265)
94 (32-186)
152 (87-253)
153 (92-220)
55 (29-141) 
159(113-259) 
126(112-237)
79 (27-171) 
157 (108-258) 
155 (101-228)
Body weight: Kg 
Mean at baseline (SD) 
Mean of at 6-month (SD) 
Mean at 12-month (SD)
52.5 (9.8) 
54.8(10.5) 
55.9(11.0)
52.0 (9.4) 
54.7 (9.0) 
55.2 (7.6)
51.0 (9.8) 
55.6(10.2) 
51.5 (6.8)
51.8(9.6) 
55.0 (9.6) 
54.7 (8.4)
SD=standard deviation; IQR=Inter-quartile range
When comparing CD4 cell counts after 6-month and 12-months of treatment, the CD4 cell 
counts increased over time (Table 4-41). Levels of CD4 cell counts at 6-month and 12-
month of treatment were significant higher comparing to the baseline CD4 cell counts 
(statistically significant, Wilcoxon Signed Ranks test, p=0.001). In addition, CD4 cell 
counts after 12-months of treatment were also significantly higher than that at 6-months in 
participants from doctor-led and large nurse-led clinics. However, CD4 cell counts in small 
nurse-led clinics went down (Wilcoxon Signed Rank test, p=0.043). The increase in CD4 
cell counts at 12-month compared with at 6-months did not achieve clinical significance.
4.4.4.3 Body weight gain
The average initial body weight of participants was 51.8 kilograms (Table 4-42) with half of
the participants weighing less than 50 kilograms before the treatment. Similar to the CD4
cell counts, when comparing body weight after 6-months and 12-months of treatment, the 
participants tended to gain body weight over time except the participants from the small- 
nurse clinics whose body weight reduced slightly between 6 months and 12-months of 
treatment. Overall, body weight at 6-months and 12-months of treatment was significant 
higher compared to the initial body weight (statistically significant, paired t-test, p=0.001). 
Moreover, participants’ body weight at 12-months of treatment was also significantly higher 
than that at 6-month of treatment (paired t-test, p=0.001). Unlike CD4 cell counts, only 
27.6% of participants at 6-month of treatment and 44.6% at 12-month of treatment
presented a gain in body weight >10% compared to baseline. The pattern of response of
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participants’ body weight appeared to be similar across the three clinics with no statistically 
significant differences being identified between the three treatment providers.
4.4.5 Self-reported adherence
Strict adherence to antiretroviral therapy is one of the most important factors in achieving a 
good therapeutic result (Paterson, Swindells et al. 2000); (Read, Mijch et al. 2003) with 
adherence levels being required of at least 95% to attain the best outcome from treatment. 
Adherence of each individual was summarized as the ratio between the number of taken 
doses and the total number of doses of all ARV drugs prescribed. However, in addition, 
participants were asked to recall the number of missed doses or doses that they took more 
than 30 minutes after the usual time in the past 5 days and in the previous month. In terms of 
missed doses in the past five days, 93.4% of participants reported taking all doses of ARV 
drugs (Table 4-43). In terms of missed doses in the previous month, 87.4% reported taking 
all doses of ARV drugs.
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Table 4-42: Behaviour of antiretroviral drugs taking of the participants
Doses of ARV drug taking Doctor-led
clinic
Large nurse- 
led clinic
Small nurse- 
led clinic
Total
N 100 122 80 302
In the past § days that
Missed doses: N (%)
Taken all doses 87 (87.0) 118(96.7) 77 (96.3) 282 (93.4)
1-2 doses 9 (9.0) 4 (3.3) 2 (2.5) 15 (5.0)
> 3 doses 4 (4.0) 0 1(1.3) 5(1.7)
Missed or taken later than 30 
minutes: N (%)
Taken all doses 65 (65.0) 103 (84.4) 65 (81.3) 233 (77.2)
1-2 doses 24 (24.0) 17(13.9) 13 (16.3) 54(17.9)
> 3 doses 11 (11.0) 2(1.6) 2 (2.5) 15 (5.0)
In the previous month that
Missed doses: N (%)
Taken all doses 81 (81.0) 111 (91.0) 72 (90.0) 264 (87.4)
1-3 doses 16(16.0) 9 (7.4) 7 (8.8) 32(10.6)
4-12 doses 2 (2.0) 2(1.6) 0 4(1.3)
> 13 doses 1(1.0) 0 1(1.3) 2 (0.7)
Missed or taken later than 30 
minutes: N (%)
Taken all doses 62 (62.0) 98 (80.3) 62 (77.5) 222 (73.5)
1-3 doses 31 (31.0) 19(15.6) 17(21.3) 67 (22.2)
4-12 doses 6 (6.0) 5(4.1) 0 11 (3.6)
> 13 doses 1 (1.0) 0 1 (1.3) 2 (0.7)
Adherence > 95% in the past 5 87 (87.0) 118(96.7) 77 (96.3) 282 (93.4)
days*
Adherence > 95% in the previous 97 (97.0) 120 (98.4) 79 (98.8) 296 (98.0)
month*
* Accounted for missed doses only (doses that patients did not take); ARV=Antiretroviral
One participant from the doctor-led clinic reported missing all doses of the antiretroviral
drug, both in the past 5 days and in the previous month as a consequence of moving to 
another province and thus being unable to visit the clinic after the medication ran out.
Another participant from the small nurse-led clinic reported missing all doses of the
antiretroviral drug in the past five days and 24 doses in the previous month. He stated that 
such poor compliance was due to the intolerable adverse effect of the ART. Furthermore,
two participants from the large nurse-led clinic stated that their medication was interrupted 
due to running out of the medication in the clinic. This might suggest poor logistical
management in the large nurse-led clinic.
One fifth of participants (n=302) reported missing doses of antiretroviral drugs at least once 
since entering the programme, with 70% of this group having missed a dose in the previous
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month prior to the interviews. The reason for such missed doses was mainly simply as a 
result of forgetting to take the medication (58.3%, n=60).
A multivariate analysis was performed to identify factors that predicted reported adherence 
< 95% (see Table 4-43). The analysis found that there appeared to be no association 
between reported adherence <95% and participants’ gender, age, education, ART regimen, 
type of ARV clinic, baseline CD4 cell counts, baseline body weight, time since HIV 
diagnosis or duration of ART. The correspondence between adherence in the past 5 days 
and in the previous month showed a strong association between reported adherence over 
both time periods.
Table 4-43: Multivariate analysis of factor predicting reported adherence < 95% in the past 5 
days
Predictor OR 95% Cl P value
Gender
Male 2.27 0.41-12.52 0.34
Female Reference
Age: Years 0.99 0.86-1.14 0.86
Time since HIV diagnosis: Years 1.21 0.99-1.47 0.06
Duration on ART: Months 0.99 0.94-1.05 0.83
Initial CD4 cell counts: Cell/pL 0.99 0.98-1.00 0.12
Initial body weight: Kilograms 0.98 0.90-1.07 0.63
Type of ARV clinic 0.25
Doctor-led 3.23 0.52-19.98 0.21
Large nurse-led 0.83 0.09-7.65 0.87
Small nurse-led Reference
History of adverse effects during 0.14
treatment
No 3.29 0.29-36.60 0.33
Yes, but was able to do some work 0.36 0.02-6.91 0.50
Yes, was unable to work at all Reference
Highest education 0.50
No formal education 0.54 0.02-13.85 0.71
Primary school 0.70 0.06-8.52 0.78
Secondary school 2.54 0.19-33.86 0.48
Higher than secondary school Reference
Note. OR = odds ratio; CI=confidence interval, *P < .05.
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Table 4-44: Correlation coefficients (R) of reported adherence response to different definition 
and time frame
Correlation B C D
Number of missed doses during the past five days (A) 0.76** 0.86** 0.85**
Number of doses that missed or took later than 30 minutes in the - 0.63** 0.77**
past five days (B)
Number of missed doses in the previous month (C) . . 0.97**
Number of doses that missed or took later than 30 minutes in the 
previous month (D) - - -
** Correlation is significant at the 0.01 level (2-tailed)
4.4.6 W ellbeing of participants
Prior to initiation on ART, 28.1% of participants reported being unable to work while 32.8% 
said that they could work normally (see Table 4-45). After taking the ART, more than 70% 
of participants reported improvements in terms of either their ability to work, skin, everyday 
activities or mental health. However, 3.6% stated that they had less ability to work, and 
26.5% noticed no difference in their ability to work after taking ART. Approximately half of 
participants reported better health condition in all four aspects (ability to work, skin 
condition, daily activities and mental health) compared to before entering the treatment 
programme. The nurse-led clinics had more participants who reported having better health 
conditions in all four aspects (statistically significant, Chi-square test, p=0.001)
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Table 4-45: Well being of the participants
Well being Doctor-led 
clinic: N (%)
Large nurse- 
led clinic: N 
(%)
Small nurse- 
led clinic: N 
(%)
Total: N (%)
N 100 122 80 302
Before entering the programme
Not able to do work at all 22 (22.0) 42 (34.4) 21 (26.3) 85 (28.1)
Able to work as usual 34 (34.0) 51 (41.8) 33(41.3) 118(39.1)
Able to work normally 44 (44.0) 29 (23.8) 26 (32.5) 99 (32.8)
Ability to work comparing to that 
before entering the programme
Able to do work less 6 (6.0) 2(1.6) 3 (3.8) 11(3.6)
No difference 38 (38.0) 20 (16.4) 22 (27.5) 80 (26.5)
Able to do work more 56 (56.0) 100 (82.0) 55 (68.8) 211 (69.9)
Skin condition comparing to that 
before entering the programme
Worse 4 (4.0) 1 (0.8) 3 (3.8) 8 (2.6)
No difference 27 (27.0) 12 (9.8) 12(15.0) 51 (16.9)
Better 69 (69.0) 109 (89.3) 65 (81.3) 243 (80.5)
Daily activities e.g. take a bath 
comparing to that before 
entering the programme
Worse 1(1.0) 1 (0.8) 3 (3.8) 5(1.7)
No difference 39 (39.0) 19(15.6) 15 (18.8) 73 (24.3)
Better 60 (60.0) 102(83.6) 62 (77.5) 224 (74.2)
Mental health comparing to that 
before entering the programme
Worse 2 (2.0) 2(1.6) 2 (2.5) 6 (2.0)
No difference 24 (24.0) 10(8.2) 8 (10.0) 42(13.9)
Better 74 (74.0) 110(90.2) 70 (87.5) 254 (84.1)
Better heath condition in all four 28 (28.0) 89 (73.0) 44(55.0) 161 (53.3)
aspect
4.4.7 A RT-related adverse events
In relation to the adverse effects of ART, nearly 200 participants reported experiences of 
side effects from ART treatment (Table 4-46). Of this number, 59 participants were unable 
to work and had to stop undertaking activities because of adverse effects and ten participants 
stopped taking the medicines as a consequence of adverse events. Further analysis to 
analyse the relationship between regimen and side effects found that the adverse effects 
reported by participants were significantly related to the regimen used (Chi-square test, 
p=0.018). The analysis suggested that participants who were on a regimen containing 
efavirenz experienced more adverse effects than participants on other regimens. In 13 
patients treated with efavirenz, 12 of them reported side effects. This result supported the 
findings of a national survey (MOPH 2004) which found that participants with regimens
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other than GPO-Vir (first-line regimen) tended to experience more adverse effects than
those who prescribed with GPO-Vir.
Table 4-46: Experience of adverse events
Adverse events Doctor-led 
clinic: N (%)
Large nurse- 
led clinic: N 
(%)
Small nurse- 
led clinic: N 
(%)
Total: N (%)
N
Experience of adverse effects
100 122 80 302
No 55 (55.0) 22(18.2) 30 (37.5) 107 (35.5)
Yes (minor effect) 36 (36.0) 59 (48.8) 40 (50.0) 135 (44.9)
Yes (unable to do anything) 9 (9.0) 40 (33.1) 10(12.5) 59(19.6)
Stop taking medicine if had side 
effect
3 (6.8) 5(5.1) 2 (4.0) 10(5.2)
4.4.8 Stigm atization
The majority (90%) of participants informed their partners and their families (Table 4-47) of 
their HIV status. However, in the case of 20% of participants, their HIV status was unknown 
to their communities. This is the role of the PLHA group which provides voluntary social 
and moral support for their members’ public disclosure of their HIV status within their 
community. Participants from the doctor-led clinic (38%) tended to be less willing to 
disclose their status to their communities (statistically significant, Chi-square test, p=0.001). 
Of the participants who experienced stigmatization, 66% of them reported that they were 
more accepted after taking ART.
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Table 4-47: Participants’ experiences of stigmatization
Stigmatization Doctor-led 
clinic: N (%)
Large nurse- 
led clinic: N 
(%)
Small nurse- 
led clinic: N 
(%)
Total: N (%)
N 100 122 80 302
Inform status of HIV infected to 69 (69.0) 91 (89.2) 54 (90.0) 214(89.9)
couple or sex partner
Inform status of HIV infected to 86 (86.0) 117(95.9) 77 (96.3) 280 (92.7)
family
Inform status of HIV infected to 62 (62.0) 111 (91.0) 72 (90.0) 245 (81.1)
community
Experience of people turn away
Never 54 (55.7) 77 (63.1) 37 (46.8) 168 (56.4)
Yes 16(16.5) 27 (22.1) 23 (29.1) 66 (22.1)
Not sure 16(16.5) 11 (9.0) 14(17.7) 41 (13.8)
Neighbour and community 11 (11.3) 7 (5.7) 5 (6.3) 23 (7.7)
don’t know my HIV status 
People accepted you more after 
taking ART
Less accepted 0 0 0 0
No difference 4 (25.0) 4(14.8) 9 (36.0) 17 (25.0)
More accepted 11 (68.8) 19 (70.4) 15 (60.0) 45 (66.2)
Not sure 1 (6.3) 4(14.8) 1 (4.0) 6(8.8)
4.4.9 Sexual behaviour
In relation to sexual activities, 43.1% reported having sex within the past 3 months at the 
time of interviews (see Table 4-48) usually with a single partner. However, four participants 
(0.8%) reported having sex with more than one person in the past 3 months, with one 
participant having four partners. Approximately 55% of participants stated that they have 
not indulged in sexual activities since taking ART, while five participants reported that they 
were more sexually active since being prescribed ART. For those who reported having sex 
in the previous three months, more than 80% reported always using a condom. However, 
five participants reported that they never used a condom which might suggest an inadequacy 
of counselling and health education in these cases.
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Table 4-48: Participants’ sexual behaviour
Sexual behaviour N (%)
Have sex in the past 3 months
No 169 (56.9)
Yes 128 (43.1)
N 297
Number of people have sex with in the past 3 months
Mean (SD) 1.1 (0.3)
Range 1-4
N 126
Condom used
Never 5 (4.0)
Sometimes 8 (6.3)
Mostly 8 (6.3)
Always 105 (83.3)
r N 126
Sexual activity comparing to before entering the programme
Less often 12 (4.0)
No difference 117(39.0)
More often 5(1.7)
Never had sexual intercourse since entering the programme 166 (55.3)
N 300
SD = Standard deviation
This chapter has presented the results obtained in relation to outcomes of ART delivery in 
Thailand and identified factors that may contribute to these outcomes. The next chapter 
analyses the findings in the present study in greater detail and attempts to identify factors of 
greatest relevance. In addition, the strengths and weaknesses of the analyses are addressed, 
together with the implications for policy and practice and for further research.
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5 Discussion and Conclusion
In this chapter, the findings of the present study from previous section are discussed and 
conclusion followed by the implications and suggestion derived from the findings. Again, 
the presentation in this chapter is done according the main outcomes investigated and 
objectives like presentation in the four previous chapters of this thesis.
5.1 Introduction
This is one of a small numbers of studies of the Thai antiretroviral therapy programme. 
Thailand has been recognized as being in the vanguard of scaling up ART therapy in 
developing country. This study of factors that contribute to those outcomes with universal 
access in the Thai context is longer than any other studies conducted in Thailand with an 
average follow up 3.7 years and examines real data rather than projections and simulation. 
The study included the oldest treated cases from the implementation of the programme in 
Northern Thailand in May 2001, preceding the official roll out of the national programme 
two years later. As experience of, and evidence about, ART and its outcomes are very 
limited in middle- and low-income countries, this study explores a national ART 
programme in one middle-income country where locally produced generic ART is used as 
first-line treatment and all eligible PLHA can enter the programme. The setting is quite 
specific, and as there are significant variations between countries, local research such as this 
is very important and is likely to be an effective way of improving practice in Thailand 
(Rosen, Fox et al. 2007). Moreover, determinations of factors affecting survival and ART 
outcomes in middle- or low-income countries are relatively rare in the literature and 
therefore add to the general body of knowledge (Bennett and Chanfreau 2005); 
(Chasombat, Lertpiriyasuwat et al. 2006); (Thanprasertsuk, Lertpiriyasuwat et al. 2006); 
(Lyttleton, Beesey et al. 2007); (Nunn, Fonseca et al. 2007); (Over, Revenga et al. 2007); 
(Rosen, Fox et al. 2007)
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5.2 A ntiretroviral therapy outcomes
Five hundred and one participants who initiated the treatment during March 1, 2001- April 
30, 2004 were followed up for a median of 3.7 years. Seventy six cases died. More than half 
achieved CD4 cell counts that exceeded the level of 200 cell/uL and a quarter of them 
exceeded the level of 500 cell/uL. More than 31% had to change prescribed ART regimens 
from those initially given. Thirteen cases had disease progression with WHO staging 
changing either from stage II to stage IV, stage III to stage IV or stage II to stage III: many 
were in a very advanced stage before entering the programme. Five cases had decided to 
terminate the treatment themselves. Twenty-eight cases were lost follow up. Seventy five of 
them were referred to receive the treatment at the nearby health facilities. Approximately 
20% of them experienced adverse reaction from using ART. Moreover, 24 patients were 
resistant to the prescribed treatment.
5.2.1 M ortality
Since the commencement of HAART in 1996, many studies have shown significant 
reduction of mortality and improved survival but most were limited by short follow up 
times. In the survival analysis of our study, 76 cases died with the mean survival of 93 
months, and the main cause of death was still related to HIV/AIDS.
More than half of deaths occurred in the first year which this can be seen from the steep 
falling curve at the beginning of survival curve (see section 4.1.1) due to the fact that people 
were mostly in the advanced stage. During the follow up period in this study with mortality 
rate of 16%, it suggest a good comparable outcome with that from developed countries (van 
Sighem, Danner et al. 2005); (Kumar, Kilaru et al. 2006).
The initial phase of HAART is thought to be critical. However, two studies in Thai HIV- 
infected children showed that ART can be effective for children even in the advanced stage 
(Puthanakit, Aurpibul et al. 2007); (Puthanakit, Aurpibul et al. 2007). Moreover, the critical
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period of hospitalization and death was in the first 24 weeks and the infection mostly 
occurred in the first three months after the initiation of ART (Manosuthi, Chaovavanich et 
al. 2007). Still survival analysis studies which identify the benefit of HAART in resource- 
limited countries, especially with long follow up time, are still limited (Badri, Bekker et al. 
2004); (Fassinou, Elenga et al. 2004); (van Kooten Niekerk, Knies et al. 2006).
5.2.2 H ealth-related quality o f life
Changes in health-related quality of life after the period of three years on HAART were 
examined in 97 randomly selected patients from three facilities. At the first time to examine 
the quality of life in 2004, the participants stated that their quality of life before the initiation 
of HAART were generally poor as nearly all of the participants were in advanced stage 
(stage III and IV). However, at the interviews in 2004 when they were averagely treated 
about a year, almost all of the participants in my study felt better.
In present study, the quality of life was re-evaluated again in 2007. Over the three years on 
HAART, the HR-QOL of the participants in the present study was unchanged. This shows 
the quality of life did not deteriorate over time in keeping with a previous two-year study 
(Saunders and Burgoyne 2002). This might be due to the fact that the evaluation was done 
after the induction phase which is the critical period of change in HR-QOL (Burgoyne, 
Rourke et al. 2004).
Another interesting finding from the present study is that, the number who reported being 
better off was relatively smaller than those reported being worse off in many domains used 
to measure quality of life of the two sets of questionnaires. This present study found that the 
participants required more support comparing to what they reported in 2004. This is an 
important dimension to explore as in one study, it was shown that the family and social 
support was strongly associated with HR-QOL (Jia, Uphold et al. 2005).
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The findings in present study were similar to the findings in studies by Miners and Jia which 
stated that HR-QOL in PLHA seemed to be lower than general population (Miners, Sabin et 
al. 2001); (Jia, Uphold et al. 2007). It was also in agreement with most studies which show 
significant improvement of HR-QOL in PLHA after receiving HAART (Nieuwkerk, Gisolf 
et al. 2001); (Liu, Ostrow et al. 2006); (Jia, Uphold et al. 2007). My findings are also similar 
to the results from studies in the resource-poor environments such as Senegal, Uganda and 
South Africa , which found that the HR-QOL was improved by HAART using either 
specific measures (e.g. MOS-HIV) or generic measures (e.g. SF-36, Europol) (Jelsma, 
Maclean et al. 2005); (Poupard, Ngom Gueye et al. 2007); (Stangl, Wamai et al. 2007); 
(Philips, Zachariah et al. 2008) , One other recent Thai study of the effect of the national 
antiretroviral treatment programme on HR-QOL revealed that PLHA felt satisfied and 
contented and had courage to fight for the rights to access to HAART because of the good 
results of ART on their health. Health-related quality of life of those treated with ART was 
improved compared to those without the treatment (Chariyalertsak, Oberdörfer et al. 2006). 
The present study also showed that significant immunological improvement, as measured by 
CD4 counts in the first year after ART, occurred in the same direction as their HR-QOL. 
This is similar to the findings of Gill which showed that HR-QOL and CD4 cell counts were 
strongly associated (Gill, Griffith et al. 2002).
5.2.3 Im m unological im provem ent
The present study only used CD4 cell counts for the monitoring of treatment and disease 
progression according to the guideline of national antiretroviral therapy programme in 
Thailand at that time, except in those suspected of treatment failure in whom samples were 
sent off for viral load and resistance testing. As there are still financial barriers to routine 
CD4 count and HIV viral load monitoring in Thailand, as well as in other developing 
countries, the national ART programme only uses CD4 cell counts as the main monitoring 
tool.
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In the present study, a bit more than half and a quarter of participants could have the CD4 
cell count approach the level of 200 and 500 cell/uL during the study period. Even though 
CD4 count at baseline and response of CD4 count are important in predicting CD4 counts 
less or equal 200 cell/uL (Sterling, Chaisson et al. 2003); (Kawado, Hashimoto et al. 2006); 
(Srasuebkul, Ungsedhapand et al. 2007), clinical and immunological measurement have a 
lower sensitivity than RNA viral load in determining treatment failure (Chaiwarith, 
Wachirakaphan et al. 2007). This suggests a considerable value of viral load in addition to 
the use of CD4 cell counts.
5.2.4 D uration on the first-line regim en
Approximately 85% of the participants started the treatment with the first-line regimen 
(GPO-vir) which is the locally produced generic ART followed the recommendation of the 
national ART guideline. The regimen were changed in 30% of the participants with the two 
main reasons were either the patients developed drug resistance or experienced adverse 
event. The most common side effects were lipodystrophy (nearly 50% of all adverse events)
Drug resistance is another important problem even in PLHA who naive to the treatment. In 
our study, about 4.8% of the participants developed drug resistance, initially defined by a 
worsened clinical presentation (e.g. high viral load despite treatment, advance staging, 
developing new opportunistic infection) and confirmed by test for drug resistance during the 
period of the study. A surveillance system for drug resistance should be an essential part of 
the scale up of the treatment in Thailand.
Nearly one-fifth of the participants in our study experience some degree of toxicity of ART. 
This is in keeping with other studies from Thailand. One cohort of 417 Thai participants 
showed that one fourth of the patients developed grade III/IV toxicity including 
hepatotoxicity, dyslipidemia, hypertriglyceridaemia and anaemia (Nuesch, Srasuebkul et al. 
2006). Adverse effects of the use of ARV in relation to dyslipidemia in Thai children has
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been demonstrated by another study with a follow up period of approximately two years, 
and this was strongly associated with baseline dyslipidemia and regimen of ART (Kerr, 
Duncombe et al. 2007). In one recent study with fewer participants and a shorter follow up 
period, findings still suggested that side effects were common especially in those who 
prescribed protease inhibitors both single and double boosted (Hiransuthikul, Hiransuthikul 
et al. 2007). In group of PLHA with the non-nucleoside reverse transcriptase inhibitor-based 
antiretroviral therapy, lipodystrophy was also observed in half the children at the nearly 
three years follow up (Aurpibul, Puthanakit et al. 2007). Findings were similar in one small 
study of children who received HAART (Lapphra, Vanprapar et al. 2005).
5.3  Factors determ ining A R T  outcomes
In term of factors determining the outcomes, they can be divided into three categories
1. Socioeconomic factors (i.e., gender, occupation and income, type of health 
insurance, education)
2. Baseline clinical factors (i.e., baseline CD4 cell count-WHO staging, and history of 
previously treated with ART)
3. Factors associated with ART delivery (i.e., initial prescribed regimen, being 
member of PLHA self help group and type of ARV clinic)
In the present study, disparities of outcomes were observed and these were associated with 
factors mentioned above. For instance, from the Cox model, it was found that being male 
and people in low socioeconomic such as unemployed patients with low-income tended to 
die faster, moreover, their immunologic status (measured using CD4 cell counts) did not 
respond well to the treatment; the poorer tended to die faster. This has been described before 
by Mcfarland (McFarland, Chen et al. 2003). Baseline clinical factors such as CD4 cell 
count were also found to be highly associated with outcomes such as the rising of CD4 cell 
count to approach the level of 200 and 500 cell/uL; the higher CD4 cell count at baseline, 
the better of immunologic response to the treatment.
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The method of ART delivery was also found important as the participants in doctor-led 
tended to survive more than those who treated in nurse-led clinics. Types of health facilities 
were shown to be associated with mortality and regimen changes; fewer participants from 
doctor-led clinic died and more participants from doctor-led clinic had their prescribed 
regimen changes. These findings imply influence of doctor experience over the outcomes as 
demonstrated before (Kitahata, Koepsell et al. 1996); (Stone, Mansourati et al. 2001); 
(Landon, Wilson et al. 2003). The present study emphasizes the differences of effects on 
outcomes in relation to mortality, immunological response and changes of prescribed ART 
regimens when the care was delivered by different care takers; by doctors and by nurses. For 
instance, the treated participants in doctor-led tended to die less and more likely to be 
prescribed with alternative regimens comparing to those who treated in the nurse-led clinics. 
This might be due to the fact that doctors deliver better care and can deal with problems 
arisen from the treatment better that trained nurses. Therefore, the substitution of works of 
the doctor by nurses or other trained health personnel may end up with trade off between 
quality and costs.
In context of Thailand, The existing of PLHA self help group also affected the outcome as 
people who were the member of the group tended to respond well with treatment (defined 
by the increase of CD4 cell counts) and were likely to survive compared to those who were 
not the member. This might be due to the rolls of group to assist PLHA to adhere to the 
treatment as well as to support the members throughout the course of the treatment. The 
findings emphasize the role of PLHA self-help group in Thailand and correspond with a 
previous study which explored the function of PLHA, but this was done qualitatively with 
no outcome measures (Lyttleton, Beesey et al. 2007). The present study setting requires 
cooperation with community and PLHA self-help group similar to that described by Farmer 
in 2001 about a community based approach to ART in rural Haiti (Farmer, Leandre et al. 
2001). This was due to the shortage of health manpower which severely aggravated the
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problem of poor accessibility to HAART (Muula, Chipeta et al. 2007); (Philips, Zachariah 
et al. 2008) and might pose unfeasible monitoring demands, drain valuable resources from 
more important prevention efforts (Lange and van der Waals 2002) as one study also 
revealed that 85 clinical officers and physicians and 91 nurses had to provide HAART to 
nearly 100,000 PLHA, requiring far less use of human resources than would be estimated 
based on the literature from other countries (Muula, Chipeta et al. 2007).
Our study does not aim to identify the factors determining accessibility to HAART. 
However, a cross sectional study in Khon Kaen, North eastern Thailand indicated that there 
were inequalities in access to and use of ARV among PLHA by health insurance status, 
patients who were covered by the Civil Servant Medical Benefit Scheme were significantly 
more likely to be prescribed with ARV than those who were covered by the universal health 
scheme or a publicly-funded medical insurance (Kitajima, Kobayashi et al. 2005). However, 
this study was based merely on secondary data of those who registered themselves at the 
ARV clinics without a true control group and thus, its validity could be questioned.
5.4  N ational antiretroviral therapy program m e
The initial survey which forms the earliest part of the present study included a total of 302 
participants from three ARV clinics; doctor-led, large nurse-led and small nurse-led ARV 
clinics in Chiang Mai, Northern Thailand. Generally, patients’ characteristics and HIV 
clinical information were similar across the three clinics; they were middle-age, quite poor 
with primary education with more women than men. However, this study did note 
differences in term of incomes, types of health insurance, status as the member of the PLHA 
self-help group, level of adherence and number of patients with previous ART experience.
As the doctor-led clinic was located in the city area while the other two nurse-led clinics 
were sited in communities away from the city, participants who came to get services from 
the doctor-led clinic had to travel and spent a longer time travelling than participants from
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the nurse-led clinics. This affected method of transportation to the clinics. However overall, 
the key characteristics of participants were generally similar to that from the national survey 
which conducted by the Thai MOPH previously (MOPH 2004).
When differences occurred, they tended to be due to the geographic distribution; urban 
versus rural area. This partially determines utilisation of different type of health facilities, 
urban people are more likely to go to provincial hospital (doctor-led) and people from the 
rural area tend to seek services from district hospital (nurse-led clinic). This delivery of 
services through different types of health facilities has an effect on both users’ and 
providers’ behaviours which might cause differences in treatment outcomes.
In Thailand, delivery of ART throughout the country has been done mainly via the hospitals. 
Thus, majority of PLHA received the treatment via the hospital based ARV clinics 
(Thanprasertsuk, Lertpiriyasuwat et al. 2006). However, in rural communities such as 
districts of Chiang Mai, Northern Thailand where we conducted this study, the treatment 
was mainly delivered by trained nurses, with referral to doctors in complicated cases that 
only half of the participants saw doctor for the last visits. Still, only limited literature 
describes nurse-practitioner and HAART (Gross, Bilker et al. 2002).
Over the follow up period in present study, the number of women who were prescribed ART 
was higher than men. This was similar to what was found in one multi-centre study to 
evaluate the gender and the utilization of HAART (Beusterien, Davis et al. 2008), and what 
has been reported by UN AIDS (UN AIDS 2008). The characteristics of the treated 
individuals in present study; generally poor with low education, and in advanced stages of 
the disease is seen in much of the literature about HIV/AIDS in developing countries 
(Orrell, Bangsberg et al. 2003); (Jaffar, Govender et al. 2005); (Orrell 2005); (Wolf, Davis 
et al. 2005); (van Kooten Niekerk, Knies et al. 2006).
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In the present study, self-reported adherence was chosen as a method of measuring 
adherence as it is one of the most frequently used method in developing countries (Diabate, 
Alary et al. 2007). This is both pragmatic and valid; one meta-analysis of 65 studies has 
shown that self-reported adherence can distinguish between clinically meaningful patterns 
of medication-taking behaviour and is significantly associated with the relation between 
adherence and virologic response (Nieuwkerk and Oort 2005). Our cross-sectional survey 
showed that adherence was very high. Moreover, with the re-evaluation in 2007, their 
adherence to the medication did not change much over the period of three years as nearly all 
of them reported of having adherence above 95%. This was not unexpected as the 
participants who reported this were those who managed to survive over the interval of three 
years and to so, a high level of adherence is required.
For the high adherence in the present study, the findings are similar to one study from 
Bangkok, Thailand which showed that self-reported adherence using visual analogue scale 
was comparatively high, and this was strongly associated with undetectable viral load 
(Maneesriwongul, Tulathong et al. 2006). Still, this has to bear in mind that even the self- 
report is practical and closely related to the viral load however; cultural differences should 
be taken into account for interpretation of the findings. For instance, as mentioned earlier 
that the patients in present study valued the treatment as a hope to survive therefore they 
were very strict to adhere to the treatment and they also respected doctors and other care 
providers, they might choose to give the answer to please them.
The findings regarding adherence in present study is in agreement with many studies in 
African nations such as in Senegal where expansion of HAART was cautioned against due 
to the fear of poor compliance. It was later found that patients’ compliance is not a barrier to 
delivery of HAART and the results from those studies shows the favourable outcome in 
relation to CD4 cell counts and viral suppression (Desclaux, Ciss et al. 2003); (Orrell, 
Bangsberg et al. 2003); (Moatti, Spire et al. 2004); (Orrell 2005). However, one has to be
166
Discussion and Conclusion
aware that factors that cause poor adherence are numerous as described in one systematic 
review which included both qualitative and quantitative studies from both developed and 
developing countries. It suggested that important barriers reported in both economic settings 
included fear of disclosure, concomitant substance abuse, forgetfulness, suspicions of 
treatment, regimens that are too complicated, number of pills required, decreased quality of 
life, work and family responsibilities, falling asleep, and access to medication. The findings 
from this review were consistent amongst all nations (Mills, Nachega et al. 2006).
In the evaluation in 2004, stigma regarding HIV infection in the participants was found to be 
decreased. Mood and stigmatization of the HIV-infected patients which are one part of HR- 
QOL are another two important aspects of HIV/AIDS care which have been found to be 
related the compliance (Alfonso, Bermbach et al. 2006); (Alfonso, Geller et al. 2006). This 
suggests a requirement for assessing stigma and support from the health system that delivers 
HAART. The findings in the present study agree with a qualitative study in Brazil which has 
shown that universal access to HAART can lessen stigmatization in children (Abadia- 
Barrero and Castro 2006). Another important assessment to be mentioned here as it is one of 
the important indicator for health related quality of life (Meng, Anderson et al. 2006) is that 
the participants have shown that they were likely to be able to return to their work after the 
initiation of HAART.
In 2004, in the present study, the participants’ health conditions in relation to their skin 
condition, mentality, and physical well being improved after initiation of the ART. More 
than 80% of the participants reported improvement of their skin condition after initiation of 
HAART. However, in 2007, lipodystrophy was the commonest adverse effects among the 
participants, mainly in those on stavudine. This is not a surprise as this type of side effect 
can be caused by either NNRTI- or Pi-based regimen (Steel, Landsittel et al. 2006). Thus, 
close monitoring for side effects is also required throughout the treatment course. The 
present study found that people who experienced adverse effects from ART stopped taking
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the medication: this also seen in one Canadian qualitative study which showed that 
medication factors was the leading cause of non-adherence (Mills, Nachega et al. 2006).
Another negative consequence of HAART is the potential of the patients to resume risky 
behaviour such as unprotected sex (Crepaz, Hart et al. 2004). In this present study, less than 
half of them were still sexually active when interviewed in 2004 but the rate of using 
condoms was impressively high as people might be optimistic for the treatment; if people 
think it is effective, they also beware of risk behaviour (Huebner, Rebchook et al. 2004); 
(Obermeyer and Rajkumar 2004). In the present study, there were still some patients 
reported of not using condom during sexual intercourse which reflect the need for 
implementation of prevention strategies more aggressive in the risk group.
5.5 Study validity
The PLHA in this study were all from Chiang Mai, Northern Thailand where the ART 
programme was implemented two years prior to the official launch of the national 
programme in 2003. This may therefore be different to the overall picture of ART 
programme in Thailand. The team of staff was well trained with more financial support than 
usual and this may have led to better outcomes in these PLHA. The normal Thai criterion 
for PLHA to be entitled to ART is that the CD4 cell count should be lower than 200 cell/uL. 
However, our study showed that the programme also included PLHA with higher CD4 cell 
count than that level; this showed the flexibility of the criteria within the selected facilities. 
As PLHA’s CD4 cell counts should be lower than 200 cell/uL to be eligible to enter the 
programme, the participants were mostly in an advanced stage (WHO stage III or IV) before 
starting treatment. The treatment outcomes in this present study may therefore be less 
favourable and not comparable to those found in many studies where patients are enrolled at 
higher CD4 cell counts (e.g. < 500 cell/uL) (Moore, Stanton et al. 1994); (Strathdee, Palepu 
et al. 1998); (Cunningham, Markson et al. 2000); (Palella, Deloria-Knoll et al. 2003); 
(Galai, Vlahov et al. 2005); (Braitstein, Brinkhof et al. 2006). However some studies also
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suggest that ART initiation could generally be delayed until the CD4 cell counts approaches 
200 cell/uL (Duncombe, Kerr et al. 2005). Thus, it might still be appropriate to use that level 
of CD4 cell count as the cut point for inclusion criteria in the Thai programme.
In relation to the health-related quality of life of the PLHA, one must be aware that these 
data came only from group of PLHA who survived the three year period. The HR-QOL of 
these PLHA is therefore likely to be better than those who died or did not show up for the 
second interview. However, the aim of the study is to explore the HR-QOL after the launch 
of the programme and does not aim to generalise the findings beyond this fact. Evaluation of 
HR-QOL depends upon completion of questionnaire, the conventional approach (Wu 2000) 
and therefore no information can be obtained from those who died. The two sets of 
questionnaires used in the present study were generic and not specific to HIV/AIDS. Thus, 
the outcomes might be less precise. However, many studies regarding HR-QOL show that 
generic measures such as Euroqol and SF 36 are practical to use (Arpinelli, Visona et al. 
2000); (Delate and Coons 2001); (Wu, Jacobson et al. 2002). When comparing generic and 
specific instruments to measure HIV/AIDS HR-QOL generic measure are more sensitive 
than specific measure like MOS-HIV (Wu, Jacobson et al. 2002). With differences in 
domain measures, the tests cannot be compare directly (Wu 2000). The questionnaire used 
in the present study contains some sensitive issue such as questions regarding sex. Use of 
the qualitative approach may help us better understand such issues.
Another important aspect to be considered in interpretation of the results is that some 
baseline characteristics that influence the outcomes, such as gender, are constant; however, 
other factors such as occupation and income could alter over the course of treatment. This 
may make the contribution from those factors to outcomes very difficult to interpret. One of 
the important aspects of the present study is that it is the combination of both prospective 
and retrospective cohorts. The use of the retrospective data may lead to data loss as 
mentioned in the method section. Attempts were made to minimise this retrieving all
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possible data and trying to validate it by contacting with related health facilities and 
patients’ families. The fact that people in this setting did not relocate much also helped to 
minimise lost data. Despite this, 5.6% of data was lost although this is small compared to 
studies in the literature which could be around 25-44% (d'Arminio Monforte, Lepri et al. 
2000); (Ahdieh Grant, Silverberg et al. 2001); (Dorrucci, Pezzotti et al. 2001); (Barron, Cole 
et al. 2004).
5.6 Implications
One of the biggest limitations in determining the best possible choices of HAART for each 
individual is the shortcoming of available information from present randomized controlled 
trials that include both long term side effects and problems with long-term adherence (Jones 
and Gazzard 2006) .Most studies in developing countries in present literature are conducted 
over period less or equal to one year (Louwagie, Bachmann et al. 2007); (Poupard, Ngom 
Gueye et al. 2007); (Stangl, Wamai et al. 2007). Thus, studies with longer follow up period 
are required; the Thai context is quite specific and ART programme in Thailand is 
considered as the front line for developing countries. It may be possible to generalize the 
key findings here to many countries with a similar situation and perspective.
5.6.1 Im plications for policy and practice
HAART can be successfully initiated in people with very advanced HIV stage; low 
mortality was observed in this study where HAART was started in people with CD4 cell 
count lower than 200 cell/uL. Despite this, baseline CD4 was a strong predictor for 
immunological response; the higher at baseline, the better the response. At present, 
asymptomatic PLHA do not begin care until they are in the advanced stage (CD4 cell counts 
less than 200 cell/uL). Many other studies, suggest that initiation of the treatment at an 
earlier stage can yield higher benefit from the treatment. Thus, the proper point to start ART 
and the criteria at the enrolment should be rethought to suit each individual.
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There should be a point to inform negative and positive consequences of HAART to make 
them aware and prepare for the effects of the treatment as some of the participants still do 
not fully understood about the consequences of HAART. This is to ensure that the patients 
will understand and adhere throughout this life-long treatment course as majority of them 
are generally poor with low education level, and the role of PLHA self-help group is 
important here. Moreover, the proper prevention methods for each individual who entitle 
into the programme should be conveyed and enhanced as what found in the present study 
that risk behaviour were still found.
In relation to health-related quality of life in the present study, it was found to be stable. 
However, many participants reported becoming worse off in terms of support over time and 
as this is important to maintain a high adherence level, assessment and support from the 
health system that initiated HAART are required.
Utilization of VCT in the Thai culture was found to be rare: 75% participants from the 
survey discovered their sero-status when they or their families got sick and were suspected 
to have HIV infection. The health system should promote the use of VCT in risk groups.
Prevention is still a mandatory strategy that should not be overlooked as some PLHA who 
are receiving the ART and feel healthy may want to resume an active sexual life which 
might increase risk of HIV spreading, Thus, effective prevention is still important and needs 
to convey the right message to this group of PLHA as a minority of participants in the 
present study reported that they still had sexual activities with no protection (do not use 
condom at all).
Drug-resistance is one of the expected problems after some period of implementation of the 
treatment programme. Moreover, monitoring and surveillance system in Thailand is still 
suboptimal. In order to avoid the rapid emergence of resistant viruses in a resource-poor
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setting like Thailand, close surveillance of antiretroviral drug resistance should be 
encouraged.
As adequate human resources are a prerequisite for the success of the treatment programme, 
a long-term human resource plan needs to be developed. In Thailand, almost all of the 
treatment is delivered through hospitals; however, the trained nurses are principle carers of 
PLHA in the district hospitals which mostly play the major role in filling the need of the 
PLHA in the rural areas. Limitations of HIV/AIDS care were observed in the present study 
especially among complicated patients, particularly in the later years of the programme due 
to drug resistance and adverse effects. Empowerment of care givers should be taken into 
consideration as well as empowerment of the community to engage in the health system.
In the present study, disparities among groups with various backgrounds were demonstrated. 
Thus, assessment of disparity in term of access and benefit from HAART should be done 
periodically. Given the size of the programme, the existing challenge is also to create a 
health financing system that can ensure the fair utilization of health services and distribution 
of treatment benefit to different groups of people and to reach each individual in the country 
equally, especially people who are not covered with the universal health scheme such as 
migrants and ethnic minorities. Prevention and treatment are also inadequate in this 
population subgroup.
The ART programme should look after closely with those who in low socioeconomic due to 
their relatively high mortalities after the roll out of the programme, moreover, the roll of 
PLHA self-help group is quite important in the Thai context, strengthen and expanding the 
capacity of the group would enhance patients adherence which will later give the favourable 
outcome in both survival and immunological response
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5.6.2 Im plications for research
The area of HAART is rapidly changing, and the validity of findings has been compared 
within the contexts of other conducted studies. The main need is for knowledge which is 
relevant to policy and practice. For the present study, additional research would increase our 
insight and understanding of implementation of HAART in the Thai context. This includes. -
• Multi-centre prospective cohort study which includes more participants from 
various types of participants including university hospitals with longer follow up 
period and multiple points of assessment over a study period.
• Evaluation of the patients using disease specific such as MOS-HIV questionnaire 
would give quality of life information particular to HIV/AIDS, and this could be 
done cooperatively with qualitative approaches for more intuitive understanding.
• This study did not explore the factors determining access to HAART. However, the 
entry point of the treatment is also another predictor for treatment outcomes. A 
prospective cohort to follow up patients after their diagnosis of HIV would help to 
identify those who are likely to be prescribed and utilize HAART, especially in 
places where the criteria for the enrolment is not rigorous, and it would also help to 
identify the prevalence of health care providers in term of HAART prescription.
5 .7  Conclusion
In the present study, 76 out of 501 cases died with the mean survival of 93 months, and the 
main cause of death was still related to HIV/AIDS which comparable to those found in 
studies from developed country. When the ART programme was rolled out, the patients 
responded very well in term of better quality of life and immunologic response (CD4 cell 
counts) during the first year when they were in the very advance stage at the baseline. 
However, after the induction phase, their quality of life seemed to be stable over the study 
period of three years. A bit more than half and a quarter of participants could have the CD4 
cell count approached the level of 200 and 500 cell/uL and approximately 85 /o of the 
participants started the treatment with the first-line regimen (GPO-vir) which is the locally
173
Discussion and Conclusion
produced generic ART. The regimen were changed in 30% of the participants with the two 
main reasons were either the patients developed drug resistance or experienced adverse 
event. The role of PLHA self-help group is quite impressive as it is related to relatively high 
survival and high immunologic response to the treatment amongst the members. Thus, their 
role should be expanded, strengthened and cooperated in to the ART programme.
The study reveals another exemplar to ART delivery in a developing countries where most 
patients were poor, low educated and in advance stage of the disease. With the high volume 
of patients and shortage of doctors, some works of doctor has to be replaced and done by 
nurses especially in the rural settings. And again, as some of the doctors’ works have been 
transfers to nurses due to the shortage of manpower, we have to bear in mind that this could 
end up with trade off with high mortality of the patients. The induction phase is critical, as 
most of the patients died and most of prescribed regimens were also adjusted during this 
period. Thus, the programme should look after this risk group closely. It was also found that 
people with low socioeconomic status had relative high mortalities and react not well to the 
treatment in term of immunologic response. Thus, the programme should look after 
carefully in this risk group. Prevention is still required and emphasized in some PLHAs as 
they had reported of resuming to their risky behaviours.
This study represents the first detailed study of its type aimed at evaluating the role of 
socioeconomic factors in determining the outcome of antiretroviral therapy in Thailand. 
Given its innovative nature, a number of strengths and weaknesses underlying the study are 
acknowledged. My hope is that the strengths of this study can generate sufficient interest to 
ensure that follow-on research facilitates the correction of these weaknesses.
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Annexes
6.2 Annex 2: The Cox proportional model for four treatment 
outcomes
Table 6-5: Cox proportional hazard regression for mortality
Variable Regression
coefficient
Hazard ratio P value
Male 0.64 1.90 0.04*
Age
Main occupation
0.01 1.01 0.52
Unemployed 2.61 13.65 0.000*
General labourer 1.52 4.56 0.015*
Being main wage earner 0.02 1.02 0.96
Monthly income -0.001 0.99 0.000*
Monthly household income 
Education
0.001 0.99 0.72
No formal education -0.55 0.58 0.36
Primary education -0.60 0.55 0.31
Universal heath scheme 0.25 1.28 0.67
Distance between the hospitals and their houses 0.01 1.01 0.45
Being member of PLHA self-help group 0.84 2.31 0.005*
Being naive to the ART -0.49 0.61 0.41
Baseline CD4 cell counts -0.003 0.99 0.15
Baseline WHO stage IV 0.39 1.47 0.45
Initially prescribed with Pi-based regimen 
Type of ARV clinic
-0.60 0.55 0.14
Doctor-led -2.35 0.10 0.002*
Large nurse-led -1.28 0.27 0.002*
Monthly household income *monthly income 0.000 1.00 0.000*
Table 6-6: Cox proportional hazard regression for having CD4 approached the level of 
200cell/uL
Variable Regression
coefficient
Hazard ratio P value
Male -0.15 0.86 0.26
Age
Main occupation
-0.01 0.99 0.58
Unemployed -0.71 0.49 0.011*
General labourer -0.38 0.68 0.018*
Being main wage earner 0.04 1.04 0.80
Monthly income 0.00 1.00 0.008*
Monthly household income 
Education
0.00 1.00 0.033*
No formal education -0.13 0.88 0.59
Primary education 0.02 1.02 0.94
Universal heath scheme 0.25 1.29 0.26
Distance between the hospitals and their houses -0.01 0.99 0.34
Being member of PLHA self-help group 0.35 1.42 0.018*
Being naive to the ART 0.37 1.45 0.034*
Baseline CD4 cell counts 0.44 1.56 0.000*
Baseline WHO stage IV -0.03 0.97 0.88
Initially prescribed with Pi-based regimen 
Type of ARV clinic
-0.03 0.97 0.89
Doctor-led -2.68 0.07 0.000*
Large nurse-led -0.10 0.90 0.57
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Table 6-7: Cox proportional hazard regression for having CD 4 count approached the level of 
500 cell/uL
Variable Regression
coefficient
Hazard ratio P value
Male -0.63 0.53 0.004*
Age
Main occupation
-0.00 1.00 0.90
Unemployed -0.22 0.80 0.58
General labourer -0.50 0.61 0.04
Being main wage earner 0.17 1.20 0.47
Monthly income 0.00 1.00 0.08
Monthly household income 
Education
0.00 1.00 0.39
No formal education 0.22 1.25 0.58
Primary education 0.17 1.19 0.63
Universal heath scheme 0.76 2.14 0.05
Distance between the hospitals and their houses 0.00 1.00 0.30
Being member of PLHA self-help group 0.09 1.09 0.69
Being naive to the ART -0.15 0.86 0.55
Baseline CD4 cell counts 0.60 1.82 0.000*
Baseline WHO stage IV -0.23 0.80 0.44
Initially prescribed with Pi-based regimen 
Type of ARV clinic
0.17 1.18 0.61
Doctor-led -2.66 0.07 0.000*
Large nurse-led -0.29 0.75 0.33
Table 6-8: Cox proportional hazard regression for duration on the first-line regimen
Variable Regression
coefficient
Hazard ratio P value
Male -0.01 0.99 0.97
Age
Main occupation
0.03 1.03 0.05
Unemployed -0.42 0.66 0.26
General labourer -0.26 0.77 0.23
Being main wage earner -0.05 0.95 0.80
Monthly income 0.00 1.00 0.45
Monthly household income 
Education
0.00 1.00 0.41
No formal education 0.00 1.00 0.99
Primary education 0.30 1.35 0.27
Universal heath scheme 0.08 1.09 0.75
Distance between the hospitals and their houses -0.01 0.99 0.29
Being member of PLHA self-help group -0.16 0.85 0.43
Being naïve to the ART -0.24 0.79 0.25
Baseline CD4 cell counts -0.02 0.98 0.90
Baseline WHO stage IV -0.33 0.72 0.19
Initially prescribed with Pi-based regimen 
Type of ARV clinic
-0.44 0.64 0.17
Doctor-led 0.82 2.28 0.006*
Large nurse-led 0.46 1.58 0.11
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6.3 A nnex 3: Terminology and  definition
Terminology used in this study is mostly presented in form of “MeSH (Medical Subject 
Heading” which is the U.S. National Library of Medicine's controlled vocabulary used for 
indexing articles for MEDLINE/PubMed. MeSH terminology provides a consistent way to 
retrieve information that may use different terminology for the same concepts. Please visit 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=mesh for more information about MeSH
1. Antiretroviral Therapy, Highly Active (HAART, Highly Active Antiretroviral Therapy): 
Drug regimens, for patients with HIV infections that aggressively suppress HIV 
replication. The regimens usually involve administration of three or more different 
drugs including a protease inhibitor. Other synonyms include HAART, Highly Active 
Antiretroviral Therapy, antiretroviral treatment)
2. Developing country: Countries in the process of change directed toward economic 
growth, that is, an increase in production, per capita consumption, and income. The 
process of economic growth involves better utilization of natural and human resources, 
which results in a change in the social, political, and economic structure
3. Developed country: Countries that have reached a level of economic achievement 
through an increase of production, per capita income and consumption, and utilization 
of natural and human resources. Another related term is “High income country” is 
defined by the World Bank as a country with a Gross National Income per capita of 
$11,116 or more1. While the term "high income" may be used interchangeably with 
"First World" and "developed country," the technical definitions of these terms differ. 
The term "first world" commonly refers to those prosperous countries that aligned
1 http://go.worldbank.org/D7SN0B8YU0
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themselves with the U.S. and NATO during the cold war. Several institutions, such as 
the Central Intelligence Agency (CIA) or International Monetary Fund (IMF), take 
factors other than high per capita income into account when classifying countries as 
"developed" or "advanced economies." According to the United Nations, for example, 
some high income countries may also be developing countries. The GCC (Persian Gulf 
States) countries, for example, are classified as developing high income countries. Thus, 
a high income country may be classified as either developed or developing2
4. Doctor-led clinic: clinic that cares of are principally delivered by physicians including 
general practitioners, family doctors, specialist doctor or general internists (Miles, 
Penny et al. 2003); (Fitzsimmons, Hawker et al. 2005); (Griffiths, Edwards et al. 2007)
5. Nurse-led clinic: clinic that any qualified nurse working as a substitute to doctor. This 
could include nurse practitioners, clinical nurse specialists, advanced practice nurses 
and practice nurses. The nurse must have been the identified leader of the clinical team 
for a majority of patients in the unit. Where leadership is unclear, nurses having the 
authority to admit and discharge patients operationally defined nurse-management of 
care with intention of reducing cost or addressing workforce shortages. However, the 
nurse-led clinic is by some means usually operated under supervision or collaboration 
with physician (Caine, Sharpies et al. 2002); (Miles, Penny et al. 2003); (Fitzsimmons, 
Hawker et al. 2005); (Griffiths, Edwards et al. 2007).
2 http://www.iinctad.org/en/docs/tdstat30 enfr.pdf
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6.4 A nnex 4: Questionnaire
6.4.1 Consent Form for Research Participants
A. PURPOSE AND BACKGROUND
In Thailand, it was estimated that 80% of HIV/AIDS people are receiving antiretroviral 
therapy (ART) through the national government antiretroviral therapy program since the 
start of the programme in 2001. However, evidences of the impact of ART on survival 
and other outcomes such as survival and health-related quality of life as well as others 
factors influence the treatment outcomes in Thailand are still scarce. To identify the 
impacts of ART programme, Dr. Thammasom Piriyasupong, and his colleagues from 
Khon Kaen Hospital, Ministry of Public Health are now evaluating the outcomes of the 
antiretroviral therapy (ART) programme under Ministry of Public Health and exploring 
factors contributing to its success. This information from this interview will be used to 
see whether health-related quality of life has changed over time
B. SELECTION
I am being asked to participate in this study because I am currently on ART in the 
programme and previously contributed to the researcher’s study
C. PROCEDURES
I f  I  agree to be in this study, the following will occur:
I will talk with a trained interviewer who will go through a series of questions in 
relation to health-related quality of life with me. The interview will last approximately 
20 minutes and can be done now. The interview contains questions about my living 
situation, working and living function, health status and other related issues. Interviews 
will be conducted in place where convenient for me. Interviews will be conducted at a
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pre-arrange time that convenient and causes minimum disruption toward routine, agreed 
by the hospitals directors.
The given information will be coded (no names will be used). The code will be kept in a 
locked file and only Dr. Thammasom and his co-investigators will have access to it. The 
code and all identifiers such as names, addresses, and phone numbers will be destroyed 
at the end of the study. Therefore, no one will be able to link back to me. All data are 
considered as strictly confidential.
D. RISK/DISCOMFORTS
Some of the topics in the interview are very personal and I may feel uncomfortable 
talking about them. However, I am free to decline to answer any questions I do not wish 
to answer or to stop the interview at any time. Also, if I feel the need to talk to someone 
for further counselling and support at the end of the interview, I will be given a referral 
by my interviewer.
E. CONFIDENTIALITY
Participation in research may involve a loss of privacy; however, my records will be handled as 
confidentially as possible. The researchers are doing the study in such a way that I will be 
anonymous. Only researchers directly involved in the study will have access to my interview. I 
will not give the researchers my name and no identifying information unique to me will be 
asked so my answers cannot be linked to me when the interview is over. Study information will 
be coded and kept in locked files at all times. No names will be used in any reports or 
publications that may result from this study.
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F. BENEFITS
I may not benefit directly from this interview, however all of the information I give may lead 
to a better understanding of the services available to people with the HIV/AIDS and how to 
improve those services in relation to antiretroviral therapy.
G. ALTERNATIVES
I am completely free to choose not to participate in this study.
H. COSTS
There will be no costs to me as a result of taking part in this study.
I. CONTACT
I have talked to Dr. Thammasom or one of his research associates about this study and have 
had my questions answered. If I have further questions about the study, or should I have any 
comments or concerns about participation in this study, I may contact the investigator at
Dr. Thammasom Piriyasupong 
Khon Kaen Hospital,
Khon Kaen Thailand 40000 
Call: (+66) 85 0006261, (+66) 85 854 6523 
Fax: (+66) 43 236 789 ext 1603 
E-mail: drthammasom@vahoo,com
J. CONSENT
I will be given a copy of this information form to keep.
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K. PARTICIPATION IN RESEARCH IS VOLUNTARY
I am free to decline to be in this study, or to withdraw from it at any point and this will 
not cause any negative consequences to services I will get in the future
PARTICIPANT'S CONSENT STATEMENT
I agree to take part in the research study described here. I have read and understand the 
statement and I have had all my questions answered. I understand that my participation is 
completely voluntary.
Mark of Participant Date
Signature of Interviewer
6.4.2 Verbal Consent Script
This is [name o f trained interviewer] and I am now helping Dr. Thammasom Piriyasupong 
from Khon Kaen Hospital to evaluate the outcomes of the antiretroviral therapy (ART) 
programme under Ministry of Public Health and explore factors contributing to its success. 
Today I would like you to give me some information about your family member who used 
to be treated in the national antiretroviral therapy programme about his/her socioeconomic 
status. This should take approximately about 5 minutes and can be done now. There will be 
no costs to me as a result of taking part in this study.
Your participation is voluntary. If you do not wish to participate, you may stop at any time. 
The given information will be coded (no names will be used). The code will be kept in a 
locked file and only Dr. Thammasom and his co-investigators will have access to it. The 
code and all identifiers such as names, addresses, and phone numbers will be destroyed at
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the end of the study. Therefore, no one will be able to link the samples back to me. All data 
are considered as strictly confidential.
You may not benefit directly from this interview, however all of the information you give 
may lead to a better understanding of the services available to people with the HIV/AIDS 
and how to improve those services in relation to antiretroviral therapy.
If you would like a copy of this letter for your records, please let me know and I will [give 
you a copy now; email, mail, or fax it to you, etc.\. If you have any questions regarding the 
research, please feel free to contact
Dr. Thammasom Piriyasupong 
Khon Kaen Hospital,
Khon Kaen Thailand 40000 
Call: (+66) 85 0006261, (+66) 85 854 6523 
E-mail: drthammasom@vahoo.com
Again, you are free to decline to give the information at any point and this will not cause 
any negative consequences to services from the hospital you will get in the future 
If you agree to give me the information, I will proceed to the question, if not, I will stop now 
Thank you again for your help.
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6.4.3 Copy of Questionnaire
Questionnaire
Questionnaire for interviewing patient under the governmental 
antiretroviral treatment programme
Date____________
Patient ID___________________
Interviewer’s name______________
Hospital name________________
Province_____________________
Place of interviews 1. Patient’s home (with permission to visit)
2. Hospital
3. Patient’s working place (with permission to visit) 
____________________  4. Others, please specify
Part 1
Part 1-1: General information
1 Gender
Male= 1 ; F emale=2
2
3
4
What is your date of birth?
What religion you are?
Buddhist=l; Christian=2;
What is your main occupation? 
U nem ployeds;
Civil servant or State enterprise officer=3; 
General Labourer=5,
Others=9
Muslim=3;
Farmer or gardener=2; 
Self employed=4; 
House wife=6;
If Others, please specify
5 Are you the main wage earner?
No=l; Yes=2.
6 How much do you approximately earn per month? Baht
7 How much does your family approximately earn per month 
(total income)?
Baht
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8 What type of accommodation do you live in at the 
present?
Owner occupied=l; Rented house=2; Rented room=3; 
Live with the others, Don’t have to pay=4; Vagabond=5;
Others=9
If Others, please specify....................................................................
9
10
11
How far is it from your accommodation to the hospital?
How long did it take for you to come to the hospital for the 
last visit?
How do you usually come to the hospital?
Onfeet=l; Bicycle=2; Motorcycle=3;
Private cai=4; Bus/Coach =5; Hired car=6;
Others=9
Km.
Hr/min
12 What is your highest education level?
No formal educations; Grade 6 (Primary school)=2;
Grade 9 or equivalents?;
Grade 12 (Secondary school or equivalent) =4;
Diploma or equivalents; Bachelor degree or higher=6
13 What is your health insurance scheme?
Self-pay =1; Universal Coverage (UC)=2;
Social Security=3; Civil Servant Medical Benefit Scheme=4;
Private insurance=5; Others=9
If Others, please specify........................................................................
14 What is your present marital status?
Single=l; Married=2; Separated=3;
Widow or widower=4; Divorce=5;
Not married, but live with partner=6
mm/yy
16 Why did you go for the HIV testing?
You/your spouse underwent medical treatment and had HIV testingS; 
Premarital testing=2; Testing during ANC (for you/your spouse)=3; 
Voluntary testing=4; Testing for work application=5;
Testing for blood donation=6; Others=9
If Others, please specify..........................................................................
15 When did you know that you are HIV-infected?
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Are you a member of any PLHA (people living with 
HIV/AIDS) self-help group?
No=l; Yes=2
How many adult (age > 20) are there in your house 
(including you)? (sharing resources, sharing cost together with you)
How many of these adults are infected with HIV?
How many of these adults are currently on antiretroviral 
treatment?
How many children (age<20) are there in your 
accommodation?
I f  there is no child, p lea se  f i l l  in the box w ith 0 a n d  skip  to question  24
How many of these children are HIV positive?
How many of these children are currently on 
antiretroviral treatment?
Part 1-2: Behaviour of antiretroviral drug taking
mm/yy
Have you ever take any of ARV drugs before entering to this 
programme?
No=l; Yes=2
When was your last hospital visit for ARV drugs?
/
./..... mm/yy
When did you start taking antiretroviral (ARV) drugs in this ...../,
programme?
When will be your next hospital appointment? mm/yy
Annexes
28 What regimen of ARV are you taking now?
First-line (GPO-Vir)=l; Second-line (d4T+3TC+EFV) =2;
Third-line (d4T+3TC+IDV+RTV)=3; Others=9
If Others, please specify...........................................................
In this following days, have you not taken ARV drugs or taken them late than 30 minutes? 
The interviewers please use the instruction below to ask the interviewees backward from 
today will 5 days ago. Use this instruction to answer question 29 and 30. (For today refers to 
doses in the morning only) _______ __________________________________________
Day (please specify 
Sun, Mon, Tue, 
Wed, Thu, Fri and 
Sat)
Number of doses you 
have not taken
Number of doses you 
have taken late than 30 
minutes of usual time
Today
Yesterday
2 days ago
3 days ago
4 days ago
5 days ago
29
30
31
32
33
In total, how many doses have you not taken during the past 5 
days?
In total, how many doses have you taken late more than 5 days 
during the past 5 days?
For the last month, how many doses you have not taken?
For the last month, how many doses you have taken late more 
than 30 minutes?
When was the last time you did not take your drugs?
Never miss any doses=l, Within last week=2;
Within last month=3; Within last 2 months=4;
Within last 3 months=5; More than 3 months=6
I f  the answ er is = I , p lea se  sk ip  to question  35
Doses
Doses
Doses
Doses
34 There are many reasons why people do not take their
medicines. What was your main cause on the last occasion you 
did not take ARV drugs?
Intent not to take= 1; F orgot to take=2;
Accident (e.g. drug lost)=3; Hospital ran out of drug=4;
Others=9
If Others, please specify.....................................................................
35 If you intent not to take the ARV drugs, why?
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Part 1-3: Health status before and after taking ARV drugs
36 Before taking the ARV drugs, were you able to work?
Not able to work at all= l; Able to work but not as usual=2
Able to work as usual=3
37 Are you able to work more or less comparing with that before 
taking ARV drugs?
Able to work less=l No difference=2
Able to work more=3
38 Since starting the drugs, have you notice any difference in 
your skin?
Worse=l; No difference=2;
Better=3
39 Since starting the drugs, have you notice any differences in 
your everyday life activities (e.g. taking a bath, eating, 
walking)?
Worse=l; No difference=2;
Better=3.
40 Since starting the drugs, have you notice any differences in 
your mental health?
Worse=l; No difference=2;
Better=3.
41 Do you tell your couple or your usual sex partner that you are 
HIV positive? (in case that your couple already died, did 
he/she knew that you are HIV positive before he/she died)? 
No=l Yes=2
I f  y o u  are single, p lea se  skip  this question
42 Besides your couple, do you tell any of your family
members that you are HIV positive?
No=l Yes=2
43 Do you tell your neighbours or people in your community that 
you are HIV positive?
No=l Yes=2
44 In any occasions, have you been turned away by your
neighbours or the others because of HIV (e.g. walk away; 
refuse to have meal with you)?
Never =1, Yes=2, Not sure =3
Neighbours and community do not know =4
I f  the answ er is =1 o r =3 o r =4 p lea se  skip  to question 46
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45 If you have been turned away, do your neighbours and 
community accept you more or less after taking the ARV 
drugs?
Accept less=l No difference=2; Accept more=3;
Not sure =4
46 During the past 3 months, did you still have sex?
No=l; Yes=2
I f  th e  a n s w e r  is  =1, p le a s e  s k ip  to  q u e s t io n  4 9
47 During the past 3 months, how many people did you 
have sex with?
48 During the past 3 months, how often did you use condom?
Never=l Sometimes=2 Usually =3 Always =4
49 After taking the medicine, some people have sex more often 
but some don’t, in your case do you have sex more or less 
often compare with before you taking the medicine? 
Lessoften=l; No difference=2; Moreoften=3;
Never had sex since starting ART=4
Part 1-4: ART service and follow up system
Hr/min
51 How do you feel about amount of time you usually spend at 
the ARV clinic?
Tooshort=l; Appropriate =2; Too long=3
50 How much time do you usually spend at the ARV clinic
(including related activities with the ART)? ____
52 Did you see the doctor for your last hospital visit for the ARV 
drugs?
No=l; Yes=2
53 For the last time you saw the doctor, how much time did you 
spend with the doctor?
Minutes
54 How did you feel about time you spent with the doctor? 
Tooshort=l; Appropriate =2; Too long=3;
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55 Have you been informed about benefit, harm and adverse 
effects of the ARV drugs by hospital staff?
No=l; Yes=2
i f  the answ er is =1, p lea se  skip  to question 57
56 How did you understand the information they gave you?
Not understood= 1 ; Partly understood =2;
Well understood =3
57 Do you feel private enough at the ARV clinic?
No=l; Yes=2
58 Have you conceived of dislike by hospital staff?
Never=l; Yes, sometime=2,
Yes, always=3 Not sure=4
59 What method do you use for reminding to take medicine at the 
correct time?
60 In last 3 months, have you ever missed any of hospital 
appointment?
N o=l; Yes=2
I f  the answ er is =1, p lease  skip  to 64
61 If yes, why
62 What did the hospital do when you missed the last 
appointment?
Did nothing=l; Mailed you =2; Called
you=3; Sent someone to visit=4;
Others=9;
If Others, please specify............................................................................
63 And what did you do when you realized that you missed the 
appointment?
Went to hospital as soon as possible=l;
Went to hospital in my own free time=2;
Went to hospital for the next visit=3; Others=9
If Others, please specify............................................................................
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Part 1-5: Adverse effect of ARV drugs
64 Have you ever had any adverse effects that made you feel 
unwell?
N o=l; Yes, minor side effect and able work=2;
Yes, and unable to do anything at all=3 
i f  the answ er is - 1 ,  p lea se  skip  to question 67
65 Did you stop taking the medicine during the adverse
effect occurred?
No=l; Yes=2
66 If you have the adverse effect from the drug, who is
usually the first one you will ask for help?
Hospital staff= 1; Family members =2; Other PLHA=3;
NGO=4, Others=9
If Others, please specify...............................................................................
Part 1-6: Reported satisfaction
67 How long do you expect to keep on taking the drug?
As long as possible =1; Will quit soon=2; Until the doctor stop 
prescribing=4 Others=9
If Others, please specify...............................................................................
68 What do you expect from the program?
69 In overall, do you feel satisfied with the antiretroviral 
programme delivered by the hospital?
Very dissatisfied=l; Generally dissatisfied =2;
Generally satisfied=3; Very satisfied=4
70 Do you feel satisfied with the convenient of the ARV 
clinic?
Very dissatisfied=l; Generally dissatisfied =2;
Generally satisfied=3; Very satisfied=4
71 Do you feel satisfied with the explanation of service
procedure at ARV clinic?
Very dissatisfied=l; Generally dissatisfied =2;
Generally satisfied=3; Very satisfied=4
72 Do you feel satisfied with the knowledge of the clinic
223
Annexes
staff?
Very dissatisfied=l; Generally dissatisfied =2;
Generally satisfied=3; Very satisfied=4
73 Do you feel satisfied with the ARV clinic staff interest and
enthusiasm? _________
Very dissatisfied=l; Generally dissatisfied =2;
Generally satisfied=3; Very satisfied=4
74 Could you please give any suggestion for hospital to improve quality of ATC 
programme?
75 Will you recommend any of your relative to come to this 
hospital?
N o = l; Yes=2
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Part 2: H ealth-related quality o f  life
Date_____
Patient ID_ 
Interviewer 
Hospital__
Instructions for interviews
The questions in this questionnaire begin with a statement followed by two opposite 
answers. Numbers extend from one extreme answer to its opposite.
Please circle the number between 1 and 5 which is most true for you. There are no right or 
wrong answers. Completely honest answers will be most helpful.
EXAMPLE: I am hungry:
Not at all Extremely
1 2 3 4 5
• If you are not even a little bit hungry, you might circle 1.
• If you are a little hungry, you might circle a 2.
• If you are feeling moderately hungry, you might circle a 3.
• If you are very hungry, you might circle a 4.
• If you are extremely hungry, you might circle 5.
PART 2-1: OVERALL HEALTH STATUS
1) Considering all parts of your life - physical, emotional, social, spiritual, and financial - over the past
two (2) days the quality of my life has been:
Very bad Excellent
1 2 3 4 5
2) And considering all parts of your life- physical, emotional, social, spiritual, and financial- comparing 
to just before taking ARV drugs you life has been
Extremely worse Extremely better
1 2 3 4 5
PART 2-2: PHYSICAL SYMPTOMS OR PHYSICAL PROBLEMS
(1) For the questions in Part 2, please list the PHYSICAL SYMPTOMS OR PROBLEMS which have 
been the biggest problem for you over the past two (2) days. (Some examples are: pain, tiredness, 
weakness, nausea, vomiting, constipation, diarrhoea, trouble sleeping, shortness of breath, lack of 
appetite, sweating, immobility. Feel free to refer to others if necessary)
(2) Circle the number which best shows how big a problem each one has been for you OVER THE 
PAST TWO (2) DAYS.
(3) If, over the past two (2) days, you had NO physical symptoms or problems, or only one or two,
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answer for each of the ones you have had and write "none" for the extra questions in Part B, then 
continue with Part C.
3) Over the past two (2) days, one troublesome symptom has been:
(write symptom)
Magnitude of problem
No problem Tremendous
1 2 3 4 
4) Over the past two (2) days, another troublesome symptom has been: 
Magnitude of problem
5
(write symptom)
No problem Tremendous
1 2  3 4 
5) Over the past two (2) days, a third troublesome symptom has been: 
Magnitude of problem
5
(write symptom)
No problem Tremendous
1 2  3 4 
6) Over the past two (2) days I have felt that my physical is
5
Extremely weak Very well
1 2 3 4 5
PART 2-3: PSYCHO-SOCIAL STATUS
Please choose the number which best describes your feelings and thoughts OVER THE PAST TWO (2) 
DAYS.
7) Over the past two (2) days, I have been depressed: 
Not at all
1 2 3
Extremely
5
8) Over the past two (2) days, I have been nervous or worried:
Not at all
1 2 3 4
9) Over the past two (2) days, how much of the time did you feel sad? 
Never
1 2 3 4
Extremely
5
Always
5
10) Over the past two (2) days, when I thought of the future, I was: 
Not afraid
1 2 3 4
Terrified
5
11) Over the past two (2) days, my life has been: 
Utterly meaningless 
and without purpose
1 2 3
Purposeful 
and meaningful 
5
12) Over the past two (2) days, when I thought about my whole life, I felt that in achieving life goals I 
have:
Made no______________________________________________________  Progressed______
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Progress to complete
whatsoever fulfilment
1 2 3 4 5
13) Over the past two (2) days, when I thought about my life, I felt that my life to this point has been:
Completely Very
worthless worthwhile
1 2 3 4 5
14) Over the past two (2) days, I have felt that I have:
No control Complete
over my life control over my life
1 2 3 4 5
15) Over the past two (2) days, I felt good about myself as a person.
Completely disagree Completely agree
1 2 3 4 5
16) To me, the past two (2) days were:
Burden A gift
1 2 3 4 5
17) Over the past two (2) days, the world has been:
An impersonal Caring and
unfeeling place responsive to my needs
1 2 3 4 5
18) Over the past two (2) days, I have felt supported:
Not at all Completely
1 2 3 4 5
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PART2- 4: EQ-5D
Please make “X” mark in the square which indicate you health status the most for today 
MOBILITY
I have no problems in walking about 
I have some problems in walking about 
I am confined to bed
SELF-CARE
I have no problems with self-care 
I have some problems washing or dressing myself 
I am unable to wash or dress myself
□□□
□□□
USUAL ACTIVITIES (e.g. work, study, housework family or leisure 
activities)
I have no problems with performing my usual activities 
I have some problems with performing my usual activities 
I am unable to perform my usual activities
PAIN/DISCOMFORT
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort
ANXIETY/DEPRESSION
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed
□□□
□□□
□□□
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Best imaginable 
health state
PART 2-5: VAS
For evaluating of you health status, there is a scale on you left hand 
which has endpoints of 100 (best imaginable health state) at the top 
and 0 (worst imaginable health state) at the bottom.
Please mark on the scale to state your health status for today.
Worse imaginable 
health state
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6.5 Annex 5: Alternative method to calculate the sample size
The alternative method to calculation the sample size for the present study is to use the SSP 
programme which involved two groups with a survival outcome. It is assumed that the 
patients had an exponential survival distribution. Each patient was followed until either the 
event occurs in that person, the person was lost to follow-up or administratively censored, or 
the study was terminated. It allowed to specify the distribution of patient recruitment, 
whether they enter the study uniformly or non-uniformly. Specifically, non-uniform entry 
followed a truncated exponential distribution. The methods of Lachin & Foulkes (1986) are 
implemented for the calculations. From this calculation, the sample was required to be not 
fewer than 456 which in this presented study, we included 501 participants. Description and 
value of each parameter to be put in the programme were shown in Table below
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Table 6-9: Values of parameters used in the alternative method for sample size calculation
Parameters Definition Expected
value
Power The probability of rejecting the null hypothesis given the 
alternative hypothesis is true. It is a value between 0 and 1, 
though common values include 0.80 and 0.90
0.8
Ration of sample 
size, control: 
treated
The ratio of the sample size in the control group to the sample 
size in the treated group. Examples: for equal sample size, 
enter 1. For a 3:1 controhtreated ratio, enter 3. In general, if 
R=n/m, then the total sample size N is n(R+l)/R, where n and 
m are the sample sizes of the control and treated groups, 
respectively.
1
Control survival 
rate
The expected cumulative proportion surviving at the end of 
the study in the control group. A value greater than or equal to 
0 and less than or equal to 1 must be entered
0.8
Relative risk, 
treatedxontrol
The relative risk of the treated group compared to the control 
group. A value greater than 0 must be entered.
2
Length of accrual 
period
The number of time periods required to recruit all of the 
patients into the study. It must be a value greater than 0, 
usually expressed as months or years.
6
Minimum follow­
up time
The number of periods of follow-up that the last patient 
recruited must have. Hence, the length of the entire study is 
the sum of the length of accrual period and minimum follow­
up time. The exponential hazard rates are calculated based on 
the sum of these two values. This must have the same unit of 
time as the length of the accrual period.
3
Two-sided Type I 
error
The probability of rejecting the null hypothesis given the null 
hypothesis is true. It must be a value greater than 0 and less 
than 1, though common values include 0.01 and 0.05.
0.05
Non-uniform 
accrual parameter
This specifies the distribution of the patients being recruited 
into the study. Valid values are between -10 and 10. A value 
of 0 implies a uniform distribution. Otherwise, a truncated 
exponential distribution is assumed: negative values imply that 
more patients are recruited later in the accrual period, whereas 
positive values imply that more patients are recruited early in 
the accrual period. For example, -9 implies that almost all of 
the patients are recruited at the end of the accrual period, and 2 
implies that slightly more patients are recruited early in 
accrual period.
0
Control loss to 
follow-up rate
The expected cumulative proportions at which those in the 
control and treated groups are lost to follow-up by the end of 
the study. Different rates for each group is allowed. It is 
assumed that these losses are distributed exponentially. Values 
must be greater-than or equal to 0 and less than 1.
0.1
Treated loss to 
follow-up rate
0.1
Rate of crossover 
to treated
The expected cumulative proportion of patients who cross 
over to the treatment assigned to the other group. It is assumed 
that the drop-ins and drop-outs are subject to the same hazard 
rate for the treated and control groups, respectively, from 
enrolment until the end of the follow-up period.
0.1
Rate of crossover 
to control
0.1
Total sample size 456
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